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 A mis-sense point mutation in the human VAPB gene is associated with a 
familial form of motor neuron disease that has been classified as Amyotrophic 
Lateral Sclerosis type VIII. Affected individuals suffer from a spinal muscular 
atrophy (SMA), amyotrophic lateral sclerosis (ALS) or an atypical slowly 
progressing form of ALS. 
 Mammals have two homologous VAP genes, vapA and vapB. VAPA and 
VAPB share 76% similar or identical amino acid residues; both are COOH-
terminally anchored membrane proteins enriched on the endoplasmic reticulum. 
Several functions have been ascribed to VAP proteins including membrane 
trafficking, cytoskeleton association and membrane docking interactions for 
cytoplasmic factors. It is shown here that VAPA and VAPB are expressed in tissues 
throughout the body but at different levels, and that they are present in overlapping 
but distinct regions of the endoplasmic reticulum. The disease-associated mutation in 
VAPB, VAPB (P56S) is within a highly conserved N-terminal region of the protein 
that shares extensive structural homology with the major sperm protein (MSP) from 
nematodes. The MSP domain of VAPA and VAPB is found to interact with the ER-
localized transcription factor ATF6. Over expression of VAPB or VAPB (P56S) 
attenuates the activity of ATF6-regulated transcription and the mutant protein VAPB 
(P56S) appears to be a more potent inhibitor of ATF6 activity. Moreover VAP 
proteins affect the activity of XBP1 and BiP promoter elements, two major 
components of the Unfolded Protein Response (UPR) of the Endoplasmic Reticulum 
and the different domains of VAPB have a differential effect on UPR regulation. 
Finally, over expression of the MSP domain of VAPB leads to cell death via 
apoptosis, while overexpression of other VAPB domains renders cells more 
susceptible to apoptotic death after ER stress.  
 The data presented in this thesis indicate that VAP proteins interact directly 
with components of ER homeostatic and stress signalling systems and may therefore 
be parts of a previously unidentified regulatory pathway. The mis-function of such 
regulatory systems may contribute to the pathological mechanisms of degenerative 
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1.1 VAMP/synaptobrevin -Associated Proteins (VAPs) 
 
1.1.1 Initial Characterisation 
 
 The first VAP protein (VAP33) was identified in the sea mollusc Aplysia 
californica as a 33 KDa protein in a yeast-two hybrid screen for proteins interacting 
with the synaptic vesicle protein VAMP (vesicle associated protein or 
synaptobrevin); this interaction was further validated by pull-down of a glutathione-
S-transferase fused VAP33 and an in vitro translated VAMP (Skehel et al., 1995). 
VAMPs are synaptic vesicle SNARE (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor) proteins that participate in synaptic-vesicle fusion (Chen 
and Scheller, 2001, Scales et al., 2000). When the presynaptic sensory neuron of A. 
californica was injected with VAP33 specific antibodies, inhibition of EPSPs 
(Excitatory Post-Synaptic Potentials) recorded in the postsynaptic motor neuron was 
observed, while the overall structure of the synapses was not perturbed (Skehel et al., 
1995). Expression of VAP33 was restricted in neuronal cells of A. Californica. 
 Soon after, the human homologue of VAP33 termed hVAP33 was identified 
(Weir et al., 1998) and its binding to human VAMP was shown; hVAP33 expression 
was not restricted to neuronal tissue like its A.californica homologue. Furthermore, 
in rat and human three homologues of VAP33 were characterised and termed VAPA 
(corresponding to the previously identified hVAP33), VAPB and VAPC (Nishimura 
et al., 1999). VAPA and VAPB share an overall 60% sequence similarity, while 
VAPC is a splice variant of the vapB gene. Mammalian VAPA and VAPB share the 
same basic architecture (Figure 1.1), consisting of three major structural protein 
domains: 
 A N-terminal Major Sperm Protein Homology domain termed MSP domain 
 A Coiled-Coil domain 
 A C-terminal transmembrane domain. 
 
 VAPC lacks the coiled coil and transmembrane domains but contains the 
MSP domain and 24 amino acids, which are not found in VAPA or VAPB; however 



























































































































































Figure 1.1 VAP proteins sequence, domains and subcellular localization 
 
A. Alignment of VAP proteins from human to A. californica. The conservation is 
high throughout the primary protein sequence, however the most conserved domain 
is the N-terminal MSP domain (conserved proline at position 56 highlighted in red). 
Colours correspond to the relative domains on the highlighted areas of the alignment. 
Alignment was done using Jalview (Clamp et al., 2004). 
 
B. Schematic representation of the structural domains of mammalian VAPs. 
 
C. VAP proteins in HEK293 cells and yeast YPH500 cells (Images respectively from 




(Nishimura et al., 1999). Homologues of VAPA or VAPB have also been 
characterised in yeast (Kagiwada et al., 1998), Drosophila (Pennetta et al., 2002)  and 
mouse (Skehel et al., 2000) and identified in other mammals; a VAP33 homologue 
(VAP27) was identified in plants (Laurent et al., 2000). 
 
1.1.2 Subcellular localization 
 
 The yeast homologue of VAP33, SCS2, was shown to be C-terminally 
anchored to the Endoplasmic Reticulum membrane and the majority of the protein 
resided in the cytoplasm (Kagiwada et al., 1998). Human VAPA was shown to 
interact and colocalize with occludin, which is a transmembrane protein localized at 
tight junctions between endothelial and epithelial cells, or plasma membrane 
domains (Lapierre et al., 1999). Mouse VAP33 is associated with microtubules and 
Endoplasmic Reticulum membranes (Skehel et al., 2000), while in Drosophila it is 
localized at the neuromuscular junction (Pennetta et al., 2002). 
 
1.1.3 VAP protein domains 
 
The MSP domain (MSP) 
   The N-terminal domain of VAP proteins is the most conserved domain of the 
protein from Aplysia to human. This domain was termed MSP domain for its 
similarity to the nematode Major Sperm Protein (MSP). Nematode sperm displays an 
amoeboid like locomotion that is not mediated by the actin cytoskeleton, but by a 
dynamic structural web whose single component is MSP (Tarr and Scott, 2005b, Tarr 
and Scott, 2005a). Major Sperm Protein has no sequence similarity to actin and is the 
most abundant protein in nematode sperm. The MSP domain is an s-type 
Immunoglobulin-like fold (Ig-fold), which is also found in several other proteins, 
including human growth hormone receptor, fibronectin and CD4 (Bork et al., 1994). 
It comprises of a seven stranded b sandwich composed of a three-stranded sheet 
opposed by a four stranded sheet. These sheets of the Ig-fold interact with sheets of 
other Ig-like domains and therefore can mediate protein-protein interactions. The 
MSP domain of rat VAPA (amino acids 1-125) was crystallized (Kaiser et al., 2005) 
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and the structure 1z9L (Protein Data Bank) , as expected from the sequence identity 
was similar to Major Sperm Protein. It is noteworthy that VAPA MSP is monomeric 
in solution, while the nematode MSP and VAPB MSP domain dimerize (Kaiser et al., 
2005). 
 Recently it was shown that the MSP of Drosophila VAPA is released after 
cleavage of the full length protein and the MSP domain is secreted and interacts with 
the Ephrin-B receptor (Tsuda et al., 2008). This is in agreement with the function of 
MSP in nematodes, as apart from a cytoskeletal element, the MSP monomer is 
exported from the sperm cytoplasm into the proximal gonad by a membrane-budding 
mechanism (Kosinski et al., 2005) and binds to the VAB-1 Eph receptor protein-
tyrosine kinase (RPTK) (Miller et al., 2003). Moreover, in nematodes, binding of 
MSP to the VAB-1 Eph receptor stimulates NMR-1 (N-methyl D-aspartate type 
glutamate receptor) which in turn prevents signalling by the UNC-43 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Corrigan et al., 2005). 
Therefore, despite the fact that Ig-like domains are thought to be mainly involved in 
binding functions, a signalling role for the MSP domain architecture is emerging. 
 
The Coiled-Coil domain (CC) 
 Amino acids 158-211 of VAP proteins are predicted to form a  coiled- coil 
when the COILS prediction software is used (Lupas et al., 1991). The VAP protein 
CC domain resembles that of many SNARE proteins (syntaxin, synaptobrevin, 
SNAP25 (Brunger, 2005)) and therefore one would speculate that it is that domain 
that mediates the synaptobrevin-VAP interaction. The CC domain promotes VAP 
dimerization (Kaiser et al., 2005) and Coiled-Coil protein domains are known to 
participate in promiscuous protein-protein interactions (Weir et al., 1998); little is 
known so far about the structure-function association of the VAP CC domain. 
 
The Transmembrane domain (CT) 
 VAP proteins have a C terminal transmembrane domain (amino acids 220-
243) which anchors the protein to membranes (ER membranes, vesicle membranes 
etc.). VAPs are classified as type II membrane proteins (amino terminus on the 
cytoplasmic side and lack of an ER-targeting signal peptide), albeit VAP dimerisation 
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may classify them as type IV (multiple homologous domains)(Aturaliya et al., 2006, 
Matlack et al., 1998). In most metazoan VAPs, a GxxxG inner-membrane protein 
interactions motif (Russ and Engelman, 2000) is present in their C-terminal 
transmembrane domain. This suggests that VAP proteins can homo/hetero-dimerize 
via their transmembrane domains; yeast SCS2 does not contain the aforementioned 
motif and therefore is not observed as a dimer (Kagiwada et al., 1998, Kagiwada and 
Zen, 2003). 
 
1.1.4 Cellular functions of VAPs 
 
Proteins interacting with VAPs 
 VAPs interact with a plethora of other proteins and their known interactors so 
far are summarized  in the Table 1.1 (taken from (Lev et al., 2008). This broad array 
of interactions has helped assign several functions to VAP proteins. 
 
SNARE associated function 
 Human VAP proteins were shown to interact with synaptobrevin along with 
other v and tSNAREs, such as syntaxin 1a, bet1, sec22, SNAP and NSF (Weir et 
al., 2001).  Interestingly, they do not bind to syntaxin 17, a tSNARE involved in 
smooth ER traffic or to the plasma membrane tSNARE SNAP-25. The high degree 
of conservation of the SNARE core (coiled-coil) and VAP CC domain suggest that 
there might be an evolutionary conserved function as a result of the VAP-SNARE 
interaction. However, the physiological role of the VAP-SNARE interaction in 
mammals has not been yet revealed, although in A. Californica it was clearly 
demonstrated that antibodies to VAP33 block EPSPs and thus neurotransmitter 
release. The main hypothesis regarding SNARE function is that VAP proteins do not 
regulate SNAREs, but act as a chaperone that does not participate in SNARE fusion 
events; this hypothesis is strengthened by the fact that mouse VAPA does not co-
localise with VAMP at synaptic structures, but at the cell body of neurons, in lower 
quantities (Skehel et al., 2000). VAPs could rather regulate ER to Golgi transport, 
similarly to sec22, which is required for retrograde transport to the ER (Brunger, 
2005, Burri et al., 2003). 
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Table 1.1 VAP interacting proteins 
 




SNAREs    
VAMP aVAP33 - (Skehel et al., 1995) 
VAMP-1 VAPA MSP, CT 
(Weir et al., 1998, Weir 
et al., 2001) 
VAMP-2 VAPA - 
(Weir et al., 1998, Weir 
et al., 2001) 
Syntaxin 1A VAPA - (Weir et al., 2001) 
bet1 VAPA - (Weir et al., 2001) 
sec22 VAPA - (Weir et al., 2001) 
αSNAP VAPA - (Weir et al., 2001) 
NSF VAPA - (Weir et al., 2001) 
Viral Proteins    










(Hamamoto et al., 2005) 
NS5A VAPA CC, CT (Tu et al., 1999) 
NS5B VAPA MSP 
(Hamamoto et al., 2005, 
Tu et al., 1999) 
60K cowpea mosaic 
virus 
VAP27 CC 
(Carette et al., 2002) 
FFAT-proteins    
Opi1p SCS2p MSP FFAT motif 
(Loewen and Levine, 
2005, Loewen et al., 
2003) 
Osh1, Osh2, Osh3 SCS2p - (Loewen et al., 2003) 
OSBP VAPA - (Wyles et al., 2002) 
ORP1-4, 6, 7, 9 VAPA, VAPB - 
(Wyles and Ridgway, 
2004) 
CERT VAPA, VAPB - (Kawano et al., 2006) 
Nir1, Nir2, Nir3 VAPA, VAPB - (Amarilio et al., 2005) 
Other Proteins    
VAPA, VAPB VAPA, VAPB CT required (Nishimura et al., 1999) 
Occludin VAPA - (Lapierre et al., 1999) 
Insig1, Insig2 VAPA, VAPB - (Gong et al., 2006) 
Tubulin dVAP33 - (Pennetta et al., 2002) 
PRA2 VAPA - 
(Gougeon and Ngsee, 
2005) 





(Gavin et al., 2002) 
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 Lipid Metabolism 
 Yeast studies of the VAP homologue Scs2p highlight its extensive 
participation in lipid metabolism (Kagiwada and Hashimoto, 2007, Kagiwada et al., 
1998, Kagiwada and Zen, 2003).  The SCS2 gene was first identified as a suppressor 
of inositol auxotrophy of the yeast ire15 mutant and choline-sensitive dominant 
mutation, CSE1 (Hosaka et al., 1992, Nikawa et al., 1995), while the two auxotroph 
genes are on different alleles. The inositol metabolic pathway is well characterized in 
yeast and INO1 (inositol-1-phosphate synthase) is the key enzyme that catalyzes 
synthesis of Inosito-1-P from Glucose 6-P (Figure 1.2A). Notably, disruption of 
genes involved in the choline pathway reversed the INO1 auxotrophy caused by the 
SCS2-deficient yeast strains. Inositol and choline promote INO1 expression. 
Regulation of INO1 expression is mediated by an inositol-sensitive promoter 
(UASINO) and two transcription factors Ino2p and Ino4p that act on the UAS 
promoter. This transcriptional control is tightly repressed by binding of Opi1p to 
Ino2p. Dissociation of Opi1p promotes INO1 transcription and expression; the 
dynamics of this repression are modulated by phosphatidic acid (PA). PA, Opi1p and 
Scs2p all localize on the ER membrane and in addition, OPi1p binds to the MSP 
domain of Scs2p. This interaction suggests a potential role in regulating INO1 
transcriptional activation via the Scs2p MSP domain. 
 
FFAT and lipid sensing- Membrane Trafficking 
 The FFATT motif (two phenylalanines in an acidic tract) is a targeting signal 
that targets cytosolic proteins to the surface of the ER and the nuclear membrane and 
corresponds to the consensus sequence EFFDAxE. VAP proteins were found to 
interact with FFAT containing proteins (Wyles et al., 2002, Wyles and Ridgway, 
2004); apart from the aforementioned Ssc2p-Opi1p interaction which his associated 
with inositol metabolism, VAPs interact with a multitude of  lipid-binding, lipid-
sensing or lipid-transport proteins (Table 1.1). Thus, FFAT motifs are targeted to ER 






































Figure 1.2 Regulation of phospholipid biosynthesis in S.cerevisiae (image from 
(Lev et al., 2008)). 
 
A. Inositol and Choline metabolism in S. Cerevisiae. 
 
B. Op1p and Scs2 interplay in INO1 transcription. 
 
Lipids: DAG, diacylglycerol; PA, phosphatidic acid; PtdCho, phosphatidylcholine; 
PtdEtn, phosphatidylethanolamine; PtdIns, phosphatidylinositol; PME, 
phosphatidylmonomethylethanolamine; PS, phosphatidylserine. Enzymes: CDS1, 
CDP-DAG synthase; CHO1, PS synthase; CHO2, PtdEtn methyltransferase; CKI1, 
choline kinase; CPT1, CDP-choline: 1,2-DAG choline phosphotransferase; INO1, 
inositol 1-phosphate synthase; PCT1, CTP: choline-phosphate cytidyltransferase; 
PIS, PtdIns synthase; PSD1/2, PS decarboxylase. 
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proteins was mapped to a highly conserved region of the MSP domain (Kaiser et al., 
2005, Loewen and Levine, 2005, Loewen et al., 2003). Co-crystallization of rat 
VAPA MSP and FFAT reveals a MSP-FFAT complex that buries two FFATS between 
two VAPA MSP domains.  FFAT binding on VAP MSP domain is considered to be a 
pivotal physiological function of mammalian VAPs. 
 
Ceramide transport-Glucose transport 
 Sphingolipid synthesis, transport, sorting and turnover in cells are essential 
processes that preserve membrane structure of organelles and other membranous 
formations. Ceramide is converted to sphingomyelin(SM) in the Golgi by 
phosphatidylcholine ceramide cholinephosphotransferase (SM synthase); Ceramide 
is synthesized at the ER and then transported to the Golgi. The key factor 
participating in ceramide transport is CERT (Goodpasture antigen-binding protein). 
VAPA and VAPB were found to interact with CERT (Hanada et al., 2007, Kawano et 
al., 2006), a cytosolic protein that consists of three distinct domains:  
 An N-terminal phosphoinositide-binding pleckstrin homology domain (PH). 
This domain recognises PI4P (phosphatidylinositol 4-monophosphate) and targets 
CERT to the Golgi apparatus. 
 A middle domain with no similarity to any protein  structures; however this 
domain contains an FFAT motif which mediates the interaction of CERT with VAPs 
 A C-terminal START domain (lipid-transfer domain). This domain is 
responsible for ceramide transfer between membranes. 
The VAP-CERT interaction modulates targeting of CERT to the Golgi apparatus via 
the FFAT interaction and this is dependent on the available amount of CERT 
protein(Kawano et al., 2006). 
 Insulin in muscle and fat cells, in order to increase glucose entry to the cell 
causes intracellular vesicles containing the GLUT4 glucose transporter to rapidly 
recruit to the plasma membrane (Foster et al., 2000). In these cells, GLUT4 transport 
requires participation of the SNARE machinery (VAMP-2, syntaxin-4 and 
synaptosome-associated protein of 23kDa (SNAP-23) in 3T3-l1 adipocytes). 
Moreover, VAPA co-localises with VAMP-2 in L6 myoblasts and 3T3-L1 adipocytes 































Figure 1.3 Ceramide transport, glucose transport and VAP proteins  
 
A. (from (Kawano et al., 2006)) Ceramide transport by CERT via FFAT motif 
interactions with VAP proteins (see text). SMS: SM (sphingomyelin) synthase; GCS: 
GlcCer (glucosylceramide) synthase 
 
B. (from (Foster et al., 2000)) Steps in vesicle docking and fusion applied to the 
glucose transporter 4 (GLUT-4) system. SNARE complexes on the plasma 
membrane and vesicle membranes must first be dissociated by the action of the 
ATPase N-ethylmaleimide-sensitive factor (NSF) and soluble NSF attachment 
protein ( SNAP) (vesicle priming). The vesicle then becomes associated with the 
plasma membrane (vesicle tethering).  Once tethered, the SNAREs can trans-
associate, causing the vesicle to become more tightly associated with the plasma 
membrane (docking). The classic SNARE complex is formed after docking. 
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reduced GLUT4 delivery to the surface, following application of insulin. In addition, 
antibodies to VAPA reduce levels of surface GLUT4 post insulin treatment, but do 
not affect basal levels of membrane GLUT4. Remarkably, when VAPA and VAMP-2 
are co-expressed GLUT4 returned to its previous levels. Therefore, VAPA may limit 




 The Hepatitis C virus (HCV) is a single stranded RNA virus shown to be the 
major causative agent of non-A, non-B hepatitis (Moriishi and Matsuura, 2007). Its 
replication is based on the host cell protein machinery and therefore interactions of 
viral proteins with cellular components are important. VAPA and VAPB were found 
to interact with non-structural phopshoproteins NS5A and NS5B of the HCV (Tu et 
al., 1999). Overexpression of VAP proteins increases HCV replication, while 
blocking of VAPs with antibodies blocks viral replication. VAPA and VAPB 
homo/hetero-dimers modulate this interaction and there is no effect when VAPs don’t 











Figure 1.4 VAP proteins and the Hepatitis C virus (taken from (Moriishi and 
Matsuura, 2007). 
 




Unfolded Protein Response 
 VAP proteins have been implicated in the regulation of a cell’s Unfolded 
Protein Response (UPR) of the ER (see 1.3.3); when misfolded or unfolded proteins 
are accumulated in the ER lumen, a network of genes and transcription factors is 
activated via a signalling cascade that signals to the nucleus and results in attenuation 
of translation and eventually leads to apoptotic death if the cell’s capacity to handle 
the misfolded proteins is exceeded. The first report linking VAP proteins with this 
pathway comes from yeast (Kagiwada et al., 1998, Kagiwada and Zen, 2003). Scs2p 
was shown to be involved in yeast UPR via Hac1 (see Figure 1.2B). Hac1 is a 
transcription factor that initiates the UPR in yeast by binding to promoter elements of 
UPR associated genes; Hac1 regulates dissociation of Opi1 from the promoter 
element that controls transcription of the INO1 inositol associated gene. Therefore 
the Scs2-Opi1 interaction and the fact that UPR can be induced by inositol starvation 
in yeast, suggest that Scs2 might participate directly or indirectly in UPR regulation 
in yeast. 
 Apart from yeast, in HCV virus it was shown that VAP proteins may 
participate in the UPR of the host cell. NS5A and NS5B were shown to interact with 
VAPA and VAPB. NS5A can affect translocation and topology of another non-
structural protein NS4B (Lundin et al., 2006). NS4B can induce an unfolded protein 
response in the host cell which seems to be an evolutionary adaptation of the virus 
that facilitates its replication by allowing synthesis of viral proteins in huge amounts 
in the host cell’s ER (Zheng et al., 2005). 
 Finally, it was shown by Kanekura et al., 2006 that in a mammalian cell line, 
overexpression of VAPB can induce an unfolded protein response. Conversely, when 
endogenous VAPB is blocked with siRNA, the UPR response is attenuated. This 
study shows a global effect of VAP protein levels in regulating the UPR and suggests 
that this might be done through splicing of a UPR transcription factor, XBP1 
(discussed in 1.3.3). 
 
Hsp90 
 Hsp90 (Heat-Shock Protein of 90 KDa) is a molecular chaperone implicated 
in protein folding, cell signalling, and tumour repression (Pratt and Toft, 2003). 
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Hsp90 is known to control the folding of numerous cell-regulatory proteins such as 
steroid receptors and kinases. Recently it was shown that Hsp90 forms a complex 
with the co-chaperone tetratricopeptide repeat domain 1 (TPR1) that associates with 
VAPA on the ER membrane (Lotz et al., 2008). This novel interaction reveals a new 
regulatory pathway for VAP proteins. 
 
Ephrin receptors 
 Ephrin receptors are transmembrane receptor tyrosine kinases that are 
implicated in cell signalling (angiogenesis, segmentation, axon guidance), 
development (cell guidance) and cancer (elevated levels in tumours); ephrins are the 
ligands of these receptors (O'Leary and Wilkinson, 1999, Boyd and Lackmann, 
2001). Recently, Tsuda et al., 2008 showed that drosophila VAPB gets cleaved and is 
secreted from cells. Additionally, they showed that human MSP expressed protein 
binds expressed EphA4 extracellular domain in a pull-down assay; moreover MSP 
expression disrupts the interaction between mouse EphA4 and EphB2. The model 
proposed reveals a novel pathway for VAP proteins MSP domain to compete with 
ephrins for binding to ephrin receptors.  
 
ER to Golgi transport 
 Transport of proteins between membranous organelles or on the plasma 
membrane is performed with 3 types of coated vesicles: clathrin vesicles, from the 
plasma membrane and trans-Golgi to endosomes; COP I vesicles, within Golgi 
cisternae and retrograde from cis-Golgi back to the rough ER; and COP II vesicles, 
from the rough ER to the cis-Golgi (Duden, 2003). Coated vesicles fuse with the 
acceptor membrane, release their cargo and then recycle the coat proteins for reuse. 
Uncoating of transport vesicles exposes specific v-SNARE proteins on the surface of 
each type of vesicle. V-SNAREs bind to t-SNARE proteins that are in complex with 
SNAP25 on the acceptor membrane. NSF and α-, β-, and γ-SNAP proteins then bind 
to the T-SNARE/V-SNARE/SNAP25 complex, and form the prefusion complex. 
After vesicle fusion the t-SNARE/ t-SNARE/SNAP25 may be dissociated via NSF 
and SAP proteins. 
 VAPA has been shown to participate in intra-Golgi and Golgi to ER transport 
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via COP I vesicles (Soussan et al., 1999). Blocking of  VAP-B with antibodies blocks 
transport between Golgi cisternae and leads to accumulation of COP I coated 
vesicles(Soussan et al., 1999). More recently, Prosser et al., 2008 showed that VAPA 
but not VAPB overexpression blocks ER-Golgi transport as well as lateral diffusion, 
using the VSVG model (to follow movement of COP II vesicles from the ER to the 
Golgi in living cultured mammalian cells a construct encoding a chimeric protein 
consisting of green fluorescent protein fused to the cytosolic-facing C-terminus of 
the Vesicular Stomatitis Virus G glycoprotein, was used). Expression of the FFAT 
motif rescued this blocking of transport. 
 
1.2 VAP proteins and ALS8 
 
1.2.1 ALS8 and the P56S mutation 
 
ALS/MND (Veldink et al., 2004) 
The term Motor Neuron Disease (MND) is used to describe a number of 
illnesses concerning motor neuron malfunction. Known subtypes of MND are 
Amyotrophic Lateral Sclerosis (ALS), Progressive Muscular Atrophy (PMA), 
Progressive Bulbar Palsy (PBP) and Primary Lateral Sclerosis (PLS). The general 
term MND is widely used in Europe, whilst ALS is used more generically in the 
USA. Also this type of disease is often referred to as “maladie de Charcot” - first 
described by French physiologist Charcot in 1874 - aka “Lou Gehrig’s Disease” after 
the famous American baseball player who died of the disease. 
ALS is one of the most common neurodegenerative disorders with an 
incidence of 2 per 100,000 of total population. Though it can affect anyone, 
ALS/MND is more often found in the 40-70 year group; juvenile cases have also 
been observed. The life expectancy for patients after diagnosis is about 3 years, 
although great deviations have been observed. The most typical feature of ALS is 
degeneration of cortical, bulbar and spinal motor neurons (spinal cord - brainstem - 
motor cortex), except for bladder controlling neurons (Onuf’s nuclei) and the ocular-
motor neurons. The results of this degeneration are generalized muscle weakness, 
fasciculation, muscle atrophy, speech and swallowing disabilities, progressive 
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paralysis and ultimately death due to respiratory failure. However, there may be 
heterogeneity in the body regions affected, as well as the progression of the disease. 
Undoubtedly, the unique nature of the disease affects social life, family and career. 
The disease is progressing rapidly and this requires increased attention and 
adaptation to different levels of support and care for patients and their families. 
 Approximately 10% of ALS cases are dominantly inherited (Familial ALS- 
FALS) while 90% of them are sporadic. The main difference between FALS and 
sporadic ALS is the age onset, which is often lower for FALS.  
 
ALS8-P56S (Nishimura et al., 2005, Nishimura et al., 2004) 
 After studying the genealogy tree of a large white Brazilian family, with 28 
members affected across 4 generations a new locus for ALS/MND was mapped at 
20q13.3 (chromosome 20, long arm, region q13.3), ALS8 (Figure 1.5). ALS8 is an 
autosomal dominant disorder with a slow progression of the disease (fasciculation, 
cramps, postural tremor). More elaborate studying of the genomic area in which the 
recombination events took place has revealed the existence of a missense mutation 
in VAPB in all affected members of this family. Moreover, the same mutation was 
found in six additional families with a different diagnosis. Although no immediate 
link could be found between those test cases, historical data points to a common 
Portuguese ancestor that expands the genealogy of affected patients throughout the 
various generations. 
 Mutation screening of the possible candidate genes identified that the 
missense mutation was a C→T substitution in exon 2 of the VAPB gene. The effect 
of the mutation is that a HaeIII restriction site is removed and at codon 56 a Proline 
(that is conserved) is substituted by a Serine (Pro56Ser or P56S). The proline is 
within the MSP domain and thus conserved in H. sapiens, M. musculus, R. 
norvegicus, A. californica, D. melanogaster and S. Cerevisiae (Figure 1.1A). 
Interestingly, this mutation was present in all affected members of the family, but not 
















Figure 1.5 Mapping of the VAPB locus and mutation analyses (taken from 
(Nishimura et al., 2004). 
 
Pedigree from the first family reported with a diagnosis of ALS/MND (an asterisk [*] 
indicates DNA was available). VAPB locus at 20q13.3 is shown. The mutation with 
homologous recombination reduces the region to 1.5 Mb, between marker D20S430 
and the TUBB1 gene. 
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1.2.3 Cell biology of ALS associated P56S 
 
 Since 2004 when the P56S ALS8 associated mutation was identified in the 
large Brazilian pedigree, several groups have offered models on how the mutant 
behaves aberrantly and might lead to motor neuron degeneration. The theoretical 
prediction for changing a Proline to a Serine at P56S was that the 2 β-sheets of the 
Ig-like fold of the MSP domain would no longer be held together in their original 
conformation and either the structure would collapse leading to a non-functional 
MSP domain for the protein or the fold would change and therefore the domain 
might participate in a different subset of interactions-functions than the wild-type. 
Therefore, the mutant VAPB
P56S
 would either be loss or gain of function mutation. 
 
Protein Aggregates 
 The first observation in Nishimura et al., 2004 was that when the P56S 
mutant was expressed in mammalian cells and primary hippocampal rat neurons (as a 
GFP or myc fusion protein), it would form cytoplasmic aggregates (Figure 1.6). 
Protein aggregates are a common theme in many neurodegenerative diseases like 
Parkinson’s, Alzheimer’s, Huntington’s and prion diseases; misfolded proteins 
aggregate and can lead to cell death (Gorman, 2008). This process does not 
necessarily happen immediately and aggregates can remain within cells for many 
years before starting to induce cell death. More groups have validated this result and 
additionally shown that these aggregates are tubular and immobile (Teuling et al., 
2007), increase the insolubility of the protein (Kanekura et al., 2006) and are not 
localised in the ER. Moreover, Teuling et al, 2007 have shown that VAPB
P56S
 cannot 
interact with the FFAT motif via its MSP domain which suggests that the mutation 
potentially leads to loss of the FFAT binding capacity of VAPB. However, a recent 




  As previously mentioned in 1.1.4 overexpression of VAPA blocks ER to 
Golgi transport of membrane proteins; VAPB does not. VAPB
P56S






























Figure 1.6 The ALS8 associated mutant P56S of VAPB forms aggregates. 
  
A. (Skehel unpublished and (Nishimura et al., 2004)) VAPBP56S forms aggregates – 
PDI is an ER protein. 
 
B. (From Prosser et al., 2008) FFAT rescues formation of P56S aggregates. 
 
C.  The P56S substitution in the VAPB MSP domain (here depicted rat 1z9L VAPA 
MSP domain) takes place in a pivotal position for the Ig-like fold of the MSP domain 
(image was made using the open-source visualization tool PyMol). 
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blocks trafficking by trapping the VSVG marker in the aggregates. FFAT application 
rescues this inhibition, restoring trafficking of proteins from the ER to Golgi (Prosser 
et al., 2008). However in this case they do not observe rescue of a “lost” function, as 
overexpression of VAPB had no effect on trafficking; it seems like the P56S mutant 




 Yeast, HCV and in mammalian cells studies have highlighted the role of VAP 
proteins in the Unfolded Protein Response (see 1.1.4).Although, most studies focus 
on the wild-type protein, only two of them propose a model for the P56S mutation. 
Kanekura et al., 2006 have shown that the P56S mutant cannot activate the Unfolded 
Protein Response through splicing of the UPR associated transcription factor XBP1. 
Therefore this study suggests that the P56S mutation is a loss of function mutation. 
Tsuda et al., 2008 have shown that overexpression of the mutant P56S of the 
drosophila homologue of VAP activates the UPR via the chaperone Hsc3 more than 
the wild-type protein. Thus, the effect of the P56S mutation on the UPR of a cell has 
not been extensively studied. 
 
1.2.3 New VAPB mutations and ALS 
 
 In 2008, two new mutations of VAPB were described in ALS patients 
(Landers et al., 2008).: 
 D130E (aspartic acid to glutamic acid at position 130). A missense T→G 
substitution was observed within exon 4 in 2 individuals.  However, previously a 
study in southern Italy found the same ratio of the D130E substitution between ALS 
patients and healthy individuals suggesting that it might not be a causative gene of 
ALS (Conforti et al., 2006).  
and 
 del160 (deletion of amino acid at position 160, which is a serine). A three base 
pair deletion of CTT at nucleotide 478 within exon 5 of the vapB gene (Figure 1.7). 




Figure 1.7 The del160 mutation in family F089 (from (Landers et al., 2008)). 
 
The asterisk denotes individuals whose DNA was not available for sequencing. The 
arrow indicates the individual that the mutation was first discovered. Disease onset is 
at about 50 years of age, while a 51 year old individual (6) is still asymptomatic. 
 
 Amino acids at positions 130 and 160 of VAPB are not conserved amongst 
different organisms. Both D130E and del160 mutants do not form cytoplasmic 
aggregates like the P56S mutant, which suggests that if they are causative genes for 
ALS8, they might act via a different mechanism or pathway than P56S. 
 
1.3 The Endoplasmic Reticulum 
 
1.3.1 A dynamic organelle (Borgese et al., 2006, Voeltz et al., 2002) 
  
 The Endoplasmic reticulum is a membranous organelle with diverse functions 
including the translocation of proteins (such as secretory proteins) across the ER 
membrane; the integration of proteins into the membrane; the folding and 
modification of proteins in the ER lumen; the synthesis of phospholipids and steroids 
on the cytosolic side of the ER; and the storage of calcium ions in the lumen and 
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their regulated release into the cytosol. The large amounts of membrane belonging to 
the ER are organized by folding into tubular and lamellar structures. The ER 
membranes vary not only between different cells but even within the same cell and 
form subdomains which serve the diverse functions of this organelle; therefore, 
although the ER is a continuous membrane formation, it is divided into various 
structural and functional subdomains (Voeltz et al., 2002).  
 The ER can be divided into two major parts: the nuclear ER (nuclear 
envelope-NE) and the peripheral ER (PE). The NE connects with the nucleus at the 
nuclear pores and a network of lamins underlies the entire ER-nuclear membrane 
complex. Continuous with the NE, the PE takes up 10% of the whole cell volume. 
The next division of the ER membranes is between the Rough ER (RER- enriched in 
ribosomes) and the Smooth ER (SER-smooth area) (see Figure 1.8).In different cell 
types, according to their function, there is a different relative distribution of RER and 
SER (Voeltz et al., 2002). 
 ER membranes are in contact with various other membranous organelles 
(plasma membrane, Golgi, vacuoles, mitochondria, peroxisomes, late endosomes and 
lysosomes) and at these junctions specialized ER microdomains are formed. 
Moreover, ER membranes are connected to the actin cytoskeleton and microtubules; 
elongation and retraction of ER tubules contribute to ER membrane rearrangement 
and maintenance of its shape and form. During cell division the ER maintains its 
structure and divides between cells with cytokinisis. In skeletal muscle, the ER is 
termed Sarcoplasmic reticulum (SR)(Rossi and Dirksen, 2006) and participates in 
calcium homeostasis which is essential for muscle cell function. Several calcium 
associated proteins (sarco(endo)plasmic reticulum Ca2+ -ATPase (SERCA) for Ca
2+ 
exchange, calsequestrin for calcium binding), including ryanodine receptors (RyRs), 
which are ER calcium release channels are associated with SR subdomains. 
 
1.3.2 ER in neurons  
 
 In neurons the ER is not limited in the soma, but also exists in the distal 
dendrites, where it has the capacity for local protein synthesis (Ju et al., 2004). The 

























Figure 1.8 The Endoplasmic reticulum architecture. 
 
A. (from (Voeltz et al., 2002))The Nuclear Envelope (NE). Targeting and retention of 
an inner nuclear membrane protein (ER membranes→ peripheral ER→ nuclear pore 
membrane→ inner nuclear membrane→ binding to nuclear lamina and chromatin). 
 
B. (from (Borgese et al., 2006)) The different membrane organisations of the 
Endoplasmic Reticulum (a) a karmella, (b) a lamella, (c) a whorl, (d,e) sinusoidal 
arrays with cubic symmetry, and (f) a bundle of packed tubules with hexagonal 
symmetry. (N: nucleus, M: mitochondria) 
 
C. (from (Voeltz et al., 2002)) Ultrastructure of the RER, SER and NE. (a) a GFP ER 
fusion protein is COS cells displaying a characteristic ER reticular pattern, (b) 
Electron micrograph of RER and SER in a liver cell, (c) connection between NE and 




there it extends to the presynaptic terminal where it might enwrap mitochondria. In 
dendrites the ER terminates in the spines and effectively connects them with the ER 
lumen. 
 Regulation of Ca
2+
 in neurons by the ER is associated with synaptic plasticity 
and rapid response to signalling events coupled with protein synthesis or 
modifications or long term changes to synapses (Figure 1.9). Calcium is released 
from the ER and participates in activation of Ca
2+
 dependent pathways via calcium 
binding proteins or calcium membrane channels. Luminal calcium creates the driving 
force for the calcium wave that favours exit from the ER to the cytosol. Regulation 




Figure 1.9 ER calcium signalling and neuronal integration (from (Verkhratsky, 
2005).  
 
Regulation of calcium diffusion from the ER can modulate the propagating Ca
2+
 
wave that can participate in rapid or long lasting (via the nucleus) responses. 
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1.3.3 The unfolded protein response (Back et al., 2005, Schroder and Kaufman, 
2005). 
 When the influx of unfolded proteins in the ER lumen exceeds the folding 
capacity of the ER machinery (folding chaperones, or trafficking molecules) then the 
cell steps into a state of stress termed Unfolded Protein Response (UPR). This 
coordinated response starting from the ER involves activation of a complex gene 
cascade transferring the stress signal via second messengers to the nucleus. The 
purpose of this activation of the ER stress associated genes is to return the cell to its 
normal physiological state; this is done by halting protein translation and facilitating 
protein folding by producing more folding chaperones, or by sequestering unfolded 
products to the cytosol via a mechanism termed ERAD (Endoplasmic Reticulum 
Associated Degradation- unfolded proteins are selectively recognised and transported 
to the cytosol where they are degraded by the proteasome). If the insult caused by 
unfolded proteins persists and the cell cannot recover, programmed cell death may be 
initiated. 
 In yeast the only protein-sensor for induction of the UPR is Ire1p, a 
transmembrane ER protein that has a luminal dimerization domain and a cytosolic 
domain with serine/threonine kinase and RNAse activities. Ire1p is activated via 
dimerization and subsequent autophosphorylation. The activated Ire1p recognises an 
intron in HAC1 mRNA and cleaves it, producing a spliced form of HAC1 which 
yields an active transcription factor that binds to UPR responsive elements (UPRE) 
of UPPR associated genes in the nucleus. 
 In mammalian cells, the three major transducers of the UPR are inositol-
requiring 1(IRE1), PKR-like endoplasmic reticulum kinase (PERK), and activating 
transcription factor 6 (ATF6), which sense the presence of unfolded proteins in the 
ER lumen; all three aforementioned proteins are transmembrane proteins with a 
cytosolic and a luminal part (Figure 1.10). All three UPR transducers luminal 
domains associate with BiP in their inactive state. BiP/GRP78 (immunoglobulin 
heavy chain-binding protein/glucose-regulated protein of molecular weight 78 kDa) 
is a member of the Hsp70 heat-shock protein family and a highly expressed ER 













Figure 1.10 The mammalian Unfolded Protein Response (from(Wu and Kaufman, 
2006)). 
 
 The mammalian UPR has three pathways coupling events in the ER lumen to 
regulating gene transcription in the nucleus; the IRE1, PERK, and ATF6 pathways 
(also see text). 
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preference for hydrophobic areas, while its N-terminal domain regulates dissociation 
via ATP hydrolysis. Upon accumulation of unfolded/misfolded proteins in the ER 
lumen, BiP is dissociated from all three sensors. ATF6 is shuttled to the Golgi where 
it is cleaved by S1P/S2P proteases and the cytosolic fragment of ATF6 migrates to 
the nucleus. IRE1 and PERK are oligomerized and autophosphorylated. Activated 
IRE1 mediates splicing of XBP1 mRNA, which generates the active form of the 
XBP1 transcription factor. Phosphorylated PERK phosphorylates eIF2a, which 
attenuates translation and allows translation of selective mRNAs with inhibitory 
uORFs in their 5’ UTR (i.e. ATF4). These three distinct pathways finally signal to the 
nucleus and induce UPR associated gene transcription acting on ERSE (Endoplasmic 
Reticulum Stress Response Elements) promoter elements (ATF6 nuclear fragment, 
spliced XBP1 and ATF4 act together on promoter elements). BiP/GRP78, GRP94, 
calreticulin, calnexin protein disulfide isomerases PDI, ERP57, and ERP72 are some 
of the activated genes. This increases ER protein folding capacity and accelerates 
ERAD (Endoplasmic Reticulum Associated Degradation). Finally, all three pathways 
are simultaneously activated; however the PERK pathway is identified as the 
immediate response to ER stress, while the other two pathways act subsequently. 
 When the ER folding capacity is restored, a negative feedback loop is 
activated to reinstate the basal equilibrium of transcription factors and chaperones. 
Initially, PERK and/or eIF2a are dephosphorylated. This effect is mediated via p-
eIF2a phosphatase, CreP (constitutive repressor of eIF2a phosphorylation), and a 
stress-induced regulator of p-eIF2a phosphatase, GADD34 (growth arrest and DNA 
damage-inducible gene 34). Subsequently, the level of BiP and prevents further 
activation of ATF6, IRE1 and PERK by binding to their luminal domains. Little is 
known about inactivation of ATF6 and XBP1; it has been suggested that endogenous 
levels of ATF6 and XBP1 autoregulate their inactivation via negative feedback. 
 Finally, a microarray study in the nematode C.elegans (containing all 3 
transducers) identified during normal development inducible UPR (i-UPR) and 
constitutive (c-UPR) genes that require the three transducers of UPR (termed ire1, 
pek1 and atf6 in C.elegans)(Shen et al., 2005).Although xbp1 is downstream of ire-1 
and they work synergistically in regulating most i-UPR genes identified, they do not 
overlap in the c-UPR genes regulated, thus suggesting they might act via different 
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pathways. On the other hand, atf6 regulates c-UPR genes rather than i-UPR genes, 
suggesting it is important during development and homeostasis. 
 
1.3.4 ER stress and disease 
 
Apoptotic death following ER stress 
 If the activation of UPR associated genes and ERAD fail to restore a cells 
luminal balance of unfolded proteins, mitochondrial-dependent and independent cell 
death pathways are activated and mediate apoptotic (programmed cell death) (Wu 
and Kaufman, 2006). The main genes/pathways involved are: 
 
 Bak/Bax-regulated Ca2+ release from the ER  
 procaspase-12 cleavage and activation 
and 
 IRE1-mediated activation of ASK1 (apoptosis signal-regulating 
kinase 1)/JNK (c-Jun amino terminal kinase) (Figure 1.11) 
 
 In response to Ca
2+
 entry via Bak and Bax, m-Calpain cleaves procaspase-12, 
which in turn activates the entire caspase cascade via pro-caspase-9. Released 
calcium activates the mitochondrial apoptotic branch by releasing cytochrome c 
release and thus activating apoptosis via procaspase-9 and Apaf-1(apoptosis 
protease-activating factor 1) (Wu and Kaufman, 2006, Nicotera et al., 1999). 
 Apart from this well characterised pathway, individual UPR transducers 
signal to the apoptotic pathway. Ire1 via its interaction withTRAF2 (TNF receptor-
associated factor-2) and ASK1 can lead to cell death. ATF6 and PERK/eIF2a/ATF4 
regulate transcription of CHOP (CEBP homologous protein), which in turn inhibits 
expression of Bcl-2 and thus induces apoptosis (Wu and Kaufman, 2006). 
 
Neurodegeneration 
 Apoptosis has been associated with many neurodegenerative diseases like 
Alzheimer’s, Parkinson’s, Huntington’s diseases and stroke (Chan and Mattson, 
1999, Nicotera et al., 1999). 
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Figure 1.11 The mammalian UPR and programmed cell death (from(Wu and 
Kaufman, 2006)). 
See text 1.3.4. 
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 The ER contributes to neuronal excitotoxicity by releasing Ca
2+
. 
Excitotoxicity is a mechanism of neuronal death through overactivation of glutamate 
receptors, especially under metabolic and oxidative stress, resulting in cellular Ca
2+
  
overload (Mody and MacDonald, 1995). Treatment of neurons with agents that 
reduce or block ER-mediated Ca
2+
 release protects against excitotoxicity. The same 
has been shown in models of cerebral ischaemia and epilepsy (Frandsen and 
Schousboe, 1991, Pelletier et al., 1999, Wei et al., 1998). BiP/GRP78 can suppress 
elevations of intracellular Ca
2+
 following exposure of neurons to glutamate; this 
results from reduced Ca
2+
 release from ryanodine associated calcium stores (Yu et 
al., 1999). 
 Abnormalities of ER-mediated Ca
2+
 signalling have been linked to the 
pathogenesis of Alzheimer’s. Alzheimer’s is a neurodegenerative disease that 
manifests through memory loss, cognitive decline, gradual loss of bodily function 
and ultimately death; in Alzheimer’s extracellular plaques of β-amyloid are deposited 
and believed to be neurotoxic. Numerous mutations in presenilin 1, a transmembrane 
ER protein lead to early-onset inherited Alzheimer’s; overexpression of presenilin 1 
alters proteolysis of the β-amyloid precursor protein, which results in increased 
production of the neurotoxic β-amyloid peptide. Presenilin 1 interacts with RyR or 
RyR-associated proteins and increases channel activity of the RyR receptor 
(Hayrapetyan et al., 2008). Another ER amyloid-binding protein (ERAB- 
endoplasmic reticulum β-amyloid-peptide-binding protein) was found to be increased 
in neurons in the brains of individuals with Alzheimer’s disease, and it was suggested 
that binding of β-amyloid  to ERAB might be important for the cytotoxicity of the 
amyloid peptide (Oppermann et al., 1999). 
 Huntington disease is an autosomal dominant polyglutamine disorder that 
leads to selective loss of striatal neurons.  Affected individuals exhibit involuntary, 
jerky movements and alterations in memory and mood.  It is caused by expansion of 
[CAG]n repeats in the huntingtin gene. In response to ER stress, huntingtin releases 
from membranes and translocates into the nucleus; subsequently huntingtin can be 
released and re-associated with membrane; albeit mutant huntingtin does not 
translocate (Atwal and Truant, 2008). Mutant huntingtin also elevates BiP and CHOP 
levels and phosphorylation of c-Jun-N-terminal kinase (JNK) (Reijonen et al., 2008). 
43 
 
 A common observation in Parkinson’s disease (PD) is the deposition of 
intracytoplasmic inclusion bodies (Lewy bodies) in neurons. Affected individuals 
display tremor, muscle rigidity and postural instability; a common pathological 
finding in PD is degeneration of dopaminergic neurons in the substantia nigra. In a 
cellular model of PD, when 6-hydroxydopamine is added numerous UPR genes are 
upregulated (Ryu et al., 2002); 6-hydroxydopamine, causes a type of 
neurodegeneration similar to that observed in PD (Ungerstedt et al., 1974). 
  In conclusion, the Endoplasmic Reticulum  stress response to unfolded 
proteins is associated with programmed cell death and upregulation of many 
components of the UPR are observed in a wide spectrum of neurodegenerative 
diseases. 
 
1.4 Thesis Aim 
 
 VAP proteins are ER integral membrane proteins, enriched on the ER surface. 
Until now several functions have been ascribed to them including membrane 
trafficking, targeting of proteins, vesicle fusion, lipid metabolism and they interact 
with a broad spectrum of proteins. There is increasing literature linking VAP proteins 
with the Unfolded Protein Response. On the other hand, misregulation of the 
unfolded protein response has been implicated in neurodegenerative diseases. In this 
thesis we investigate the regulation of the UPR by VAP proteins and study the ALS8 
associated P56S mutant in this context. 
 
In detail: 
 We investigate the interactions of VAPB with UPR components and look for 
specific effects on transcriptional activation of the UPR. 
 We examine the neuron specificity of VAPB 
 We investigate the effect of perturbation of VAPB levels in cell viability 
 We perform a large scale bioinformatics screen for predicting novel protein 
interactors for VAPB 



















Materials and Methods  
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2.1 Fluorescent Protein Fragment Complementation Assay (FPCA), 
adapted from (Remy and Michnick, 2007) 
 
 FPCA is a technique for detecting protein-protein interactions in cells. Full 










and pCMV-ATF6-3xFLAG7.1 respectively. All PCR products had either BspEI-XbaI 
or NotI-ClaI flanking restriction sites. Amplified products were cloned into pVenus1 
BspEI-XbaI site and pVenus2 NotI-ClaI  site; the Venus plasmids are based on the 
Invitrogen p-CDNA3.1Zeo(+) backbone; pVenus1 contains residues 1-157 of YFP 
(Yellow Fluorescence Protein, 1YFP-PDB entry) fused to a b-leucine zipper and 
pVenus2, residues 158-238 fused to a b-leucine zipper. Insertion of VAP proteins or 
ATF6α CDS replaces the leucine zippers which were cloned in the BspEI-XbaI or 














Figure 2.1 Schematic of split-YFP reassembly of fragments by b-leucine zippers. 
NYFP (residues 1–157) is green, CYFP (158–238) is green, and the b-leucine zippers are 












HEK293 cells were plated and transfected at 40% confluency using 
INVITROGEN Lipofectamine2000 with 200 ng of each Venus plasmid; in total 
400ng of plasmid DNA per transfection were used. Images of living cells were 
acquired 24 h after transfection on an Olympus IX70 fluorescence microscope using 
Openlab software (Improvision); images were prepared using ImageJ (Collins, 2007). 
Representative images are shown. 
 
2.2 Dual Luciferase Transcription Assay (Promega Dual GloTM 
Luciferase Assay System) 
 
 Transcriptional dual luciferase assays are widely used for transcription factors 
to monitor transcriptional activity from a given promoter by measuring luciferase 
bioluminescence. HEK293 or NSC-34 cells were plated and cultured to 40% 
confluency and transfected using Lipofectamine2000 (Invitrogen). Each transfection 
mixture contained 300 ng of p5xATF6-GL3 (ATF6α reporter) or pGL3-XBP1(-330)-
luc(XBP1 reporter) or pGL3-GRP78(-132)-luc (Bip reporter) and 100 ng of the 
internal control renilla luciferase reporter, pTK-RL. VAPB and VAPBP56S were 
expressed as EGFP-fusion proteins derived from pEGFP-C1 (Clontech), or as myc 
epitope tagged fusion proteins where the EGFP coding sequence was replaced with a 





, CC/CT, CT) were previously described (Middleton, 2005).  The total amount 
of DNA per transfection when studying the endogenous response (of ATF6 or XBP1 
or Bip) was 500 ng. ATF6 was over expressed as a FLAG-tagged fusion protein from 
pCMV-ATF6-3xFLAG7.1. When studying the expressed ATF6 effect 100 ng of each 
VAPB and ATF6 expression plasmid was used, with the total amount of DNA in each 
transfection made up to 600 ng with the vector pEGFP-C3 (Clontech). Twenty-four 
hours after transfection ER stress was induced for 12 h with 2 µg/ml tunicamycin 
(Calbiochem). Cells were assayed for firefly and renilla luciferase activity using the 





Figure 2.2 Bioluminescent reactions catalyzed by firefly and Renilla luciferases 
(image from Promega technical manual). 
Mono-oxygenation of beetle luciferin is catalyzed by Firefly luciferase in the presence of 
Mg
2+
, ATP and O2. Coelenterazine mono-oxygenation is catalyzed by Renilla luciferase and 
requires only O2 (Alam and Cook, 1990). 
 
 Cells were lysed at room temperature using a proprietary lysis buffer by 
Promega included in the Firefly luciferase reagent. Both firefly and renilla 
luminescence were measured using a FLUOstar OPTIMA micro-plate reader (BMG 
LABTECH). Firefly luciferase luminescence was measured first and then the 
STOPnGLOTM reagent was added; this reagent stops the first reaction and contains 
the renilla luciferase substrate for the second reaction; finally the renilla 
luminescence was measured. Firefly luciferase luminescence values are normalized 
to renilla firefly luminescence values and are averages of four experiments (n=4) 
with SE (standard error). 
 
2.3 Cell Death Assays 
 
2.3.1 Propidium Iodide Cell Viability Assay 
 
 NSC34 or HEK293 cells were plated and cultured to 40% confluency and 
then transfected using Lipofectamine2000 (Invitrogen). Each transfection mixture 
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contained 100 ng of the relative expression plasmid and control samples were 
pEGFP-C3 and pCDNA3.1Tubulin. Twenty-four hours after transfection ER stress 
was induced for 12 h with 2 µg/ml tunicamycin (Calbiochem). Cells were then 
washed with pre-warmed (37
o
C) PBS and growth medium was replaced. After 12 
hours 1X propidium iodide from a 50X stock solution of 250 l/ml of propidium 
iodide (Sigma) was added to the growth medium. The cells were incubated for 20 
min at 37oC and then imaged on an Olympus IX70 fluorescence microscope using 
Openlab software (Improvision).  Viable cells were detected on a fluorescent 
microscope as those, which excluded the propidium iodide; dead cells could be 
detected using the red 650 nm filter. Results are averages of 4 experiments with SE 
(standard error). Rescue of cell death by addition of caspase inhibitor results were 
evaluated using a one-way ANOVA. 
 





 NSC34 cells were cultured to 40% confluency and then were transfected 
using Lipofectamine2000 (Invitrogen). Each transfection mixture contained 100 ng 
of the relative expression plasmid and control samples were pEGFP-C3 and 
pCDNA3.1Tubulin. The caspase inhibitor Z-VAD-FMK (R&D Systems), where 
applied, was 50 μM and added when transfection medium was changed. Twenty-four 
hours after transfection ER stress was induced for 12 h with 2 µg/ml tunicamycin 
(Calbiochem). Cells were then washed with pre-warmed (37
o
C) 1X phosho-buffered 
saline (PBS) and growth medium was replaced. After 12 hours cells were assayed for 
bioluminescence using the CytoTox-GloTM Cytotoxicity Assay (Promega).  
 The CytoTox-GloTM Cytotoxicity Assay (Niles et al., 2007) luminescent assay 
allows measurement of the number of dead cells in cell populations by measuring the 
activity of a protease associated with cytotoxicity. Dead-cell protease activity is 
measured using a luminogenic peptide substrate (alanyl-alanylphenylalanyl-
aminoluciferin; AAF-GloTM Substrate) which has high affinity for the protease 
released from cells that have lost their membrane integrity; conversely the intact 
membrane of live cells cannot be crossed by the AAF-Glo™ Substrate and thus no 
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signal is produced. 
 The AAF-GloTM Substrate was added to live cells and luminescence was 
measured using a FLUOstar OPTIMA micro-plate reader (BMG LABTECH); this 
value corresponds to dead cells. Lysis buffer containing digitonin was then added to 
the cells and luminescence was measured again; this value corresponds to the total 
number of dead cells. Cell death values are normalised to total cell death number and 
are averages of 4 experiments with SE (standard error). Rescue of cell death by 
addition of caspase inhibitor results were evaluated using a one-way ANOVA. 
 
Figure 2.3 Bioluminescence assay based on dead-cell protease activity (image from 
Promega technical manual). 
Proprietary luminogenic AAF-GloTM peptide substrate picks up released dead cell proteases 
and thus dead cells correspond to an increase in luminescence. 
 
2.4 siRNA knockdown of endogenous proteins – transcription assay 
 
 106 HEK293 cells were nucleofected with 20 pMoles of VAPB 
siRNA(Appendix I, #P22, #P23, 10 pMoles each, Qiagen) or a control GFP-siRNA 
(Dharmacon) using the Amaxa Biosystems nucleofector. Twenty-four hours after 
nucleofection, cells were transfected with p5xATF6-GL3 or pGL3-XBP1(-330)-luc 
or pGL3-GRP78(-132)-luc and pTK-RL as described above. After a further 24 h, 
cells were treated with 2 µg/ml Tunicamycin (Calbiochem) for 12 h and then assayed 
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for luciferase activity as above. Where specified, siRNA knockdown was performed 
using Lipofectamine2000 instead of nucleofection, using the same amount of siRNA. 
 
2.5 Cell Lines and Primary Neuron Culture Experiments 
 
2.5.1 HEK293, NSC34, C6 Culture 
  
 HEK293, NSC34 or C6 cells were maintained in DMEM (Gibco) 
supplemented with 10% FBS (Foetal Bovine Serum) and 1% penicillin/streptomycin 
(Invitrogen) at 37
o
C in 5% CO2 in a Galaxy R (Scientific Instruments Ltd) CO2 
incubator. Early passage cell stocks were maintained in liquid nitrogen storage and 
cells that were used in experiments were not passaged more than 20 times. 
 
2.5.2 Dissection and preparation of rat E18 primary cortical cultures and glial 
cultures 
 
Cortices from E18 Sprague-Dawley rat embryos were dissected and 
transferred intact to a 35mm dish containing 2ml of Hank’s/Hepes Solution on ice. 
200 l of Trypsin and 20 l of DNAse solution were then added and the dish was 
placed in a Galaxy R (Scientific Instruments Ltd) CO2 incubator (37
o
C in 5% CO2) 
for 20 minutes.  After 20 minutes growth medium was added to the dish to stop 
trypsinisation.  The contents of the dish were then transferred to a tube and made up 
to 10 ml by adding growth medium. Cells were washed twice, each time allowing 
cortices to settle down. Cells were then centrifuged at 800rpm for 2min and the 
supernatant was removed. After adding 2ml of growth medium and 20 l of DNAse, 
cells were then triturated using a fire polished Pasteur pipette. Finally, cells were 
counted using a haemocytometer (100.000 to 800.000 cells per well) and plated in 
poly-D-lysine coated plates or glass coverslips. The next day plating medium was 
removed, cells were washed with 1X PBS and fresh growth medium was added (see 
Appendix II, Figure 5).  
For glial cultures, dissociated cells were plated in DMEM (Gibco) 












































Figure 2.4 Dissociated primary cortical neuron and neuron-depleted glia cultures.  
 
A. Representative images from DIV2 dissociated primary cortical Sprague-Dawley 
rat embryos neuron cultures. Cells are stained with DAPI using VECTASHIELD 
DAPI containing mounting medium (VECTORLABS). DAPI is indicative of the 
viability of neurons in culture. Serum-free medium inhibits glial growth. 
 
B. Representative images from dissociated DIV8 Sprague-Dawley cortical rat 
embryos neurons after 24 hours of treatment with NMDA (SIGMA) 1mM. Neurons 
are dying (indicated with white arrows), while glial cells are rapidly growing in the 




 NMDA  (SIGMA) 1mM was added for 24 hours to kill all neurons and then washed 
with pre-warmed 1X PBS and replaced with growth medium supplemented with 10% 
FBS. Cultures are washed several times in the following days and finally glia are 
trypsinised at DIV9 and replated. 
 Growth medium for 500 ml- (500 ml BME(Basal Medium, GIBCO), 5 ml 
Penicillin-Streptomycin(invitrogen), 8 ml of a 32.5% Glucose solution (in water, 
sterile, SIGMA), 5 ml Sodium Pyruvate 100 mM (Invitrogen), 5 ml N2 
supplement(GIBCO) and 10 ml B27 supplement (GIBCO)). 
 Hanks/Hepes solution – HBSS (Hepes buffered Calcium and Magnesium free Earls BSS 
pH 7.3) 500ml + 1.19g Hepes (PH to 7.3 and Filtered). 





 free PBS 
 DNAse solution - 5mg DNAse (SIGMA) dissolved in 1ml of PBS. 
 
2.5.3 Lipofectamine2000 Transfection Of Mammalian Cell Lines or Glial Cells 
 
 Cells were cultured to 40% confluency. Two hours prior to transfection, 
growth medium was replaced with antibiotic free medium (no 
penicillin/streptomycin). The DNA and lipofectamine complex was prepared in Opti-
MEM® I Reduced Serum Medium (GIBCO) and added to cells. After 2 hours cells 
were washed in 1X PBS and the transfection complex was replaced with growth 
medium plus antibiotics. 
 
2.5.4 Nucleofection Of Mammalian Cell Lines or Primary Cortical Neurons 




 The required number of cells was cultured to 90% and harvested by 
trypsinisation. An aliquot of the trypsinised cells was taken and the cells were 
counted using a haemocytometer to determine cell density (for neurons cells were 
not trypsinised, but used immediately after dissection and dissociation). 10
6
 cells per 
nucleofection sample were centrifuged at 800xg for 2 minutes.  The supernatant was 
discarded and the pellet was resuspended in 100 μl of prewarmed at room 
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temperature Nucleofector solution V. The relative amount of DNA was added to each 
nucleofection reaction, gently mixed using the pippette tip and finally transferred to 
an electroporation cuvette, placed into the Nucleofector and electroporated using the 
appropriate program. Then 500μl of culture medium was added to the cuvette and 
cells were plated to the desired density in the appropriate culture vessels. 
 
2.5.5 Cell Imaging and Immunofluorescence 
 
 Live cells were imaged in 6 or 12 well poly-L-Lysine coated plastic plates. 
An Olympus IX70 fluorescence microscope using Openlab software (Improvision); 
images were prepared using ImageJ. 
 For immunofluorescence cells cultured on poly-D-lysine coated cover slips 
were fixed in 3% paraformaldehyde, 0.03% glutaraldehyde (w/v) in PBS, at room 
temperature for 20 min. Fixative was quenched and cells permeablized with a 
solution of 50 mM NH4Cl, 0.2% (w/v)
 Saponin (Sigma), for 15 min at room 
temperature. Cells were then washed once in PGAS (0.2% (w/v) fish skin gelatin 
(Sigma G-7765), 0.02% saponin, in PBS) and incubated in PGAS for 5 mins at room 
temperature. Antibodies were diluted in PGAS solution. Primary antibody was added 
to the coverslip which was incubated in a humidified chamber for 1 hour.  The 
coverslip was then washed 3 times in PGAS and then the secondary antibody was 
added and incubated in a humidified chamber for 1 hour. Finally the coverslip was 
washed in PGAS and then was washed 3 times in PBS. Inverted cover slips were 
mounted in Mowoil, and examined on a Zeiss Imager Z1 microscope fitted with a 
LSM 510 Meta confocal excitation/acquisition system. 
 
2.5.6 Subcellular Fractionation 
 
 Cells were then homogenised in ice-cold 20mM Hepes (pH7.4), 320mM 
sucrose plus COMPLETE protease inhibitors (Boeringer).  The homogenate was 
centrifuged at 1500 rpm for 10 min at 4
o
C in a benchtop cooled centrifuge.  The 
supernatant was decanted into another tube leaving the P1 pellet.  The supernatant or 
post nuclear fraction was centrifuged for a further 30 min at 20000 rpm to produce 
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the P2 and S2 layers. Samples were either frozen at -20 
o
C or immediately used. 
 
2.6 Triton X114 (Bordier, 1981) Extraction 
 
 This method is a detergent (Triton X114) extraction of membrane proteins. 
The P2 layer was resuspended in resuspension buffer (10mM Hepes pH 8.0 with 
KOH, 400mM KCl, 1.0% Triton X114 (BDH)) and incubated for 10 min on ice (or 
until cleared).  The resuspended P2 was layered on to 300 l of sucrose cushion (6% 
(w/v) Sucrose, 10 mM Hepes pH 8.0, 400 mM KCl, 0.06% Triton X114 (BDH)) and 
then incubated at 30
o
C for 3 min.  This was then centrifuged at 300g for 3 min.  The 
upper aqueous layer was removed and kept.  150 l of 10% Triton X114 was 
centrifuged at 14000 rpm in a bench top centrifuge to remove the remaining 
detergent phase.  
 
2.7 DNA Preparation, PCR, Cloning 
 
2.7.1 Mini-Prep of Bacterial DNA (Qiagen) 
 
 A single bacterial colony was picked and incubated in 2ml Luria-Bertani (LB) 
medium at 37
o
C in a rotary shaker-incubator for 16 hours.  1.5ml of the bacterial 
culture was pipetted into an eppendorf tube and centrifuged at 14K rpm in a tabletop 
microfuge.  The supernatant was discarded and the pellet was resuspended in 250 l 
of buffer P1 containing RNase A to remove RNA contamination produced by 
bacterial lysis.  The bacterial cells were then lysed in 250 l NaOH/SDS (buffer P2) 
for 5min.  350 l of buffer N3 were added to neutralize the reaction; buffer N3 
replaces NaOH/SDS with KOH/SDS and bacterial chromosomal DNA and proteins 
precipitate out of solution, while plasmid DNA stays in solution.  The suspension 
was then centrifuged at 14K rpm for 10 min.  The supernatant was carefully pipetted 
to a Qiaprep column and passed through using a vacuum manifold.  0.5ml of buffer 
PB followed by 0.75ml of buffer PE were added to the column and washed through.  
The column was then centrifuged for 1min at 14K rpm to remove residual PE.  
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Finally, 50 l of buffer EB was added to the column. After incubation at room 
temperature for 1min, samples were centrifuged for 1min at 14K rpm to elute the 
DNA. 
 
2.7.2 Transformation of Chemically Competent Bacteria 
 
 One 50 µl vial of TOP10 One Shot® cells (Invitrogen) or DH5α (NEB) for 
each transformation was thawed on ice.  1 l of DNA or ligation mix was added to 
the cells and after mixing gently using the pipette tip, the vial was incubated on ice 
for 30min.  Bacteria were heat-shocked at 42
o
C in a pre-heated water bath for 30s 
and placed immediately back on ice. After 2 minutes, 250 l of prewarmed SOC 
medium was added  and cells were incubated at 37
o
C for one hour in a rotary shaker-
incubator.  A fifth of the total volume was spread on the relative antibiotic selection 
LB agar plates. 
 
2.7.3 Gel Electrophoresis of DNA 
  
 Gels were made from 0.8-1.0% agarose melted in 1x TAE buffer (40mM Tris-
HCl, pH7.8; 20mM sodium acetate; 1mM EDTA, pH8.0) containing 0.5µg/ml 
ethidium bromide solution.  The melted agarose was cast in a horizontal gel tray after 
cooling to 60°C with a suitably positioned comb to form slots in the gel.  The gel, 
once solidified, was submerged in 1x TAE buffer.  DNA solutions (0.1µg-10µg) were 
resuspended in loading buffer (0.25% w/v bromophenol blue; 100mM EDTA; 30% 
glycerol) and loaded into the wells of the gel.  The samples were electrophoresed at 
65V in parallel with double-stranded DNA size markers.DNA was visualised under 
an ultra violet light visualizer.    
 
2.7.4 Gel Extraction of DNA (QIAGEN) 
 
 Bands were carefully excised from the agarose gel using a clean scalpel under 
a UV (long wave) light visualizer. Three volumes of buffer QXI were added to the 
weighed excised band.  The Qiaex II was vortexed for 30s and then 10 l were added.  
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The mixture was then incubated at 50
o
C for 10min and vortexed every 2min.  The 
solution was then centrifuged at full speed in a tabletop microfuge for 30s and the 
supernatant discarded.  The pellet was washed twice in 500 l of buffer QXI and then 
washed twice in 500 l of solution PE (70% ethanol).  The pellet was air dried for 10-
15min and then resuspended in 20 l of dH2O. 
 
2.7.5 Digestion of DNA with Restriction Endonucleases 
 
 DNA was digested with restriction enzymes using the manufacturer's 
recommended 10x restriction buffers and digestion temperatures (New England 
Biolabs).  Plasmid DNA was digested for 1 hour and 30 mins at 37°C in a total 
volume of 10µl or 15 μl of 1x restriction buffer using between 5-10 units of 
restriction endonuclease, such that the volume of restriction enzyme did not exceed 
one tenth of the reaction volume.   
  
2.7.6 Polymerase Chain Reaction (PCR) 
 
 The standard PCR conditions described by Ashworth (1993) were used.  Each 
50µl reaction contained the following components:   
 5µl of 10x PCR buffer (150mM Tris-HCl pH 8.8, 600mM KCl, 22.5mM,  
 MgCl2),  
 1.25µl of 10mM dNTPs,  
 1µl (10pmol) of each of two primers,  
 1Unit of PFU DNA polymerase  
 Water and 50ng template DNA to a total volume of 50µl.   
  
 The PCRs were carried out on a programmable thermocycler (ABI9700). 
Generally, the samples underwent 25 cycles of: 
 (a) denaturation at 94°C for 0.5 min. 
 (b) annealing at 50-55°C for 0.5 min. 
 (c) extension at 72°C for 1 min. 
 followed by 5 min. at 72°C (poly-A extension using Taq polymerase). 
  
In most cases the products of the PCR reaction were treated with restriction enzymes 
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and ligated into the relative plasmid vectors. These vector constructs were then 
introduced into chemically competent bacteria. 
 
2.7.7 Spectrophotometric Quantitation of Nucleic acids  
  
 Nucleic acid concentrations were determined by measuring the UV 
absorbance at 260nm of diluted samples (Beckman DU-7 spectrophotometer).  
Assuming the molecular weight of a nucleotide pair is 660 Daltons, an OD260 
absorbance of 1 is equivalent to 50µg/ml for double stranded DNA, 40µg/ml for 
RNA and 33µg/ml for 20mer oligonucleotides. 
 
2.7.8 DNA Sequencing 
 All samples were sequenced using the DNA sequencing service MWG 
Biotech AG. 
 




 Samples in 1X SDS loading buffer were run on a 10% or 4-20% SDS gel at 
125V in 1X Tris-Glycine running buffer.  They were then transferred to a PVDF 
(Millipore or Hybond-P from Amersham) membrane in 1X CAPS buffer at 25V for 
16 hours.  The PVDF membrane was then incubated in 5% non-fat milk for 1hr at 
room temperature. The relative primary antibody was added at 1:5000 dilution for 
1hr.  The membrane was washed twice in PBS plus 0.1% Tween20 for 5 minutes and 
then incubated for 1hr in the appropriate secondary at 1:10:000 dilution.  The blot 
was then washed three times in PBS plus 0.1% Tween20 for 10 minutes.  ECL 
detection reagent was added to the blot, which was then exposed on Kodak film and 
analysed. 
 
All chemicals purchased from SIGMA unless otherwise stated: 
SDS loading Buffer (2X) – 80mM Tris (pH 6.9), 2% SDS (Bio-Rad), 100mM DTT, 10% Glycerol 
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(Bio-Rad), 0.004% bromophenol blue 
10% Resolving Gel – 2.5ml acrylamide (Bio-Rad), 2.5ml resolving buffer (pH 8.8), 4.8ml dH2O, 
200 l 10% APS (Bio-Rad), 5 l Temed (Bio-Rad) 
Stacking Gel – 0.5ml acrylamide (Bio-Rad), 1.3ml stacking buffer (pH 6.8), 3.2ml dH2O, 40 l 10% 
APS (Bio-Rad), 5 l Temed (Bio-Rad) 
Tris-Glycine Running buffer (10X) – 30g Trizma, 140g Glycine, 50ml 20% SDS (Bio-Rad), dH2O 
to 1litre 
CAPS transfer Buffer (50X) – 0.5M CAPS (pH 11.5) 
 
 
2.8.2 Protein Quantification 
  
 Images of the immunoblot film were taken at 30 seconds, 90 seconds and 5 
minutes. Band intensities were calculated using Image J (Collins, 2007). Where error 
bars are shown they are averages of all relative experiments with standard error. 
 
2.8.3 BCA (bicinchoninic acid-containing protein assay) Protein Assay 
(PIERCE) 
 





by protein in an alkaline medium with the highly sensitive and selective colorimetric 
detection of the cuprous cation (Cu
1+
) by bicinchoninic acid. The assay was 

















anti-VAPA mouse as described in (Skehel et al., 2000) 
anti-VAPB mouse sheep  raised multi antigenic peptide (MAP) 
form of a peptide corresponding to amino 
acids 174–189 of mouse VAPB 
(AltaBioscience) 
anti c-myc mouse monoclonal, 9E-10 epitope (SIGMA) 
anti-FLAG mouse monoclonal (SIGMA) 
donkey anti-Sheep Cy2 (Jackson Laboratories) 
donkey anti-Rabbit Cy3 (Jackson Laboratories) 
anti-p38 rabbit polyclonal (Abcam) 
anti-ATF6α rabbit polyclonal (Santa Cruz 
Biotechnology) 
anti-ATF6α mouse monoclonal (IMGENEX) 
anti-GFP rabbit polyclonal (Molecular Probes) 
 
 
2.10 Statistical Analysis 
 
 Both luciferase and cell viability assays had an n=4 and results were analysed 
using a one-way ANOVA (ANalysis Of VAriance) statistical test; moreover each n 
contains duplicate samples. P-values and statistical significance are mentioned in the 


















  Chapter 3 






ATF6α is one of a family of transmembrane transcription factors (Bailey and 
O'Hare, 2007). There are two mammalian genes, ATF6 and CREBL1(G13) encoding 
ATF6α and ATF6β proteins respectively (Yoshida et al., 2000). ATF6α functions in a 
regulated transcription pathway involved
 
in ER homeostasis and response to stress 
known as the Unfolded
 
Protein Response (UPR). ATF6β is a poor transcriptional 
activator of the UPR (Haze et al., 2001, Thuerauf et al., 2004). All experiments 
described here are based on ATF6α and hence forth wherever ATF6 is mentioned it 
corresponds to ATF6α protein encoded by the ATF6 gene. Upon accumulation of 
unfolded
 
proteins in the lumen of the ER, ATF6α translocates from the
 
ER to the 
Golgi and is proteolyzed in turn by S1P and S2P. This results in the release of the 
DNA binding and transcription
 
trans-activation domain of ATF6α from the ER 
membrane allowing
 
it to enter the nucleus and activate transcription (Figure 3.1). 
ATF6α appears to interact with several promoter elements. A synthetic 
promoter has been generated that acts as an ATF6/XBP1 dependent transcription 
reporter (Wang et al., 2000). The luciferase gene in the p5xATF6-GL3 reporter is 
under the control of a synthetic promoter containing the c-fos minimal promoter and 
5 tandem copies of the ATF6α consensus binding site identified by in vitro gel 
mobility shift assays with recombinant ATF6α; DNA oligonucleotides binding to 
ATF6α were selected from a pool of oligonucleotides (Shen et al., 2005). However it 
was shown that the UPR associated transcription factor XBP1 can bind to the same 
ATF6α sites with high affinity (Yoshida et al., 2001). Moreover, Yamamoto et al., 
2007 showed that ATF6α forms heterodimers with XBP1. Studies with knockdown 
of endogenous ATF6α with siRNA have shown that the p5xGL3ATF6 is responsive 
to changes in ATF6α levels (Lee et al., 2003). Thus, the p5xGL3ATF6α reporter 


























Figure 3.1 ATF6a transcription factor participating in the Unfolded Protein 
Response (from (Wang et al., 2000)) 
 
ATF6α upon UPR activation follows the path ER→the Golgi→Nucleus. The Golgi-
localization sequence (GLS) upon ER stress is unmasked by dissociation of BiP and 
ATF6α is transported to the Golgi. ATF6α is cleaved by S1P, S2P shuttled to the 
nucleus were it acts on ERSE promoters via NF-Y (a CCAAT box binding factor). 
The right side of the figure corresponds to ER stressed cells. 
 
MSP and ATF6α 
  It was previously shown ((Middleton, 2005) and Skehel unpublished) that 
overexpression of  the MSP domains of VAPA or VAPB as EGFP fusion proteins is 
toxic to HEK293 cells and primary rat hippocampal cultured neurons; moreover they 
form large cytoplasmic aggregates. Therefore, in order to elucidate the MSP domain 
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overexpression associated toxicity and discover proteins that might interact with the 
MSP domain a yeast two hybrid screen was performed using as bait the VAPA MSP 
domain. A sequence corresponding to amino acids 1-107 of mouse VAPA (MSP) was 
used to screen a rat brain cDNA library in a yeast two hybrid screen (Middleton, 
2005). A partial clone of ATF6α was found as an interacting partner. 
 
VAPB domains 
 In Chapter 1- Introduction we have described the three structural domains of 
VAP proteins and their participation in various protein-protein interactions (Table 1.1 
and text). In Figure 3.2 we depict EGFP mouse VAPB (and ALS8 associated 
VAPB
P56S
) full length and truncation constructs described in Middleton, 2005 that 
were used for the purposes of our study. These constructs are all mouse N-terminal 
EGFP fusion proteins: 
 
 Full length mVAPB 
 Full length mVAPBP56S (proline 56 substituted for a serine) 
 ΔHB (containing the MSP domain and Coiled Coil domains; lacking the 
hydrophobic C-terminal membrane anchor) 
 ΔHBP56S (containing the MSP domain and Coiled Coil domains; lacking the 
hydrophobic C-terminal membrane anchor – proline 56 substituted for a serine) 
 MSPB (containing the MSP domain; lacking the Coiled Coil and hydrophobic 
C-terminal membrane anchor) 
 MSPBP56S (containing the MSP domain; lacking the Coiled Coil and 
hydrophobic C-terminal membrane anchor – proline 56 substituted for a serine) 
 CC/CTB (containing the Coiled Coil and hydrophobic C-terminal membrane 
anchor; lacking the MSP domain) 
 CCB (containing the Coiled Coil; lacking the hydrophobic C-terminal membrane 
anchor and the MSP domain) 
 CTB (containing the hydrophobic C-terminal membrane anchor; lacking the 
Coiled Coil and the MSP domain) 
  
 In this chapter we will explore the reported VAP-ATF6α interaction.
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Full length mVAPB 














 interact with 
ATF6α in a peptide complementation assay. 
 
 ATF6α was identified in a yeast-two-hybrid screen as a positive interactor of 
the VAPA MSP domain (Middleton, 2005); a sequence corresponding to amino acids 
1–107 of mouse
 
VAPA was used to screen a rat brain cDNA library. In addition
 
to a 
number of FFAT- and MSP domain-containing proteins, a partial
 
clone of the ER 
stress regulated transcription factor ATF6α was
 
identified. Yeast-two-hybrid assays 
are powerful tools for discovering novel protein-protein interactions, but positive 
results should be validated with additional experiments. To characterize this 
interaction further, expression constructs
 
for full-length VAPA, VAPB and ATF6α 
were analysed by a fluorescent
 
peptide complementation assay (Remy et al., 2002, 
Remy and Michnick, 2007). In this assay,
 
a fluorescent protein is generated from two 
separate parts of
 
a split GFP, termed Venus1 and Venus2, only by the association
 
of 
two test polypeptides expressed as fusion proteins. A functional
 
fluorescent protein is 
generated when the two test proteins
 
directly interact. Although the initial yeast two-
hybrid interaction
 
was between a truncated form of ATF6α and the MSP domain of 
VAPA,
 
an interaction between full-length forms of VAPA and VAPB with
 
ATF6α was 





was shown to be capable of interacting with
 
ATF6α. No interaction was detected 
between VAPA, VAPB
 
or ATF6α when co-expressed with heterologous leucine 
zipper-Venus
 
fusions. The reconstitution of a fluorescent protein clearly
 
indicates that 
VAPA and VAPB are capable of interacting with
 
ATF6α. Similar results were also 
obtained with the converse Venus
 
combinations, where ATF6α was expressed as a 
fusion with Venus
 

















Figure 3.3.1 Fluorescent Protein Fragment Complementation Assay. 
 
A. VAPA, VAPB and VAPB
P56S
 interact with ATF6α in HEK293 cells in a 
Fluorescent Protein Complementation Assay. The coding sequences of mouse VAPA, 
VAPB and VAPB
P56S
 were expressed in HEK293 cells as fusion proteins with a 
truncated non-fluorescent form of YFP, Venus 1. These proteins were co-expressed 
with the complementary ATF6α-Venus 2 fusion protein. Fluorescence indicates 
reconstitution of a functional YFP and therefore a direct interaction of VAPA and 
VAPB with ATF6α. Wild-type VAPB and mutant VAPB
P56S
 are capable of interacting 
with ATF6α. Controls in which a homodimerizing leucine zipper peptide was 
expressed as either a Venus 1 or Venus 2 fusion proteins show no fluorescence when 
expressed with the complementary VAP or ATF6α fusion proteins. Bright field or 
fluorescence images were acquired from live cells through cell culture plastic. 
 
B. Schematic representation of a Fluorescent Protein Complementation Assay in 
HEK293 cells (see 2.1 Materials and Methods). An interaction between two proteins 
X and Y can be detected in HEK293 cells when fusion proteins fused to truncated 
forms of YFP (two subunits of YFP) are co-expressed. YFP reconstitution is 
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Figure 3.3.2 VAPA, VAPB and VAPB
P56S
 interact with ATF6α in HEK293 cells in 
a Fluorescent Protein Complementation Assay using converse Venus combinations 
from 3.3.1.  
 
The coding sequences of mouse VAPA, VAPB and VAPB
P56S
 were expressed in 
HEK293 cells as fusion proteins with a truncated non-fluorescent form of YFP, 
Venus 2. These proteins were co-expressed with the complementary ATF6α-Venus 1 
fusion protein. Fluorescence indicates reconstitution of a functional YFP and 
therefore a direct interaction of VAPA and VAPB with ATF6α. Wild-type VAPB and 
mutant VAPB
P56S
 are capable of interacting with ATF6α. Controls in which a 
homodimerizing leucine zipper peptide was expressed as a Venus 1 fusion protein 
show no fluorescence when expressed with the complementary VAP or ATF6α fusion 
proteins (also see Figure 3.3.1). 
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3.3 Co-localisation of mVAPB or mVAPB
P56S
 and ATF6α 
 
Fluorescence analysis of HEK293 cells expressing EGFP-VAPB and
 
FLAG-tagged 
ATF6α shows extensive regions of co-localization
 
on the ER, but also some 
complementary distribution (Figure 3.6).
 
The aggregates of EGFP-VAPB
P56S
 show 
some but not extensive
 
co-localization with ATF6α, although we cannot discount that
 





aggregates. Expression of VAPB
P56S
 does not appear
 
to cause gross disruption of 


















Figure 3.3 Co-localization of VAPB and ATF6α. 
 
HEK293 cells were transfected with FLAG-ATF6, EGFP-VAPB and EGFP-
VAPB
P56S
. In colour plates, FLAG-ATF6 is shown in red and EGFP-VAPB or EGFP-
VAPB
P56S
 is in green. There is extensive, but not total co-localization of VAPB and 
ATF6α in a reticular distribution. ATF6α co-localizes with the aggregates formed by 
VAPB
P56S
, but not in a punctate pattern. Note that VAPB
P56S
 does not cause a gross 
change in the distribution of ATF6α. 
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ATF6α appears to interact with several promoter elements (Hai et al., 1989, 
Wang et al., 2000, Yoshida et al., 2000).
 
A synthetic promoter has been generated 
that acts as an ATF6/XBP1
 
dependent transcription reporter (Wang et al., 2000). To 
determine if the interaction
 
with VAPB affects the ability of ATF6α to activate 
transcription,
 
luciferase-based transient transcription assays were done using
 
this 
ATF6/XBP1-dependent reporter of transcription (Appendix I, #P18). In
 
HEK293 
cells, basal levels of transcription from this promoter
 
are reduced by over-expression 




 (Figure 3.4.1A). When the UPR was 
activated by the glycosylation inhibitor, tunicamycin, ATF6/XBP1-mediated 
transcription was also significantly
 





Increasing levels of ATF6α by co-expression of a FLAG-tagged
 
recombinant 
form of human ATF6α (Appendix I, #P17) increased basal and tunicamycin-induced
 
expression from the ATF6αXBP1 reporter. In both cases, the elevated
 
levels of 
ATF6/XBP1 dependent transcription were also reduced
 
by over expression of either 
VAPB or VAPB
P56S
 (Figure 3.4.1B and C). This
 
effect requires the cytoplasmic 
domains of VAPB and does not
 
appear to be a non-specific consequence of 
increasing levels
 
of protein in the ER membrane since over expression of a DsRed
 
fluorescent fusion protein of the C-terminal hydrophobic domain
 
of VAPB does not 
reduce the basal or tunicamycin-induced expression
 
from the ATF6/XBP1 reporter 
(Figure 3.4.1A and Figure 3.4.2).
 
Over expression of VAP proteins does not reduce 
expression levels
 
of luciferase directed from a CMV promoter; therefore, the 
repressive
 
effect on the ATF6/XBP1 reporter is unlikely to be the result
 
of a general 
repression of transcription (Figure 3.4.3). A similar inhibitory effect was also seen in 
the motor neuron
 
derived cell line NSC34 (Figure 3.4.1C and D). In NSC34 cells, 
basal
 
levels of expression from the ATF6/XBP1 reporter are less than
 
in HEK293, 
perhaps indicating lower levels of endogenous ATF6α. Finally, the p5xGL3-ATF6 






















Figure 3.4.1 VAPB and VAPB
P56S
 inhibit transcription from an ATF6 regulated 
transcription reporter. 
  
A. HEK293 were transfected with a reporter plasmid containing the luciferase cDNA 
regulated by five ATF6/XBP1 binding sites, pGL3(5X)ATF6. Cell cultures were co-
transfected with expression plasmids encoding VAPB or VAPB
P56S
 as myc-tagged 
fusion proteins (VAPB-myc and VAPB
P56S
-myc) or a monomeric red fluorescent 
fusion protein containing the C-terminal 41 amino acids of VAPB (VAPB-Cterm). 
Where indicated cultures were treated for 12 h with 2 µg/ml tunicamycin to induce 
ER stress. VAPB and VAPB
P56S
 reduce constitutive levels of ATF6/XBP1 activity, 
while VAPB-Cterm had no effect (p=0.012932). 
B. Over expression of ATF6α as an ATF6-FLAG fusion protein increased basal and 
tunicamycin-induced activity of the ATF6/XBP1 reporter gene, but in both cases, 




 C and D. The transcriptional assay using the motor neuron-like cell line NSC34 







Figure 3.4.2 ATF6/XBP1-dependent transcription is not affected by over-
expression of an ER membrane protein.  
 
A. A monomeric red fluorescent fusion protein containing the C-terminal 41 amino 
acids of VAPB (VAPB-Cterm) was expressed in HEK293 cells. Fluorescence 
microscopic analysis indicates that the protein is distributed throughout the cell in a 
reticular pattern.  
 
B. Basal or tunicamycin-induced levels of ATF6/XBP1 dependent transcription are 
not affected by expression of VAPB-Cterm. Therefore the observed inhibition 
requires the cytoplasmic domains of VAPB, and is not simply the result of increasing 
levels of protein in the membrane of the ER. Increasing the synthetic load on the 
lumen of the ER by over expression of the integral membrane protein p-selectin 
enhances ATF6/XBP1-dependent transcription, as expected. Results are averages of 








Figure 3.4.3 Overexpression of VAPB does not affect the activity of a CMV 
promoter.  
 
HEK293 cells were transfected with a plasmid (pCMV-GL3-luc, PROMEGA) in 
which the expression of luciferase was under the control of a CMV 
(CytoMegaloVirus) promoter. Co-expression of VAPB-myc or VAPB
P56S
-myc had 
no affect on the level of luciferase expression. All transcription assays are normalised 
to the expression levels of a co-expressed renilla luciferase gene. Results are 
averages of four experiments and error bars correspond to standard error (SE), 
p=0.012927. Therefore, the inhibitory affect of VAPB and VAPB
P56S
 on 



























Figure 3.4.4 The ATF6 synthetic reporter is responsive to ATF6 siRNA.  
When HEK293 cells were transfected with GFP siRNA, there is no effect to the 
relative luciferase activity as measured by Firefly luciferase light units normalised to 
the renillin control. When the ATF6α siRNA (20 pmoles) (QIAGEN Hs_ATF6_5 HP 
Validated siRNA ( SI03019205 )) is applied, there is a reduction in relative luciferase 
activity in tunicamycin induced and baseline samples. Although we could not get a 
representative immunoblot to associate this observation with actual protein levels 
(the endogenous ATF6α antibodies used did not produce a signal when analysed in 
western blots; 2 different antibodies were used, see materials and methods chapter) 
this suggests that the reporter based on the synthetic ATF6α promoter is responsive 
to reduction of endogenous ATF6α. 
 

























3.5 VAPB siRNA reduces the levels of endogenous VAPB and 
increases basal ATF6/XBP1-dependent transcription 
 
Consistent with the inhibitory affect seen by over expression
 
of VAPB, 
siRNA-mediated reduction of endogenous VAPB results
 
in an increase of basal 
(60%) and induced levels (30%) of ATF6/XBP1-dependent
 
transcription (Figure 3.5). 
HEK293 cells were nucleofected with siRNA to endogenous hVAPB, washed and 
cultured for 24 hours. Then cells were transfected using Lipofectamine2000 with the 
ATF6 reporter, and cultured for 24 hours before being treated with 2 µg/ml 
tunicamycin. GFP siRNA was used as a control. This experiment was also repeated 




 accumulates to lower levels than mVAPB and 
therefore may be a stronger inhibitor of ATF6α 
 
When equal amounts of expression plasmid DNA for VAPB and VAPB
P56S 
were used for cell-transfections, the overall level of attenuation
 
was similar between 
the wild type and mutant forms of VAPB (Figure 3.4.1). Immunoblot analysis of total 
protein from transfected cells,
 





to significantly lower levels, reaching only 20% of the level
 
of 




may exert a 
stronger inhibition on ATF6α than the wild-type VAPB-myc,
 
since a similar level of 
inhibition is achieved from a lower
 
amount of protein. The difference in protein 
levels is less
 
pronounced when VAPB and VAPB
P56S
 are expressed as EGFP fusion
 
proteins, which indicates that the presence of the
 





with this, the inhibition of ATF6/XBP1-dependent 
transcription
 
is more pronounced for VAPB
P56S
-GFP than VAPB-GFP (Figure 
3.6.1B).
 
Moreover, increasing amounts of VAPB and VAPB
P56S
 DNA have a stronger 
inhibitory effect, while the mutant still accumulates to lower levels (Figure 3.6.2). 
Thus, VAPB
P56S
 appears to have a significantly greater inhibitory
 
effect on ATF6α 
















Figure 3.5 VAPB siRNA reduces the levels of endogenous VAPB and increases 
basal ATF6/XBP1-dependent transcription. 
 
A. Transcriptional Assay in HEK293 cells nucleofected with siRNA to VAPB. 
Reduction of endogenous VAPB expression levels increases basal and tunicamycin-
induced, transcription from an ATF6/XBP1-regulated transcription promoter n=4, 
p=0.025817. 
 
B. Immunoblot analysis of HEK293 cells nucleofected with VAPB siRNA or GFP 
siRNA and non-transfected cells shows a 25% reduction in levels of endogenous 
VAPB when treated with VAPB siRNA and no reduction in GFP siRNA treated cells. 
*A 60 kDa non-specific band from longer exposures of the immunoblot serves as a 





















 accumulates to lower levels than VAPB. 
 
A. Immunoblot analysis of HEK293 cells expressing myc or GFP-tagged forms of 
VAPB and VAPB
P56S
. Duplicate samples are shown, and relative levels expressed as 
a histogram of signal intensities. As both myc and GFP fusion proteins, VAPB
P56S
 
accumulates to lower levels than VAPB. VAPB
P56S
-myc is 15% the level of VAPB-
myc, and VAPB
P56S
-GFP is 50% the level of VAPB-GFP. The GFP moiety appears 
to have a stabilizing affect on the levels of mutant protein, allowing it to accumulate 
to higher levels than the myc-tagged form. Band intensities were determined using 
ImageJ (NIH) Intensities for both myc and GFP, VAPB and VAPB
P56S
 were 
normalized to the p38 loading control; error bars correspond to standard error (SE). 
 
B. Consistent with this the inhibition of ATF6-dependent reporter gene expression is 




-myc; results are 

































































































Figure 3.6.2 Inhibition of ATF6 activation by increasing amounts of VAPB and 
VAPB
P56S
 DNA.  
 
A. Transcriptional assay in HEK293 cells overexpressing myc-VAPB or myc-
VAPB
P56S
. Total amount of DNA is balanced with pEGFP-C3. Increasing DNA 
amounts of the VAP proteins cause greater inhibition of the ATF6α reporter. The 
concentration used in our assays is 100 ng – It is clear that the inhibitory effect is still 
present at low (25 ng) or high concentrations (400 ng). 
 
B. Immunoblot of representative samples from the titration of DNA amounts assay. 
VAPB
P56S
 always accumulates to lower amounts than wild-type VAPB. 30 μg of 
total protein were loaded using a micro-BCA assay (PIERCE). 
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3.7 Effect of overexpression of mVAPB and mVAPB
P56S
 truncations 
on ATF6α reporter transcriptional activation 
  
ATF6α was identified as a positive interactor of the VAPA MSP domain 
(Middleton, 2005). In addition to this we have shown that full length VAP proteins 
and the P56S mutant interact with ATF6α. VAP proteins have three major structural 
domains (MSP, CC, CT – see Figure 1.2) and we proceeded to examine their effect 
on ATF6α activation by overxpressing various EGFP truncations of VAP proteins. 
HEK293 or NSC34 cells were transfected with all the mouse VAPB and VAPB
P56S
 
EGFP constructs and truncations along with the ATF6α reporter and the internal 
renillin control (Figure 3.7). Results are consistent in the two different cell-lines 
examined. Tunicamycin treatment induces the ATF6α reporter by 6-fold. Although 
basal levels of transcription do not seem to be affected, there is inhibition of the 
activity of the synthetic ATF6α promoter when cells are induced with tunicamycin. 
This inhibition is true for VAPB (40%), VAPB
P56S
 (45%), MSPB (65%), MSPB
P56S
 
(35%), ΔHB (45%) and ΔHB
P56S
 (49%), CC/CTB (40%), CCB (38%) but not for the 
CTB construct. Therefore, the Coiled-Coil domain of VAPB affects ATF6α synthetic 
promoter dependent transcription. MSPB
P56S
 inhibits less that wild-type MSPB, 
which is the strongest inhibitor out of all domains; consistent with Figure 3.4.1A, the 
C-terminal construct had no effect on ATF6α activity. 
 
3.8 VAPB overexpression blocks glycosylation associated activation 
of expressed ATF6α 
   
 The luminal domain of ATF6α contains two highly conserved cysteines that 
form a disulfide bond that holds together dimmers of ATF6α. When the reducing 
agent dithiothreitol or the N-glycosylation inhibitor tunicamycin are added ATF6α is 
reduced and the extent of reduction correlates with its activation (Nadanaka et al., 
2007). When HEK293 cells were transfected with the FLAG-tagged expression 








































































































Figure 3.7 Effect of overexpression of mVAPB and mVAPB
P56S
 truncations on 
ATF6α transcriptional activation. 
 







, CC/CTB and CCB but not  the CTB construct 
inhibits activation of ATF6α in tunicamycin treated samples as measured from the 
relative luciferase activity produced by transcriptional activation of the synthetic 
ATF6 promoter. Amongst the different truncations, MSP is the most potent inhibitor, 
while MSP
P56S
 cannot inhibit to the same extent. Results shown are averages of 4 
experiments and error bars correspond to standard error (SE), p=0.031245. 
 
C. Immunoblot of representative samples from the assayed for relative luciferase 
activity HEK293 and NSC34 samples. Relative expression of mVAPB, mVAPB
P56S
 
and truncations EGFP constructs is shown; p38 is used as a loading control. 
Expression is similar for all VAPB truncation and full length constructs for HEK293 





















































































































Figure 3.8 Overexpression of mVAPB inhibits glycosylation associated activation 
of expressed human ATF6α in HEK293 cells 
 
HEK293 cells were transfected with the FLAG-tagged version of human ATF6α and 




 or mCTB. 
Cells were treated with tunicamycin for 12 hours. ATF6α when treated with 
tunicamycin is activated and this activation is correlated with its glycosylated and 
non-glycosylated forms; a doublet is formed after 1 hour of tunicamycin treatment 
(top band corresponds to glycosylated and lower band to non-glycosylated) while 
after 12 hours of treatment the top band of the doublet disappears. Magnification of 
the immunoblot shows the relative bands and the effect of tunicamycin treatment. 
Equal amounts of total protein (15 μg) were loaded in each lane, as determined using 















single band in non-induced cells (equal amounts of total protein were loaded); after 
12 hrs treatment with tunicamycin two bands are detected. At 100 KDa, the top band 
corresponds to the glycosylated form of ATFα, while the lower band is the non-
glycosylated form. Consistent with the pattern of activation of ATF6α, the top band is 
reduced in intensity after 12 hours and this is correlated with ATF6α activation. 
When cells are co-transfected with mVAPB, mVAPB
P56S
, mMSPB or mMSPB
P56S
, 
we do not detect the same pattern as with GFP only. Two bands are now clearly 
visible at 100 KDa and both forms of ATF6α (glycosylated and non-glycosylated) are 
now detected; suggesting a reduced ATF6α activation. This result is consistent with 
the observed inhibition of ATF6α in the transcriptional assay. In addition, in the 
immunoblot a ~60 KDa band is detected. This band is the N-terminal proteolytic 
fragment of ATF6α, which migrates to the nucleus. ATF6α overexpression is known 
to activate promoters of various mammalian ER chaperone genes even in the absence 
of ER stress and induces the formation of the nuclear targeted fragment (Yoshida et 
al., 1998); for endogenous ATF6α, the proteolytic fragment is not formed without 
tunicamycin treatment, while here we can see it forming at basal condition. 
Nevertheless there is a difference at the quantity of the proteolytic fragment between 
wild-type and mutant constructs. Specifically, mVAPB
P56S
, mMSPB and mMSPB
P56S
 
overexpression samples when induced with tunicamycin for 12 hours retain the 
proteolytic fragment; while in CTB and GFP samples the fragment has disappeared. 
After tunicamycin treatment the fragment is reduced and that is basically due to its 
short half-life (Nadanaka et al., 2007, Yoshida et al., 2000); however we should note 
that these results should be verified for the endogenous protein, as expression of 
ATF6α interferes with the autoregulation of the molecule’s activation (Yoshida et al., 
1998). Despite that, this experiment clearly demonstrates that VAPB overexpression 
inhibits the activation of ATF6α as monitored by glycosylation of its luminal domain 







3.9 Overexpression of full length and truncated wild type mVAPB 
but not mVAPB
P56S
can rescue the effects of the siRNA mediated 
reduction of endogenous VAPB on the synthetic ATF6 promoter in 
HEK293 cells  
 
ATF6α reporter transcriptional activation is inhibited by VAPB 
overexpression. All experiments so far were performed in cells where the 
endogenous protein was present while overexpressing the fusion-proteins. VAPB is 
known to form wild-type homodimers and heterodimers with the mutant protein, 
therefore when we express an EGFP VAPB or VAPB
P56S
 fusion protein (or 
truncation) we cannot discount the fact that they might interact with the endogenous 
protein. In this experiment, we used siRNA mediated reduction of endogenous 
hVAPB levels in HEK293 cells. Performing this experiment in HEK293 cells offers 
two advantages; blocking of endogenous VAPB expression with the human specific 
siRNA (Appendix I, #P22, #P23) and simultaneous expression of mouse EGFP 
constructs of VAPB, VAPB
P56S
 and truncations. As it can be seen in Figure 3.7B, 
application of the human specific siRNA does not block expression of VAPB EGFP 
fusion proteins and truncations. This can be explained by the fact that mouse and 
human sequences recognised by the siRNA are different as depicted in Figure 3.8. 
HEK293 cells were transfected with siRNA to endogenous hVAPB or GFP siRNA. 
After 24 hours cells were transfected with the ATF6 reporter and EGFP VAPB and 
VAPB
P56S
 full length proteins and truncations. Cells were cultured for another 24 
hours and then treated with tunicamycin for 12 hours to induce an unfolded protein 







) retain their full inhibitory effect on 
ATF6α when endogenous hVAPB expression is reduced by the siRNA; the relative 
luciferase activity measured is now comparable to the levels of the GFP control 
transfected samples. In contrast, wild type constructs: full length VAPB, MSPB and 
ΔHB constructs, retain their inhibitory effect on ATF6α activation. Moreover, 
Coiled-Coil and C-terminal tail CC/CTB, CCB do not inhibit ATF6α activation, 



















































































































































Figure 3.7 Effect of overexpression of mVAPB and mVAPB
P56S
 truncations on 
ATF6α transcriptional activation, when endogenous hVAPB is blocked by siRNA. 
 
A. HEK293 cells were transfected with siRNA to endogenous VAPB and then with 
the ATF6α reporter along with wild-type mVAPB and mVAPB
P56S
 full length and 
truncations EGFP constructs. P56S mutant constructs are no longer able to suppress 
transcriptional activation of ATF6α, while the wild-type constructs still retain their 
inhibitory effect. This trend is now evident and in baseline (no tunicamycin 
induction) levels of relative luciferase activity. Moreover the Coiled-Coil constructs 
(CC/CT and CCB) that displayed inhibition previously now have lost their repressive 
effect. Results shown are averages of 4 experiments and error bars correspond to 
standard error (SE) ), p=0.031245. 
 
B. Immunoblot of representative samples from the transcriptional assay in siRNA 
VAPB transfected HEK293 cells. This blot demonstrates that mouse constructs are 
not affected by the application of the siRNA and are expressed to similar levels as 
when the siRNA is not present (Figure 3.7C). On this blot some sample duplicates 
have been loaded. There is a discrepancy observed from other transcriptional assay 
immunoblots; the P56S full length now accumulates to similar levels as the wild-
type. 30 μg of total protein were loaded; protein concentration was determined using 
a micro-BCA assay. 
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HUMAN mRNA: accaatagtg tctaagtctc tgagttcttc tttggatgac accgaagtta 
agaaggttat ggaagaatgt 
 





HUMAN mRNA: cgtgtgttga ctgattgacc cagcgctttg gaaataaatg gcagtgcttt 
gttcacttaa agggaccaag 
 




Figure 3.8 mRNA sequences of mouse and human vapB genes. 
 
Mouse and human mRNA sequences of vapB around areas where the two siRNAs 
bind (Appendix I, #P22, #P23). The two areas where the siRNAs bind (denoted by 
arrows) are different between mouse and human; a BLAST search with the 
nucleotides of the siRNAs returns only human vapB sequences and no mouse ones.
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effect. This shows that the previously observed inhibitory effect of P56S and Coiled-
Coil constructs on ATF6α transcriptional activation is dependent on the presence of 
the endogenous VAPB protein; this could be explained by the fact that VAPB 
homodimerizes, and thus P56S and Coiled-Coil expressed constructs can interact 




 VAP proteins are integral membrane proteins that are enriched on the ER 
membrane. Data presented in this chapter support the earlier finding (Middleton, 
2005) that VAPB interacts with the ER stress associated transcription factor ATF6α. 
In addition, VAP proteins modulate the activity of this transcription factor and 
therefore can potentially regulate a cell’s response to stress induced by unfolded or 
misfolded protein accumulation in its Endoplasmic Reticulum (UPR). The ATF6α 
branch of the UPR includes many points of regulation, as ATF6α migrates from ER 
to Golgi, where it is proteolysed and subsequently targeted to the nucleus and 
interacts with ERSE promoter elements (Wang et al., 2000). Thus it can be concluded 
that ATF6α regulation can occur in different subcellular compartments and therefore 
a multitude of genes can be present at a given place. This chapter reports the novel 
interaction of ATF6α with VAP proteins and suggests a direct effect of it in ER stress 
modulation; also, it proposes a different regulation by the ALS8 associated P56S 
mutant. 
  
VAP proteins interact with ATF6α 
 In this chapter we present evidence for a direct interaction between VAP 
proteins and ATF6α. As it was previously shown the MSP domain of VAPA interacts 
with ATF6α in a yeast two hybrid assay (Middleton, 2005). We demonstrate that 
VAPA, VAPB and VAPB
P56S
 interact with ATF6α in a fluorescent protein 
complementation assay, while the relevant b-zipper controls do not. This observation 
is important because it shows that full length VAP proteins can interact with ATF6α 
in HEK293 cells. Moreover ATF6α and VAPB and VAPB
P56S
 when expressed as 
fusion proteins display extensive colocalization. Although we were not able to co-
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immunoprecipitate VAPB and ATF6α in a pull-down assay, this does not necessarily 
suggest that the interaction might be a false positive. Usually transient interactions 
cannot always be verified with a co-ip pulldown; moreover the commercial ATF6α 
antibody is not a particularly good antibody, as for the purposes of this study it has 
never worked to satisfactory standards. The direct interaction we are proposing is 
supported by the effect we are describing in this chapter. VAP overexpression or 
reduction of endogenous VAP by siRNA affect ATF6α activity as measured by the 
p5xGL3ATF6 luciferase reporter; in addition we demonstrate how VAPB can 
interfere with glycosylation associated activation of ATF6α. Nevertheless, a direct 
pull-down verification of the interaction would strengthen the hypothesis that we 
formulate in this chapter. 
 
VAPB inhibits ATF6/XBP1 dependent transcription 
   As outlined in this chapter’s background paragraph 3.1, the promoter used in 
p5xGL3ATF6 is not the endogenous promoter of ATF6α, but a synthetic promoter 
which has been shown to be responsive to changes in endogenous or expressed 
ATF6α (Wang et al., 2000). We have also shown that the reporter’s activity is 
reduced when cells are co-transfected with ATF6α siRNA, but not GFP siRNA 
(Figure 3.4.4) and that the reporter is induced when FLAG tagged ATF6α is 
expressed. However we cannot discount the fact that as described in Wang et al. the 
promoter can be affected by other ER stress related components i.e. XBP1. Even so, 
in the next Chapter we proceed to demonstrate that VAPB affects the entire Unfolded 
Protein Response. In conclusion, from the aforementioned data and in conjunction 
with the proposed VAP-ATF6α interaction we can deduct that a significant amount of 
the observed inhibition or activation of the ATF6α reporter is ATF6α dependent. 
 Overexpression of VAPB and VAPB
P56S
 inhibits transcriptional activation of 
the ATF6α reporter in HEK293 and NSC34 cells. Conversely, siRNA mediated 
inhibition of endogenous VAPB induces the ATF6 reporter. Those two results clearly 
display a modulation of ATF6α activation as monitored by this reporter. After 
showing evidence for a direct interaction between VAPB and ATF6α we now 
demonstrate that this interaction has a functional effect. It becomes clear that levels 
of VAP proteins affect a cell’s response to ER stress via ATF6α; as it has been shown 
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by other groups VAP overexpression and reduction of endogenous levels affect the 
UPR (Kanekura et al., 2006).  
  
The ALS8 associated P56S mutant may be a stronger inhibitor of ATF6α than the 
wild-type 
 When VAPB and VAPB
P56S
 are overexpressed, they both inhibit ATF6α 
activation to the same extent; however, when samples from the assay are probed for 
protein expression, VAPB
P56S
 always accumulated to lower levels than the wild-type 
protein. This finding may suggest that for the same amount of protein, the P56S 
mutant is a stronger inhibitor of ATF6α. In both myc and EGFP fusion proteins, the 
mutant is always found in lower levels, but the GFP moiety seems to have a 
stabilizing effect on the mutant protein and in the EGFP fusions, the difference is less 
than the myc between wild-type and mutant. This finding is true in both HEK293 and 
NSC34 cells. Moreover when increasing amounts of DNA are used, the mutant P56S 
for the same amount of protein inhibits ATF6α more (Figure 3.6.2). While other 
groups have associated VAPB
P56S
 with the UPR in general (Kanekura et al., 2006), 
this is the first reported difference regarding the ATF6α branch of the UPR. 
Evidently, this suggests that the UPR can be misregulated by P56S, as greater 
inhibition of ATF6α can lead to a reduced response to ER stress, which can lead a 
cell (or a motor neuron in ALS8) to death. However, the P56S mutant forms 
cytoplasmic aggregates that may increase the insolubility of the protein and render it 
less accessible to the antibody.  In addition, the P56S mutant may not be as stable as 
the wild-type and therefore proteolysed and degraded. Our VAPB domain analysis in 
this chapter highlights a different aspect of this issue. 
 
ATF6α and the various domains of VAPB 
 The ATF6α-VAP interaction was first identified using the MSP domain. When 
VAPB truncations (EGFP fusions of functional domains of VAPB as predicted from 
its sequence and homology or similarity to known protein architectures) are 
overexpressed, they still display the inhibitory effect observed for the full length 
sequences (apart from the hydrophobic tail construct); MSP is the most potent 
inhibitor of ATF6α and MSP
P56S
 does not inhibit to the same levels as the wild-type; 
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the CC/CTB and CCB constructs still inhibit, while the C-terminal anchor does not. 
This analysis reveals that the MSP domain is the strongest inhibitor of the ATF6α 
reporter, while the P56S mutant of the MSP cannot retain this functionality; the same 
trend is not observed for the ΔΗ constructs, as ΔH
P56S
 inhibits the same as ΔH; the 
coiled-coil domain of VAPB inhibits ATF6α activation, while the C-terminal anchor 
has no effect. 
 Thus, the cytoplasmic domains of VAPB when overexpressed modulate the 
activity of ATF6α; as predicted, the C-terminal has no effect. This functional effect 
reveals a potentional regulatory complex formed on the ER membrane by VAPB and 
ATF6α, with their cytoplasmic portions interacting and affecting activation of 
ATF6α. The MSP domain has the highest affinity for ATF6α and the Coiled-Coil also 
participates in this modulation. For the VAPB mutant, the Coiled-Coil still has the 
same effect, but the P56S MSP cannot inhibit to the same extent as wild-type MSP. 
This preliminary observation is further discussed and more aspects of it are revealed 














Figure 3.9 ATF6α and VAPB on the ER membrane. 
 
The cytoplasmic portion of VAPB contains the MSP and CC domains. The 
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ATF6’s cytoplasmic part contains the Transcriptional Activation Domain, the Basic 
DNA Binding Motif and a Basic Leucine Zipper. 
 
The effect of the P56S mutant on ATF6α is dependent on the presence of the 
endogenous protein 
 When VAPB fusion proteins are expressed in HEK293 or NSC34 cells, the 
endogenous protein is present. The endogenous protein affects (without any VAPB 
construct expressed) ATF6α activation, because siRNA mediated blocking of 
endogenous VAPB expression induces the ATF6α reporter (Figure 3.5). VAPB 
overexpression could affect endogenous VAPB as VAP proteins are known to 
homo/heterodimirize. In HEK293 cells we can reduce the endogenous human protein 
expression and simultaneously express the mouse EGFP fusion proteins that are 
“insensitive” to the siRNA, as the recognition sequence varies between mouse and 
human (see Figure 3.7B and Figure 3.8). By doing this we can study the effect of 
overexpression when the endogenous protein levels are reduced. This experiment 
reveals that the P56S mutant (full length and truncations) are dependent on the 
presence of the endogenous protein, as the previously observed inhibitory effect is 
now reduced or totally abolished; the P56S constructs cannot rescue the 
overexpression effect. Conversely, the wild-type VAPB full length, ΔΗ and MSP still 




















Figure 3.10 Model for the modulation of ATF6α activity via the VAPB Coiled-Coil 
domain. 
 
Overexpression of the CC domain of VAPB inhibits activation of ATF6α; this effect 
is dependent on the presence of the endogenous protein during overexpression. The 
CC could potentially modulate the activity of ATF6α by interfering with other VAPB 
molecules (their MSP or CC domains) or autoregulate a given VAPB molecule (by 
interacting with the MSP domain). 
 
 This experiment also highlights an important aspect of the CC effect on 
ATF6α. SiRNA mediated reduction of expression of endogenous VAPB blocks the 
effect of overexpression of the CCB; activation levels are now comparable to the 
GFP control. From this we can speculate that the overexpression of CCB interferes 
with endogenous VAPB in a way that ATF6α activation is blocked; this effect is not 
seen when the endogenous protein levels are reduced. Therefore, CCB 
overexpression could potentially interfere with the VAP-ATF6α interaction by 
interacting with the endogenous protein Coiled-Coil or the MSP domain. 
Nevertheless, the Coiled-Coil of VAPB could affect the regulation of ATF6α activity 
by VAPB either via other VAPB molecules or via interactions within a VAPB 
molecule (MSP-CC interaction, see Figure 3.10). 
 
One possible mechanism for ATF6α regulation by VAPB  
 When VAPB and VAPB
P56S
 are overexpressed in the presence of the 
endogenous VAPB protein, ATF6 activitation as monitored by the p5xGL3ATF6 
reporter is inhibited. This inhibition observed can be either by retention of ATF6 on 
the ER membrane, or by blocking its migration to Golgi, or even by blocking binding 
of nuclear ATF6α on ERSE promoter elements. Reduction of the luminal disulfide 
bond and glycosylation of ATF6α are correlated with activation of ATF6α. Here we 




 but not CTB or GFP 
inhibit glycosylation associated activation of ATF6. This could be one of the 
regulation points of VAPB over ATF6α. The experiment provides one possible 
explanation for the observed inhibition; however VAPB could be acting in the Golgi 
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or nucleus where ATF6α is shuttled. 
  
Chapter Conclusion 
 In this chapter we show a direct effect of the VAPB-ATF6α interaction; 
overexpression of VAPB and VAPB
P56S
 inhibit ATF6α activation, while siRNA to 
endogenous VAPB induces ATF6α. The mutant protein accumulates to lower levels 
than the wild-type protein. VAPB domains (MSP, CC but not CT; MSP is the most 
potent inhibitor) inhibit ATF6α activation and the observed effect is dependent on the 
presence of the endogenous protein. In conclusion, the ALS8 associated P56S mutant 
displays a gain of negative function (inhibition) behaviour regarding ATF6α activity, 
































 In the previous Chapter we show that VAPB interacts with and modulates the 
activity of the Unfolded Protein Response associated transcription factor ATF6α 
(Gkogkas et al., 2008). The reporter used in the previous Chapter is a synthetic 
reporter (Wang et al., 2000) that apart from ATF6α binds other UPR associated 
elements like XBP1. This suggests that apart from the VAP-ATF6α interaction, VAP 
might participate in regulation of the UPR via other promoter elements. Moreover, 
ATF6α and XBP1 form heterodimers (Yamamoto et al., 2007) and display single and 
combined action in UPR activation. ATF6 and XBP1 act on Endoplasmic Reticulum 
Stress Response Elements – ERSEs (CCAAT-N9-CCACG motif) and activate 
transcription of UPR chaperones (i.e. BiP/GRP78) and associated genes. For that 
matter we will study regulation of the UPR by VAP proteins using the following two 
reporter-constructs: 
 
  pGL3-XBP1(-330)-luc (Yoshida et al., 2000)(Appendix I, #P19-termed the 
XBP1 reporter)  
 pGL3-GRP78(-132)-luc (Yoshida et al., 1998) (Appendix I, #P20-termed the 
BiP reporter)   
 
 The XBP1 reporter contains the human XBP1 promoter fused to the firefly 
luciferase gene. Transcription is regulated by the hXBP1 promoter which has a size 
of 459 bp (-330 to +129, 0 indicates beginning of transcription – Figure 4.1A). This 
reporter is responsive to ER stress inducers. The hXBP1 promoter contains an ERSE 
element in the region from +32 to +65. When this element is deleted, the relative 
XBP1 reporter is no longer responsive to ER stress induction (Figure 4.1.A). 
 The BiP/GRP78 reporter contains the human BiP promoter fused to the firefly 
luciferase gene. Transcription is regulated by the hBiP/GRP78 promoter which has a 
size of 397 bp (-363 to +34, 0 indicates beginning of transcription – figure 4.1.A and 












































































Figure 4.1 XBP1 and BiP UPR associated promoter elements (from (Yoshida et al., 
1998, Yoshida et al., 2000). 
 
A., B.  Analysis of the XBP1 and BiP promoters using Luciferase based transcription 
assays. HeLa cells were transfected with human XBP1 or GRP78 promoter luciferase 
based reporter constructs and scrambled versions (deletion of promoter regions or 
mutation of ERSE elements) and then ER stress was induced with 2 μg/ml 
tunicamycin for 16 hours. The right panels depict relative luciferase activity. For BiP, 
scrambling ERSE1 makes the promoter insensitive to ER stess induction with 
tunicamycin. ERSE2 and ERSE3 together or individually cannot induce transcription 
after ER stress, while ERSE1 (seen in B) can induce transcription of a luciferase 
construct following ER stress. Deletion analysis of the human XBP1 promoter fused 
to the firefly luciferase gene reveals that the ERSE1 sequence is essential for 
initiating transcription following ER stress. Results are averages of 4 experiments 
and error bars correspond to standard error (SE). 
 
C. Schematic representation of ATF6 and XBP1 binding to ERSE promoter elements 





ERSE elements termed ERSE1 (-61 to -37), ERSE2 (-94 to -76) and ERSE3 (-126 to 
-114). ERSE1 is the only element out of three that can initiate transcription of a 
luciferase gene in a reporter construct following ER stress. Thus, the role of the 
ERSE2 and ERSE3 elements is not known. 
 Kanekura et al., 2006 showed that VAPB overexpression can induce the IRE1 
pathway by promoting splicing of an immature XBP1 mRNA reporter construct, 
while the P56S mutant of VAPB cannot. In addition, siRNA to endogenous VAPB 
reduces splicing of the reporter construct. This study reveals a connection of VAP 
proteins with the IRE1 branch of the UPR. 
 In this Chapter we will study regulation of the UPR by VAP proteins using 
the XBP1 and BiP human endogenous promoters in luciferase based reporter 
contructs. As with ATF6α we will examine here also the effect of VAPB domains 
(Table 3.1) and especially the MSP domain.
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4.2 VAPB and XBP1 and BiP promoters 
 
4.2.1 Overexpression of full length and truncated forms of mVAPB and 
mVAPB
P56S
 in HEK293 and NSC34 cells inhibits transcriptional activation from 
the human promoter of XBP1  
 
 In Chapter 3 we showed that VAPB interacts with and modulates the activity 
of the ER stress associated transcription factor ATF6α and in order to investigate 
whether the other pathways of the Unfolded Protein Response were affected we used 
a human XBP1 promoter luciferase based construct (Appendix I, #P19). HEK293 or 
NSC34 cells were transfected with all the mouse VAPB and VAPB
P56S
 EGFP 
constructs previously described along with the XBP1 reporter and the internal 
renillin (Appendix I, #P21) control plasmid (Figure 4.2). Tunicamycin treatment 
induces the XBP1 reporter by 6-fold. Although basal levels of transcription do not 
seem to be affected, there is inhibition of the activity of the XBP1 promoter when 
cells are induced with tunicamycin. This inhibition is true for VAPB (50%), 
VAPB
P56S
 (50%), MSPB (66%), MSPB
P56S
 (33%), ΔHB (49%) and ΔHB
P56S
 (48%), 
but not for the CC/CTB, CCB and CTB constructs. To strengthen this finding we use 
HEK293 cells and motor neuron-like NSC34 cells and results are consistent in the 
two different cell types. Therefore, the Coiled-Coil and C-terminal anchor domains 
of VAPB do not seem to affect XBP1 promoter dependent transcription, while 
MSPB
P56S
 inhibits less that wild-type MSPB. Expression of VAPB-EGFP constructs 
is previously shown in Figure 3.7 Chapter 3. 
 
4.2.2 Overexpression of full length and truncated forms of mVAPB and 
mVAPB
P56S
 in HEK293 and NSC34 cells induces transcriptional activation from 
the human promoter of BiP/GRP78 
  
 BiP/GRP78 is a key component of the Unfolded Protein Response. We have 
shown that VAPB affects the activity of the ATF6α synthetic promoter and the 
hXBP1 promoter and to check whether the hBiP promoter is affected, we used a 



































































































Figure 4.2 Effect of overexpession of mVAPB and mVAPB
P56S
 on human XBP1 
promoter dependent transcription. 
 





, ΔHB and ΔHB
P56S
, but not CC/CTB, CCB and CTB constructs inhibits 
activation of the XBP1 reporter in tunicamycin treated samples as measured from the 
relative luciferase activity produced by transcriptional activation of the human XBP1 
promoter. Amongst the different truncations, MSP is the most potent inhibitor, while 
MSP
P56S
 cannot inhibit to the same extent. Results shown are averages of 4 








































































































Figure 4.3 Effect of overexpession of VAPB and VAPB
P56S
 on human BiP 
promoter dependent transcription. 
 







, CC/CTB, CCB and CTB constructs potentiate 
activation of the BiP reporter in tunicamycin treated samples as measured from the 
relative luciferase activity produced by transcriptional activation of the human BiP 
promoter. Amongst the different truncations, MSP is the most potent activator, while 
MSP
P56S
 does not affect BiP activity. Results shown are averages of 4 experiments 





Transcriptional assay was carried out as previously. Overexpression of the various 
constructs does not affect basal levels of transcription but there is potentiation of the 
activity of the BiP reporter when cells are induced with tunicamycin (Figure 4.3). 







, CC/CTB, CCB and CTB constructs. Thus, it 
seems that the P56S mutation in VAPB and its truncations that contain the MSP 
domain cannot induce the BiP reporter, unlike the wild-type constructs. Moreover, 
overexpression of the Coiled-Coil and C-terminal anchor domains of VAPB do not 
activate transcription from the human BiP promoter more than control samples 
(GFP). 
 
4.2.3 siRNA mediated reduction of expression of endogenous hVAPB in HEK293 
cells has a differential effect on basal and induced activity levels of the XBP1 
and Bip reporters 
 
  As it was previously shown for ATF6α, reducing endogenous VAPB levels 
using siRNA induces the activity of the ATF6α reporter, which is the opposite effect 
from overexpressing mVAPB. The same experiment was conducted for the XBP1 
and BiP reporters to check whether reduced expression of the endogenous protein 
had the opposite effect from overexpression (Figure 4.4). For the XBP1 reporter, 
siRNA to VAPB increases basal and induced levels of transcription; in Figure 4.2 it is 
shown that overexpression of VAPB inhibits the activation of the XBP1 reporter and 
now we show that siRNA mediated reduction of endogenous VAPB levels has the 
opposite effect. Conversely, siRNA to endogenous VAPB reduces the activity of the 
BiP reporter in non-induced and induced samples; this is the opposite from the 
activation of the BiP reporter that is observed when VAPB is overexpressed in Figure 
4.3. In this experiment GFP siRNA is used as a control. Western blot analysis of 
representative samples shows that VAPB siRNA reduces the amount of expressed 



































































































































Figure 4.4 Effect of siRNA mediated reduction of endogenous VAPB expression on 
the transcriptional activation of XBP1 and BiP reporters. 
 
A. HEK293 cells were transfected with siRNA to endogenous VAPB and then with 
ATF6, XBP1 or BiP reporters; ATF6 results are a repeat of the Chapter 3.7, Figure 
3.5 experiment. Reduction of endogenous VAPB levels affects both basal and 
induced levels of XBP1 and BiP reporters. For XBP1, there is an increase in relative 
luciferase activity by 33%, while for BiP there is a 5% reduction which is statistically 
significant by a one-way ANOVA (p=0.001238). Results shown are averages of 4 
experiments and error bars correspond to standard error (SE). 
 
B. Immunoblot of representative samples from the assayed for luciferase activity 
HEK293 cells. GFP siRNA is used as a control. There is a significant reduction of 
endogenous VAPB in siRNA treated samples but there is not a 100% inhibition of 
expression of endogenous VAPB protein. *A 60 kDa non-specific band from longer 
exposures of the immunoblot serves as a loading control. Also staining with the 






4.2.4 Wild type mVAPB but not mVAPB
P56S 
can rescue the effects of the siRNA 
mediated reduction of endogenous hVAPB protein levels on XBP1 and BiP 
reporters in HEK293 cells 
 
In order to examine whether inhibition of XBP1 and induction of BiP reporter 
activities are dependent on the presence of the endogenous VAPB protein we used 
siRNA mediated reduction of expression of endogenous hVAPB in HEK293 cells as 







) retain their full inhibitory effect on XBP1 
reporter activation when siRNA to endogenous hVAPB is applied; the relative 
luciferase activity measured is now comparable to the levels of the GFP control 
transfected samples. In contrast, wild type constructs: full length VAPB, MSPB and 
ΔHB constructs, retain their inhibitory effect on the XBP1 reporter, while coiled-coil 
and C-terminal tail CC/CTB, CCB and CTB constructs still exhibit no effect. This 
shows that the previously observed inhibitory effect of P56S constructs on 
transcriptional activation from the hXBP1 promoter is dependent on the presence of 
the endogenous hVAPB protein in HEK293 cells (Figure 4.5). For the BiP reporter in 
HEK293 cells, P56S constructs did not have an effect on BiP activation in Figure 
4.3. When VAPB siRNA is applied, overexpression of wild type mVAPB constructs: 
VAPB, MSPB and ΔHB, still potentiates the transcriptional activity of the BiP 
reporter. P56S mutation, coiled coil and C-terminal tail constructs still did not have 


































































































Figure 4.5 Effect of overexpression of mVAPB and mVAPB
P56S
 full length proteins 
and truncations on XBP1 and BiP reporters’ activity in HEK293 cells, when 
endogenous hVAPB expression is reduced by siRNA. 
 
HEK293 cells were transfected with siRNA to endogenous hVAPB and then with 
XBP1 or BiP reporters along with wild-type mVAPB and mVAPB
P56S
 full length and 
truncated EGFP constructs. In tunicamycin treated samples, for XBP1, 
overexpression of the P56S mutant did not suppress the activation of the XBP1 
reporter, while the wild-type constructs retained their inhibitory effect. This trend is 
now evident and in baseline (no tunicamycin induction) levels of relative luciferase 
activity. Similarly, for the BiP reporter, reduction of endogenous hVAPB expression 
levels does not affect potentiation by overexpression of wild-type VAPB. However, 
overexpression of P56S mutation constructs still had no effect. Results shown are 





 4.3 Overexpression of mVAPB and mVAPB
P56S
 domains in NSC34 
increases cell death following ER stress 
  
 Misregulation of the UPR has been associated with neurodegeneration 
(Paschen and Mengesdorf, 2005). We proceeded to examine whether overexpression 
of the MSP domain and other VAPB domains had an effect on cell survival after ER 
stress. There is increasing evidence in literature associating misregulation of the 
Unfolded Protein Response with apoptotic cell death in neurodegenerative disease 
(Paschen and Mengesdorf, 2005, Wu and Kaufman, 2006). Therefore we wanted to 
investigate whether the observed regulation of the UPR by overexpression of VAPB 
domains had an effect on cell viability following ER stress in the motor-neuron like 
cell line NSC34. For this experiment NSC34 cells were transfected with VAPB 
expression plasmids, washed, induced with 2 μg/ml tunicamycin for 12 hours, 
washed again, cultured for another 12 hours and finally assayed for viability using 
propidium iodide or the  Cytotox Glo
TM
 cytotoxicity assay (Figure 4.6.1). NSC34 
cells overexpressing GFP, tubulin or the C-terminal of VAPB (CTB) did not display 







, CC/CTB, CCB but not CTB display an increase 
in cell death as measured by the two assays after tunicamycin induced ER stress (also 












































































































































































Figure 4.6.1 Effect of overexpression of full length and truncated mVAPB and 
mVAPB
P56S 
on NSC34 viability after ER stress. 
 
A., B. Propidium iodide and Cytotox-Glo cell viability assays. Results are consistent 
for both assays. NSC34 cells were transfected with full length mVAPB and 
mVAPB
P56S
 and truncations and after 24 hours induced with 2 μg/ml tunicamycin for 
12 hours, washed and cultured a further 12 hours before assayed for cell death. 
Overexpression of MSPB and MSPB
P56S
 in non-induced and induced samples scores 
the highest in both assays while ΔH and ΔH
P56S
 come next. Samples marked with * 
have a p<0.002 by a one-way ANOVA. Cells recovering from treatment with 




, ΔHB and 
ΔHB
P56S
, CC/CTB, CCB but not CTB die more than the control samples (no DNA, 
GFP or GFP-tubulin overexpressing cells or non-transfected cells). Results shown 
are averages of 4 experiments and error bars correspond to standard error (SE). 
 
C. Immunoblot of representative samples from the assayed for cell death NSC34 
samples. Relative expression of mVAPB, mVAPB
P56S
 and truncated EGFP constructs 
is shown; p38 is used as a loading control. Expression levels in NSC34 cells are 






























   






Figure 4.6.2 Propidium Iodide Cell Viability assay from Figure 4.10.1B. 
 
Representative images are shown from the propidium iodide cell viability assay 
shown in Figure 4.10.1B. Cells that have lost their membrane integrity allow the vital 
dye propidium iodide to enter their cytoplasm. Cells recovering from treatment with 




, ΔHB and 
ΔHB
P56S





4.4 ER stress vulnerability of NSC34 cells overexpressing mVAPB 
and mVAPB
P56S
 domains is caspase dependent 
 
 In 4.3 we showed that overexpression of VAPB and VAPB
P56S domains 
renders cells more vulnerable to ER stress. It is a common theme in 
neurodegenerative disease for cells to die via programmed cell death pathways, 
especially apoptosis (Paschen and Mengesdorf, 2005, Wu and Kaufman, 2006). 
Caspases are the effector molecules of apoptotic cell death. In order to examine 
whether the cell death observed in our aforementioned experiments is caspase 
dependent, we used the pan-caspase blocker zVAD-FMK (carbobenzoxy-valyl-
alanyl-aspartyl -[O-methyl] -fluoromethylketone), which binds to the caspase 
catalytic site and inhibits induction of apoptosis (Craighead et al., 1999). Application 
of zVAD-FMK at 50 μM increases survival after tunicamycin induced ER stress of 




, CC/CTB or CCB and thus 
reduces cells death and reverses a significant amount of the effect previously 
observed (Figure 4.7). Therefore, cell death observed after ER stress in NSC34 cells 
overexpressing mVAPB or mVAPB
P56S










































































































































 cell viability assay was used to examine whether cell death 
observed after ER stress of NSC34 cells overexpressing mVAPB or mVAPB
P56S
 
domains is caspase dependent. In samples marked with * 50 μM of zVAD-FMK pan-
caspase inhibitor has been applied. Samples marked with # have a p<0.002 by a one-
way ANOVA test. Application of zVAD-FMK increases cell viability which indicates 
that cell death after overexpression of VAPB domains and ER stress is caspase 
dependent. Results shown are averages of 4 experiments and error bars correspond to 

























 In the previous Chapter, we have shown that VAPB interacts with and 
modulates the activity of the Unfolded Protein Response (UPR) associated 
transcription factor ATF6α. Moreover, the various domains of VAPB have a different 
effect on ATF6α activation. Regulation of a cell’s ER stress response is essential for 
its survival and there is increasing literature linking misregulation of such pathways 
with neurodegenerative diseases (Hoozemans et al., 2005, Paschen and Mengesdorf, 
2005, Xu et al., 2005). In this chapter we explore how VAP proteins affect two ERSE 
containing endogenous promoters (XBP1 and BiP) and potentially affect cell 
viability. 
 
VAP proteins and XBP1, BiP promoters 







, but not CC/CTB, CCB and CTB inhibit transcriptional activation 
of an XBP1 luciferase based reporter (under the control of the human XBP1 
promoter). This result is similar to that previously shown for ATF6α, but the 
CC/CTB and CCB constructs do not have an effect on XBP1 reporter activation. 
Also, we have presented evidence for a direct interaction between ATF6 and VAP 
proteins, while there is no evidence for a VAP-XBP1 interaction. Therefore it cannot 
be discounted the fact that maybe the XBP1 promoter effect is not a direct effect – or 
that it is mediated via ATF6α. XBP1 and ATF6α form a heterodimer (Yamamoto et 
al., 2007), especially under ER stress conditions. Additionally, we show that this 
modulation of XBP1 reporter (as we have shown for ATF6α) depends on the 
expression levels of the endogenous protein. When levels of endogenous VAPB are 







) fails to inhibit XBP1 reporter activation. Similar to ATF6α this 
clearly shows that the P56S mutation’s functionality depends on the presence of the 
endogenous protein. This is a finding that might explain why in some instances the 
mutant behaves like a gain of function (Chai et al., 2008) or rather like a gain of a 
negative function (i.e. inhibition of ATF6α activation) instead of a dominant loss of 
function (Ratnaparkhi et al., 2008); which becomes more important when 
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considering that in humans there are two alleles of VAPB and in ALS patients one of 
them is the mutant P56S. Therefore, the presence of the wild-type protein could 
potentially stabilize the mutant protein, which on its own does not display the same 
stability as the wild-type. 
 Overexpression of VAPB, MSPB and ΔHB but not VAPBP56S, MSPBP56S, 
ΔHB
P56S
, CC/CTB, CCB or CTB potentiates transcriptional activation of a BiP 
luciferase based reporter (under the control of the human BiP promoter). Clearly the 
overexpression of the P56S mutation cannot activate the BiP promoter; the same 
thing applies for the Coiled-Coil and C-terminal domains of VAPB. This pattern is 
not altered when the endogenous protein expression levels are reduced with siRNA. 
Thus, in this context, the P56S mutation is a loss of function and effectively may fail 
to activate the cascade of chaperones and genes associated with BiP activation and 
the UPR. 
 
VAP and ERSE 
 All three promoters in the relative reporter constructs (ATF6α synthetic 
promoter and hXBP1 and hBip endogenous promoters) examined in this study are 
associated with ERSE elements. The synthetic ATF6α promoter can bind both ATF6α 
and XBP1, while both proteins bind to ERSE elements. The human XBP1 promoter 
contains one ERSE element which is essential for transcriptional activation of the 
reporter upon ER stress, while the BiP promoter contains three ERSE elements; only 
one of those three ERSE elements is necessary for transcriptional activation upon ER 
stress. Our data show a differential effect on the aforementioned promoters; 
inhibition for the ATF6α and XBP1 reporters and potentiation of the BiP reporter. 
Given the fact that all three promoters contain ERSE elements, the prediction would 
be that VAP proteins should have the same effect on the reporters. However, our 
results suggest that the inhibition and induction observed on similar promoter 
elements could be due to other elements within those promoters. For example the BiP 
promoter contains two ERSE elements that are not transcriptionally activated after 
ER stress; it could be that VAPB has an affinity for ERSE elements and in the BiP 




VAPB, cell death and ER stress 
     Apart from the MSP domain, we show that the other domains of VAPB 
(Coiled Coil and C-terminal anchor) are not toxic to cells; it is only the MSP domain 
or truncations of VAPB that contain the MSP (ΔΗ) that display increased death levels 
(both wild-type and P56S). When cells are stressed for 12 hours with the N-
glycosylation inhibitor tunicamycin and then cultured for another 12 hours, 
overexpression of VAPB domains apart from the C-terminal anchor reduces the 
viability of cells in a caspase dependent manner; compared to controls (GFP and 
GFP-tubulin). This observation suggests that overexpression of VAP protein domains 
renders cells more vulnerable after their ER stress pathway has been induced; while 
in non-induced cells, their overexpression does not increase cell death (apart from the 
MSP domain). These results reveal that the balance of VAP proteins and VAP protein 
domains is essential for the survival of a cell when its UPR has been initiated; 
overexpression might interfere with the homeostasis of endogenous VAP proteins or 
their interactions with other cellular components. In this study we highlight the 
regulation of the UPR by VAP proteins and the ALS8 associated mutant, therefore 
caspase dependent cell death after recovery from ER stress might be a result of 
misregulation of transcriptional activation of ERSE containing promoters by VAP 
proteins. Failure to regulate the UPR might lead to programmed cell death (Paschen 
and Mengesdorf, 2005). 
 
Chapter conclusion 
 The ER stress response to unfolded proteins in the ER lumen is based on an 
intricate network of interactions between transcription factors, chaperones and a 
plethora of other genes. VAP proteins are present on the ER membrane and our data 
suggest that they can be part of this regulatory network via regulation of ERSE 
































 The MSP domain is the most conserved domain of VAP proteins from A. 
Californica to humans. Previous results of the laboratory indicate that the MSP 
domain when overexpressed is toxic to primary hippocampal neurons and HEK293 
cells (Middleton, 2005). Moreover, Skehel et al., 2000 showed that endogenous 
mouse VAPA in whole mouse brain homogenates apart from the predominant ~33 
KDa band displayed an 18KDa proteolytic product. 
 If VAP proteins are proteolyzed, this could result in release of various 
domains (i.e. MSP or CC). In the previous two chapters we have shown that 
overexpression of VAP protein domains affects differentially regulation of the UPR 
via ERSE elements on UPR associated promoters. Moreover we showed that VAP 
protein domains overexpression reduces cell viability following an ER stress insult. 
 In this chapter we will study expression of VAP proteins in neuronal and non-
neuronal tissues.  
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5.2 VAPA and VAPB are expressed ubiquitously but at differing 
levels in different tissues 
 
 We proceeded to examine VAPA and VAPB expression in various tissues. 
Immunoblot analysis of selected tissues from an adult male Sprague-Dawley rat 
demonstrated that both VAPA and VAPB proteins are present in all tissues examined, 
but at different relative levels (Figure 5.1A) This is in agreement with the wide 
expression profile of mRNA published previously (Nishimura et al., 1999, Skehel et 
al., 2000, Weir et al., 1998). VAPA is expressed at higher levels in testis, cerebellum 
and forebrain while for VAPB pancreas is the tissue with the highest expression.  
 
5.3 Endogenous VAPA and VAPB are cleaved; VAPB cleavage is 
restricted in neuronal tissue  
 
  In Figure 5.1A an additional, less abundant, protein of approximately 14 kDa 
is detected by both VAPA and VAPB antisera in Figure 5.1A. The VAPB-related 
signal is a doublet, the expression of which is tightly restricted to neuronal tissue 
(forebrain and cerebellum extracts) and not detected in the other tissues tested 
(Figure 5.1A). The 14 kDa VAPA-related polypeptide is more widely expressed and 
detectable in pancreas, liver, forebrain, lung and thymus, kidney and testis; low 
levels are seen in the cerebellum and no signal is detected in heart or skeletal muscle. 
A peptide of similar size has been predicted from a splice variant of VAPB, termed 
VAPC. However, the peptide used to generate the VAPB anti-serum is not present in 
VAPC (Nishimura et al., 1999), and the VAPA antisera do not cross react 
significantly with VAPB-derived species (Figure 5.1C).  Moreover VAPB does not 
behave like a typical integral membrane protein when extracted with Triton X114 as 
it is found predominantly in the aqueous phase, while VAPA is seen exclusively in 
the detergent phase (Figure 5.1C, also see (Bordier, 1981) and (Middleton, 2005)). It 
is concluded that these smaller molecular weight immunoreactive species are most 
likely generated by proteolysis of the VAP proteins. Finally our results published in 
Gkogkas et al., 2008 were also confirmed by Tsuda et. al., 2008, who showed that 
























Figure 5.1 Expression of VAPA and VAPB in different adult male rat tissues. 
 
A. Detection of VAPA and VAPB in different tissues. 
Anti-peptide anti-serum was raised to residues 174–189 of mouse VAPB. In the 
tissues indicated, the predominant immunoreactivity is at approximately 27 kDa, in 
agreement with the molecular weight predicted from the cDNA. Both VAPA and 
VAPB are expressed widely but at different levels. A faster migrating VAPB-related 
doublet signal of approximately 14 kDa is clearly detected in forebrain and 
cerebellum protein extracts (arrows). The immunoblot is deliberately over exposed to 
demonstrate the restricted nature of this expression pattern. A faster migrating 
immunoreactive species of approximately 14 kDa is also seen with VAPA antisera, 
however, in contrast to that seen for VAPB; this species is detectable in pancreas, 
liver, forebrain, lung and thymus, kidney and testis. Low levels are seen in the 
cerebellum and no signal is detected in heart or skeletal muscle. 
 
B. Loading and Transfer control for immunoblot analysis of tissue extracts.  
The membranes used for immunoblotting of tissue extracts with VAPA and VAPB 
antisera were stained with a Ponceau S solution prior to blocking with non-fat milk 
and antibody incubation. Antisera used on relative membranes are marked. Even 
abundant proteins such as cytoskeletal constituents are not expressed equally in 
different tissues. Therefore, a general protein detection reagent such as Ponceau S is 
a more appropriate control for loading. Comparable lanes between each blot have 
transferred equally and contain equivalent amounts of protein. Picture is shown in 
grayscale – original colour is red. 
 
C. Specificity control for VAPA and VAPB antisera.  
A post-nuclear fraction (PNF) from a rat brain homogenate was extracted with 1% 
Triton X114. Aqueous and detergent phases were then separated and analysed with 
either VAPA or VAPB specific antisera. VAPA is seen predominantly as a doublet 
that is almost completely extracted into the detergent phase. VAPB is a single 27kD 
species that is present largely in the aqueous phase. There is negligible cross 
reactivity between the two antisera. 
137 
 
5.4 Proteolysis of endogenous and expressed hVAPB 
 
 VAPA and VAPB are cleaved and VAPB is cleaved only in neuronal tissue. 
The fact that the VAPB antibody was raised to aminoacids 174–189 which lies 
between the MSP and Coiled Coil regions of VAPB, suggests that the 14 KDa 
truncation observed in the tissue blot (Figure 5.1A) is most likely a proteolytic 
product of VAPB that contains the coiled coil. VAPB when extracted with Triton 
X114 does not behave as a typical membrane protein as it is found predominantly in 
the aqueous phase instead of the detergent phase (Skehel et al., 2000). When whole 
brain extract from  an adult Sprague Dawley rat was extracted using Triton X114, the 
14 KDa band was found only in the detergent fraction, while the 27 KDa full length 
protein was in the aqueous phase (Figure 5.2B also see (Bordier, 1981), (Middleton, 
2005) and Figure 5.1C). This suggests two things: 
-The 14 KDa band is hydrophobic and therefore must contain the C-terminal 
membrane anchor of VAPB. 
-The presence of the 14 KDa fragment missing has a significant effect on the 
hydrophobicity of the protein as it is essential for the protein to extract in the aqueous 
phase. Moreover the 14 KDa missing correspond to the predicted molecular weight 
of the MSP domain in isolation. 
 Thus, the MSPB domain is cleaved and in full length VAPB satisfies the 
protein’s hydrophobicity and promotes its solubility in aqueous solutions. 
Neuron specific cleavage of VAPB was observed in adult Sprague-Dawley 
rats in Figure 5.1A. In post-nuclear fractions of homogenized brain and spinal cord 
from E18 Sprague-Dawley embryos, the 14 KDa truncation can be again detected 
when probed with the VAPB antisera (Figure 5.2A). When E18 cortical cells were 
dissociated and cultured for 11 days in vitro (DIV11) endogenous VAPB was 
proteolysed in a similar manner. Surprisingly, in DIV1 E18 cortical neurons 
endogenous VAPB was not cleaved and appeared as a single 29 KDa band. No 
cleavage products were detected in cultured glial cells (depleted of neurons by 
NMDA induced toxicity) from the same E18 embryos and in the 3 cell-lines 
examined: HEK293 (kidney), NSC34 (motor-neuron like), C6 (glioma); Figure 5.2A. 

































































































































Figure 5.2 Neuron specific proteolysis of endogenous and myc-tagged VAPB. 
 
A. Immunoblot of post-nuclear fractions from homogenate of spinal cord, whole 
brain and primary cortical neurons in culture DIV11 and DIV1 and glia, from E18 
Sprague-Dawley rat embryos, as well as HEK293, NSC34 (motor-neuron like) and 
C6 (glioma) cell line extracts. Cleaved VAPB is detected only in spinal cord, whole 
brain and DIV11 neurons. 30 μg of total protein were loaded in each lane; protein 
concentration was determined by a micro-BCA assay. 
 
B. Immunoblot of P2 and S2 from post-nuclear fraction and Triton X114 extracted 
P2 of adult Sprague-Dawley rat whole brain. When extracted with Triton X114, 
endogenous VAPB does not behave as a typical membrane protein as it is found 
predominantly in the aqueous phase instead of the detergent phase. If extracted using 
Triton X114, the 14 KDa band is found only in the detergent fraction, while the 27 
KDa full length protein is in the aqueous phase. 
 
C. Immunoblot of DIV5 primary cortical Sprague-Dawley rat neurons nucleofected 
with hVAPB wild-type and mutant N-terminally c-myc tagged expression constructs. 
No cleavage products are detected for any of the expressed VAPB contructs; β-
tubulin is used as a loading control. 
 
D. Immunoblot of DIV11 primary cortical Sprague-Dawley rat neurons nucleofected 










 gets cleaved more than all the other constructs, as the intensity of the band 
corresponding to the proteolytic 14 KDa fragment is higher for D130E than for the 
other constructs.  After 11 DIV, the amount of protein is significantly reduced, albeit 
the cleavage pattern is clear. *A 70 kDa non-specific band from longer exposures of 




expressed VAPB behaves in the same manner in neurons in terms of its proteolysis. 
In HEK293 or NSC34 cells we have not detected proteolysis of expressed mVAPB or 
mVAPB
P56S
 (Chapter 3,4 Skehel unpublished and Middleton, 2005). Recently two 
novel ALS associated  human VAPB mutations, D130E and del160 have been 
described (Landers et al., 2008). When D130E and del160 mutants were expressed as 
EGFP fusion proteins they display subcellular localization similar to wild-type 
(Landers et al., 2008). In order to study those new mutants along with the already 






 in the 
pEGFP-C1 vector where the EGFP fusion protein was replaced with a c-myc epitope 
(cloning performed by Dr. Caroline Wardrope). We expressed myc-tagged versions 






 by nucleofecting 
primary dissociated cortical E18 Sprague-Dawley neurons. At DIV5 of culture, when 
cell extracts are probed with the anti-myc antibody no cleavage products are detected 





 were cleaved, but not VAPB
P56S
. Moreover, the D130E 
mutant seems to be cleaved more than the wild-type protein, while the del160 mutant 
does not seem to be different from wild-type VAPB. The 14 KDa band detected in 
the immunoblot is an N-terminal myc tagged product, since all hVAP constructs were 
N-terminally tagged with the c-myc epitope. The size of this band corresponds to the 
size of the MSP domain and is consistent with our hypothesis that VAPB is cleaved 
in a neuron specific manner; the P56S mutant is not proteolysed after 11 DIV, while 
the D130E is proteolysed more. 
 
5.5 The effect of the proteolysis of VAPB on the Unfolded Protein 
Response 
 
 In order to study the effect of the release of the MSP domain in the regulation 
of the Unfolded Protein Response we used HEK293 cells and “simulated” the 
cleavage of VAPB (wild-type and mutant). This was done using the EGFP 
truncations of mVAPB and mVAPB
P56S
. Co-expression of MSPB and CC/CTB or 
MSPB
P56S
 and CC/CTB “simulates” cleavage of full length mVAPB and mVAPB
P56S
 












































































































































Figure 5.3 Simulation of VAPB cleavage by co-expression of the complementary 
VAPB truncations and its effect on transcriptional activation of the Unfolded 
Protein Response. 
 
A, B, C. HEK293 cells were transfected with complementary truncations of VAPB 
and VAPB
P56S
 that “simulate” cleavage of full length proteins to MSP and CC/CT 
domains along with ATF6, XBP1 and Bip reporters. Co-expression of MSP and 
CC/CT has an effect similar to that of MSP on its own, which is more potent than full 
length or CC/CTB single expression. The P56S MSP mutant, still has no effect on 
BiP reporter activation, but inhibits both ATF6 and XBP1 reporter activities. 
However, for the ATF6 reporter the inhibition is 16% for MSP
P56S 
+ CC/CTB and 
33% for MSP
P56S
 only. Results shown are averages of 4 experiments and error bars 
correspond to standard error (SE). 
 
D. Immunoblot of representative samples from the transcriptional assay simulating 
VAPB cleavage. Relative expression of mVAPB, mVAPB
P56S
 and truncations EGFP 
constructs is shown. Co-expression of MSP and CC/CT can be seen as a doublet in 















co-transfected with ATF6 or XBP1 or BiP reporters as previously and DNA 
quantities are balanced using pEGFP-C3. This experiment clearly shows that 
simulation of VAPB cleavage by co-expression of the two complementary 
truncations (MSPB+CC/CTB) that make up the full length protein has the same 
effect as expression of only the MSP domain (Figure 5.3). For ATF6 and XBP1 
reporters this means more potent inhibition of their activation and for the BiP 
reporter more potentiation than full length or CC/CTB single expression. The P56S 
mutant of the MSP domain when co-expressed with CC/CTB still has no effect on 
BiP reporter activation, but inhibits both ATF6 and XBP1 reporter activities; albeit 
for the ATF6 reporter the inhibition is 16% for MSP
P56S 
+ CC/CTB and 33% for 
MSP
P56S
 only. This suggests that co-expression of the MSP
P56S
 domain along with 
CC/CTB blocks the effect of the CC/CTB domain (when it’s expressed on its own).  
From all this data we conclude that in cases where the MSP domain is cleaved, there 
can be differential modulation of the Unfolded Protein Response. 
 
5.6 The A130E mutant of mVAPB gets cleaved and affects 
transcriptional activation of the UPR 
 
 In DIV11 cortical neurons, hVAPB
D130E
 is cleaved more than hVAPB, and 
hVAPB
del160
. In mouse VAPB, at position 130 there is an alanine instead of the 







 as c-myc fusion proteins as previously described for the 
relative human constructs (cloning performed by Dr.  Caroline Wardrope). HEK293 
cells were transfected with the ATF6, XBP1 or BiP reporters as previously. 
Overexpression of mVAPB
A130E
 inhibits ATF6α and XBP1 reporters and induces the 







(Figure 5.4A, B and C); the last construct has an aspartic acid in the 
position of the alanine in the mouse sequence, which makes the mouse sequence 
identical to the human wild-type sequence. Moreover, an immunoblot of samples 
from the assayed cells (Figure 5.4D) shows that the N-terminal tagged A130E mutant 


































































































































Figure 5.4 Effect of the 130E ALS associated mutation on ER stress response in 
HEK293 cells. 
 
A., B., C. Transcriptional assay using ATF6α, XBP1 and BiP reporters in HEK293 









 are overexpressed. Mouse VAPB
A130E
 inhibits ATF6α and XBP1 
reporters and induces the BiP reporter more than all the other constructs. Since in the 
mouse sequence there is an A at position 130, we used mVAPB
A130D
 as a control to 
introduce the D that is in the wild-type human sequence at that position. Results 
shown are averages of 4 experiments and error bars correspond to standard error 
(SE), p=0.014398. 
 
D. Immunoblot of representative samples from the transcriptional assay in HEK293 
cells. None of the mVAPB constructs is cleaved apart from the mVAPB
A130E
. The 
proteolytic fragment generated is approximately 15 KDa which corresponds to the 







 are not. This suggests that the substitution of the 
alanine at position 130 for a glutamic acid in mVAPB renders the protein more 
susceptible to proteolysis, and as predicted this has a profound effect on regulation of 
the Unfolded Protein Response, as the MSP domain is probably released. 
 
5.7 Overexpression of mMSPB and mMSPB
P56S
 is toxic to NSC34 
cells 
 
 Our data suggest that the MSP domain of VAPB is released after cleavage in 
a neuron specific manner. In order to examine the effect that released MSP has on 
cells, we overexpressed an EGFP fusion construct of MSPB and MSPB
P56S
 in the 
motor-neuron like NSC34 cells. It was previously suggested (Middleton, 2005) that  
overexpression of wild-type MSP is toxic in cell lines and primary neurons. We 
verified that result and confirmed that MSPB
P56S
 is also toxic to NSC34 cells 
(Chapter 4, Figure 4.6.1A and 4.6.2B) by using a vital dye assay (propidium iodide- 
cells that have lost membrane integrity allow the dye to enter the cell) or a 
cytotoxixity assay (CytoTox-GloTM, Promega). GFP and GFP-tubulin are used as 
controls. Moreover we showed in Chapter 4 Figure 4.7 that MSP and MSP
P56S
 




 In this Chapter we show neuron specific proteolysis of VAPB and release of 
the MSP domain. The MSP domain is a key regulator of the UPR and affects cell 
viability. Moreover we show in a disease paradigm (D130E mutation) how release of 
the MSP domain can misregulate the UPR. 
 
The MSP domain – neuron specificity and UPR regulation 
 We had already shown in the previous chapter that the MSP domain is a 
potent inhibitor of ATF6α activity and that the MSP
P56S
 does not display the same 
functionality. But, there was no evidence that the MSP exists in isolation, separately 
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from the full length VAPB. We clearly demonstrated in this chapter ( and (Gkogkas 
et al., 2008)) that VAPB gets  cleaved in a neuron specific manner and also that this 
proteolytic event releases the MSP domain. Moreover, Tsuda et. al., 2008 also 
demonstrated that the Drosophila homologue of VAPB is cleaved and the MSP 
domain released. Therefore, the MSP domain can exist in isolation in cells and this is 
restricted to neuronal tissue. Furthermore, we have shown that VAPB is cleaved only 
in neurons and not glial cells (or HEK293, NSC34 or C6 cells) and that in 
dissociated cultures from E18 rat embryos the proteolytic event cannot be seen at 
DIV1 but at DIV11; albeit VAPB is cleaved in extracts from cortex and spinal cord 
of embryos. This pattern of cleavage suggests that VAPB is cleaved in adult and in 
embryo, but when cortical cells are dissociated and cultured in vitro VAPB is not 
cleaved from DIV1, but at DIV11. The same applies for expressed VAPB in this 
model of primary cortical cultures. However, the P56S mutant is not proteolyzed 
after 11 days in culture.  
 VAPB cleavage is present in organised structures of neurons (whole tissue 
adult or embryo, DIV11 culture) but is not present in dissociated neurons DIV1. This 
observation highlights a dynamic regulation of VAPB cleavage that is associated 
with neuronal structure; at DIV0 when the dissociated neurons are plated, they are 
extracted from an already organised structure in the embryonic brain and after plating 
they start growing their processes. At DIV11 cortical neurons have formed a complex 
structure where cells have more synapses and their processes are considerably longer 
than DIV1. Moreover, this result could highlight a dynamic regulation of VAPB 
proteolysis dependent on neuron morphology and synaptic activity. 
 In terms of the regulation of the Unfolded Protein Response, the MSP domain 
out of all the VAP protein domains has the most profound effect on ATF6α and XBP1 
reporter inhibition and BiP reporter potentiation. If we “simulate” cleavage of VAP 
proteins by co-expressing complementary truncations (MSP + CC/CT) we observe 
the same effect as overexpressing the MSP domain; which in the case of ATF6α and 
XBP1 reporters is stronger inhibition and for the BiP reporter stronger induction 
compared to the full-length protein. These results suggest that the MSP domain 
elicits a profound regulatory effect on ER homeostasis; this becomes important in a 
neuronal context where we have shown the cleavage of VAP proteins and potential 
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release of the MSP domain. Conversely, the MSP
P56S
 does not have the same 
inhibitory effect as the wild-type MSP for ATF6 and XBP1 reporters, while it has no 
effect on BiP activation. Moreover, when the endogenous protein expression is 
reduced by siRNA, MSP
P56S
 displays reduced ability in rescuing its previously 
observed effect, which suggests its dependency on the presence of the wild-type 
protein. This potentially shows that the P56S mutation results in loss or reduction of 
the functionality of the protein, and that the interaction of the mutant protein with the 
wild-type protein may stabilise the mutant and allow it to exert its inhibitory (ATF6α, 
XBP1) or potentiating effect (BiP). 
 The aforementioned prediction of the effect of the release of the MSP domain 
on ER homeostasis is confirmed in a disease example. We show that the published 
VAPB D130E mutation (Conforti et al., 2006, Landers et al., 2008) -A130E in 
mouse- gets cleaved and produces a proteolytic fragment in HEK293 cells. The fact 
that the protein gets cleaved in non-neuronal tissue, may suggest that the substitution 
D→E can render the protein more susceptible to proteolysis than the wild-type; even 
in non-neuronal tissue. In addition, substitution of the mouse A130→D (which is the 
residue in the human sequence) does not lead to cleavage of the protein, which shows 
that it is the introduction of the E residue at position 130 that is associated with the 
observed cleavage. Also, in primary cortical DIV11 neurons the hVAPB
D130E
 gets 
cleaved more than wild-type hVAPB or hVAPB
del160
 when equal amounts of protein 
are loaded. As we predict earlier, the mVAPB
A130E
 inhibits ATF6α and XBP1 







; which is consistent with the profound effect the MSP 
domain has. 
 So far, we have presented evidence that the MSP domain of VAPB is a key 
regulator of the ER stress response and that cleavage of VAPB that produces the 
MSP domain is neuron specific. It has been previously shown by our lab (Middleton, 
2005) that overexpression of the MSP domain is toxic to cells and primary 
hippocampal neurons. We confirmed this result in the motor-neuron like NSC34 cells 
and show that MSPB
P56S
 is also toxic using two independent death assays. In 
addition to this we now show that this cell death observed is caspase-dependent, 
because the pan-caspase inhibitor zVAD-FMK rescues cell-death to a certain extent. 
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Therefore, when increased amounts of the MSP or MSP
P56S
 are accumulated, this is 
toxic for cells and induces programmed cell death via apoptosis. This result shows 
that the balance of free MSP domain in cells can be crucial for cell survival; wild 
type MSP is cleaved and MSP is produced in a cell, but when this balance is 
disturbed by overexpression, cells die. 
 
Chapter conclusion  
 The MSP domain of VAP proteins is a highly conserved protein domain that 
is a key regulator of the UPR and can be toxic when overexpressed. Neuron specific 
cleavage of VAPB which releases the MSP domain and aberrant behaviour of the 
P56S mutant can offer a new avenue for ER stress regulation in motor neurons in 
ALS8. 
 Therefore the data presented in chapters 3, 4 and 5 suggest that VAP proteins 
participate in regulation of the UPR and that the MSP is the most potent modulator 
the ER stress response. The fact that the MSP domain can be cleaved of the full 
length VAP protein reveals a novel regulatory mechanism for regulation of the UPR 
in cells. Motor neuronshave long processes and such signalling to distal sites of the 
ER could be important for their survival. It could be that in ALS8 the mutant P56S 
fails to get cleaved and thus disturbs the balance of available MSP in motor neurons. 

























 The MSP domain is an s-type Immunoglobulin-like fold (Ig-fold), which is 
also found in several other proteins, including human growth hormone receptor, 
fibronectin and CD4 (Bork et al., 1994). It comprises of a seven stranded b sandwich 
composed of a three-stranded sheet opposed by a four stranded sheet. These sheets of 
the Ig-fold interact with sheets of other Ig-like domains and therefore can mediate 
protein-protein interactions. MSP in nematodes, apart from a cytoskeletal element, is 
exported from the sperm cytoplasm into the proximal gonad where via the Eph 
receptor blocks CaMKII signalling (Corrigan et al., 2005). Therefore, despite the fact 
that Ig-like domains are thought to be mainly involved in binding functions, a 
signalling role for the MSP domain architecture is emerging. 
 VAP proteins contain an N-terminal domain that is homologous to the 
nematode Major Sperm Protein. The VAP MSP domain shares more than 60% 
sequence similarity with nematode MSP, while in VAP proteins the average sequence 
similarity is more than 70%. This high conservation of the MSP sequence from 
nematodes to human suggests that the protein architecture is associated with 
elementary cellular processes and thus is conserved through evolution. 
 The Evolutionary Trace (ET) is a method for discovering novel clusters on a 
given protein architecture that are hotspots for protein-protein interactions 
(Madabushi et al., 2002, Lichtarge et al., 1996). The algorithm uses phylogenetic 
information from a protein family to rank the residues on a sequence according to 
their evolutionary importance (high conservation amongst family members). These 
residues can be then projected onto the known 3D structure of a protein thus defining 
the evolutionary conserved cluster that is likely to participate in protein-protein 
interactions; therefore a prerequisite is a known structure for the protein. The 3D 
structure of VAPA MSP has been resolved with X-ray crystallography (1Z9L, Protein 
data bank (PDB)) (Kaiser et al., 2005). Moreover in the Protein Families Database 
(PFAM) there is a non-redundant set of 348 MSP containing proteins. 
 ET has been used to describe functional clusters on known protein 
architectures; using ET the ligand binding sites of the SH2 and SH3 domains have 
been described (Lichtarge et al., 1996). In this chapter we will use ET with a slight 
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modification. The input for ET is an alignment of proteins in a family, which is then 
scored for conservation of residues. Alignments generated by software such as 
Clustal-X (Thompson et al., 2002) show amino acid conservation in family by 
shifting a given protein sequence and introducing gaps in order to create columns of 
highly conserved amino acids; if a position is not conserved, or partially conserved, a 
gap may be introduced. This method does not take into account the fact that when a 
region corresponds to a secondary structure (i.e. β-sheet) if some of the residues are 
not well conserved then the alignment algorithm can introduce a gap; secondary 
structure organization defines tertiary folding of protein domains. When describing a 
protein family via an alignment (so that it can be used by ET), gaps in areas of 
secondary structure reduce the amount of available information for a specific spot, as 
a gap reduces scoring for a given position. Evidently, by using an automated method 
for creating an alignment of a protein family, some positions of secondary structure 
could be misrepresented in the alignment and thus this alignment would not be a 
good description of the protein family. Therefore we proceed to manually process the 
alignment for the dataset of MSP containing protein by manually deleting or 
introducing gaps in order to get a good representation of secondary structure 
residues. 
 
6.2 Evolutionary Trace (ET) Analysis of the MSP domain 
 
6.2.1 Alignment of MSP domains 
 
 In order to highlight “hotspots” for protein interactions on the MSP domain 
3D structure we carried out an ET analysis of a non-redundant set of 348 MSP 
containing proteins from the PFAM database. As we described earlier we will be 
using as input for the ET algorithm a manually edited version of the alignment. The 
dataset was aligned using Clustal-X and then gaps around areas of secondary 
structure were deleted or gaps were inserted in order to ensure good quality of 
alignment (Figure 6.2). The secondary structure of the MSP domain as observed 

















Figure 6.1 Secondary structure of the VAPA rat MSP domain. 
 
Schematic representation of the predicted by DSSP (blue) and observed by 
crystallographers (red) secondary structure of the MSP domain. Arrows indicate β-
sheets, three-loops indicate α-helices and single loops indicate turns. Letters A,B 
correspond to Ig-fold sheets. 
 
6.2.2 Conserved amino acid patch on the MSP structure 
 
 We used the manually edited alignment as input to the ET algorithm 
(Lichtarge et al., 1996). The algorithm returned a proposed 29 amino acid cluster on 
the surface of the MSP domain that is predicted to be evolutionary conserved and 
could participate in protein interactions (Figure 6.3C). Trace results are commonly 
expressed in terms of coverage: the residue is important if its coverage is small - that 
is if it belongs to some small top percentage of residues [100% is all of the residues 
in a protein], according to trace. The ET results are presented in the form of a table, 
usually limited to top 25% percent of residues (or to some nearby percentage), sorted 
by the strength of the presumed evolutionary pressure. (I.e. the smaller the coverage, 













Figure 6.2 Manual correction of the Clustal-X generated alignment for 348 MSP 
domain containing proteins from the PFAM database. 
 
Schematic representation of manual “alignment correction”, using the secondary 
MSP structure as a guide. Along with the published 3D structure of the 1Z9L VAPA 
rat MSP domain crystallographers submit to the Protein Database a secondary 
structure file as observed from the crystal. We generated an automated alignment 
using Clustal-X for the 348 MSP domain containing proteins from the PFAM 
database; using the secondary structure as a guide we manually corrected the 
alignment around areas of gaps. When a gap is present in one of the sequences and 
that area corresponds to a secondary structure (i.e. β-sheet) the gap is removed and 
the sequence shifted. This manual correction ensures that there is sequence 
information for areas of secondary structure and that the algorithm will use this 
information in its prediction. Not all 348 sequences of the alignment are shown and 





















Figure 6.3 Evolutionary Trace analysis of the 1Z9L crystal structure of rat VAPA 
MSP domain.  
 
A. Residues 0-125 in 1Z9L coloured by their relative importance as scored by the ET 
algorithm. The ET algorithm receives as input an alignment of protein sequences of a 
given family; we here introduce a manually edited alignment “corrected” around 
areas of secondary structure for 348 MSP containing proteins from PFAM. 
 
B. Colour scheme for residue scoring by the ET algorithm 
 
C. The cluster identified by ET in red. 29 surface amino acids form an evolutionary 
conserved cluster predicted to participate in protein-protein interactions. The P56 
belongs in this cluster. 
 
D. Residues in 1Z9L, coloured by their relative importance. Clockwise: front, back, 
top and bottom views. Original view as defined by the PDB 1Z9L pdb file.
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couple of residues should affect the protein somehow, with the exact effects to be 
determined experimentally (Table 6.1). To detect candidates for novel functional 
interfaces, the algorithm first looks for residues that are solvent accessible (according 
to DSSP program, copyright W. Kabsch, C.Sander and MPI-MF) by at least 10 Å
2
 
(square Angstrom), which is roughly the area needed for one water molecule to come 
in contact with the residue. Furthermore, the algorithm requires that these residues 






Table 6.1 Predicted disruptive mutations to the MSP protein-protein interactions or 
ligand binding. 
 
The algorithm proposes disruptive mutations by using residue properties as follows: 
small [AV GSTC], medium [LPNQDEMIK], large [WFY HR], hydrophobic [LPV 
AMWFI], polar [GTCY], positively [KHR], or negatively [DE] charged, aromatic 
[WFY H], long aliphatic chain [EKRQM], OH-group possession [SDETY], and NH2 
group possession [NQRK]. The suggestions are listed according to how different 
they appear to be from the original amino acid, and they are grouped in round 
brackets if they appear equally disruptive. From left to right, each bracketed group of 





6.2.3 The FFAT binding site on the MSP domain partially overlaps with the 
predicted evolutionary conserved patch 
 
 Kaiser et al., 2005 published the 3D structure of rat VAPA MSP domain as a 
dimer and as a complex with the FFAT motif. The FFAT motif is a targeting signal 
found in proteins shuttled to the ER surface or nuclear membrane. The interaction 
between FFAT containing proteins and VAP MSP domain has been shown to be 
essential for targeting these proteins to the relative subcellular location. 
 The FFAT binding site is shown in Figure 6.4C (as mapped from the 1Z9L 
complex file from PDB). The P56S proline is not part of the FFAT binding surface, 
but as hypothesized by Teuling et al., 2007, the carbon backbone of the proline could 
be interfering with the FFAT cluster. Moreover as seen in Figure 5.4D the predicted 
29 amino acid cluster from ET only partially overlaps with the FFAT binding surface. 
This means that not all FFAT residues are highly conserved in all MSP containing 
proteins. Conversely the P56 is one of the 29 residues of the ET cluster.
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Figure 6.4 The predicted conserved patch on rat VAPA MSP domain contains the 
P56 but partially overlaps with the FFAT binding site.  
 
A. Results of the Evolutionary Trace mapped onto the 1Z9L crystal structure of rat 
VAPA MSP domain. A 29 amino acid “patch” on the surface of the MSP domain is 
predicted to be highly conserved and therefore might participate in protein-protein 
interactions 
 
B. Results of the Evolutionary Trace mapped onto the 1Z9L crystal structure of rat 
VAPA MSP domain - highlighting the P56. Proline 56 is one of the 29 amino acids of 
the conserved “patch” and is a high scoring amino acid in this Evolutionary Trace. 
 
C, D. Results of the Evolutionary Trace mapped onto the 1Z9L crystal structure of 
rat VAPA MSP domain - highlighting the P56 and the FFAT motif binding surface. 
The point mutation lies outside the FFAT binding site. Moreover the FFAT binding 
site partially overlaps with the ET cluster. 
 
All pictures were prepared using PyMol and ET files as input. ET cluster shown in 





 In this Chapter we identify an evolutionary conserved 29 amino acid patch on 
the known 3D structure of rat VAP MSP domain (Figure 5.3). The MSP domain 
participates in various protein interactions (Table 1.1), while we show in Chapters 3 
and 4 that it is a key regulator of the Unfolded Protein Response  and that the MSP 
could be released after neuron-specific proteolysis of VAPB; finally overexpression 
of MSP is toxic to cells and renders them more vulnerable to ER stress. The 
conserved cluster model built by the algorithm suggests disruptive mutations for the 
29 amino acids that belong to the ET cluster; this could disrupt ligand binding or 
protein interactions. Moreover, mutagenesis of some of those 29 amino acids could 
be used to investigate the MSP-ATF6 interaction and the observed effect in the 
transcriptional assay. 
 Finally, the FFAT binding cluster which is one of the key functions of the 
VAP MSP is not well conserved in all known MSP containing proteins, therefore it 
could be a function primarily associated with mammalian VAP MSP domains rather 
than all MSP containing proteins. The P56 which is mutated to a Serine in ALS8 
patients is highly conserved and is an important residue of the ET cluster. Teuling et 
al., report that P56S disrupts FFAT binding; in the mutant MSP
P56S
 the residue at 
position 56 could be at a different position than the wild-type and thus could be part 
of the ET cluster. Solving the crystallographic structure of the mutant MSP would 
address this question. 
 
Chapter conclusion 
 We have shown in this study that the MSP domain is a toxic factor and key 
regulator of the UPR and that VAPB MSP is released only in neuronal tissue. 
Evolutionary Trace analysis of the known 3D structure of rat VAPA MSP domain 
provides a surface 29 ligand cluster that is pivotal in the MSP architecture in terms of 
its protein-protein interactions. Future design of MSP ligands that would block MSP 


































7.1 General Discussion 
 
 Various functions have been ascribed to VAP proteins; lipid and inositol 
metabolism, vesicle trafficking, FFAT binding, ER to Golgi trafficking and regulation 
of the Unfolded Protein Response. VAP proteins are type-II integral membrane 
proteins enriched on the ER surface. A mutation (P56S) in VAPB has been associated 
with a late-onset form of ALS (ALS8), while recently two new (D130E, del160) ALS 
associated mutations have been described. The P56S mutant forms cytoplasmic 
aggregates; protein aggregation in brain patients is seen in many neurodegenerative 
diseases like Parkinson’s, Alzheimer’s or Huntington’s (Gorman, 2008). P56S 
aggregation has been associated with FFAT binding (Prosser et al., 2008, Teuling et 
al., 2007), while FFAT overexpression dissolves P56S aggregates. In a recent report 
(Jaarsma D., 2008) from FENS 2008, VAPB
P56S
 overexpressing transgenic mice form 
tubular aggregates that are continuous with ER tubules, while wild-type 
overexpressing lines do not; however none of the mutant lines displayed any disease 
symptoms. Therefore, while FFAT binding is a pivotal function of VAP proteins and 
has been found to be impaired in P56S mutants, it might not be the only function of 
VAPB linked to motor neuron degeneration in ALS8. It looks like P56S aggregates 
when P56S is overexpressed do not have an acute or clear effect on cell viability. 
 In this study we highlight the role of VAPB in regulation of the Unfolded 
Protein Response. We show that the N-terminal Major Sperm Protein homology 
domain of VAPB is a key regulator of the UPR; in addition VAPB is cleaved in a 
neuron specific manner and the MSP domain is released. VAPB interacts with and 
modulates the activity of the UPR transcription factor ATF6α. Moreover, VAPB 
levels affect transcriptional activation of two other ERSE containing promoters 
(XBP1 and BiP). In addition, VAP protein levels affect the viability of motor-neuron 
like cells (NSC34) recovering from ER stress. Finally, we study the highly conserved 
structure of the MSP domain and identify an evolutionary conserved patch of 






VAPB and ATF6α 
 Full length VAPB, VAPB
P56S
 and VAPA were shown to interact with full 
length ATF6α. Both ATF6α and VAPB are transmembrane ER proteins; ATF6α upon 
ER stress translocates to the Golgi where it’s cleaved; the proteolytic fragment of 
ATF6α is shuttled to the nucleus where it activates UPR associated genes 
transcription. Additionally, VAPB overexpression blocks ATF6α glycosylation 
associated activation. These two lines of evidence suggest that VAPB-ATF6α 
interaction can happen on the ER membrane, but do not exclude it from occurring 
anywhere in the trafficking of ATF6α from ER to Golgi. 
 We proceed to show a functional effect of this identified interaction; 
overexpression of VAPB and VAPB
P56S
 inhibit activation of ATF6α as measured by 
the synthetic promoter of the ATF6 reporter. Conversely, siRNA mediated reduction 
of endogenous VAPB expression induces the reporter, reversing the inhibitory effect 
observed. Overexpression of VAPB truncations in the transcriptional assay shows 
that the MSP domain is the most potent inhibitor, the Coiled-coil is an inhibitor and 
the hydrophobic tail has no effect. The P56S mutant is a more potent inhibitor of 
ATF6α as it accumulates to lower amounts than the wild-type protein; albeit the 
inhibition observed for the P56S mutant constructs and the coiled-coil is dependent 
on the presence of the endogenous protein during overexpression. 
 Our data establish a link between VAP proteins and the ATF6α response to 
unfolded proteins in the ER lumen. The ATF6α branch of the UPR is considered to 
be a slower response than PERK or IRE1 (Yamamoto et al., 2007). Also, ATF6α 
dependent UPR associated genes are constitutive rather than induced, which suggests 
that ATF6α participates in development and homeostasis (Shen et al., 2005). ALS8 is 
a late onset neurodegenerative disease, and since ATF6 is not immediately activated 
in UPR this may suggest that the VAPB-ATF6 interaction becomes important later in 
life; PERK and IRE1 pathways are the main UPR transducers and ATF6α may 
constitute a complementary pathway; later in life the ATF6α pathway could be 
required to substitute or complement the IRE1 and PERK pathways. Failure to 
regulate the ATF6α pathway via VAPB could render the cells incapable to respond to 
accumulation of unfolded/misfolded proteins. In ALS8 the VAPB
P56S
 allele could 
exert a greater inhibition on ATF6α activation and thus fail to communicate with the 
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nucleus and initiate the UPR response. 
 From the aforementioned data it becomes clear that the VAPB-ATF6α 
interaction should be further investigated. In Figure 7.1 we depict all the potential 




















Figure 7.1 ATF6 and its potential regulation by VAPB 
 
1: VAPB overexpression blocks glycosylation associated activation of ATF6α 
(luminal domains of ATF6 forms disulfide bonds). 
2: VAPB could be dimerizing with ATF6α on the ER membrane. 
3: VAPB could block translocation of ATF6α to the Golgi cisternae. 
4: VAPB could interfere with proteolysis of ATF6 by S1P and S2P. 
5: VAPB could interfere with nuclear shuttling of ATF6α from the Golgi. 




















mediated by ATF6α in the nucleus. 
7: VAPB could be interacting with ATF6α on the nuclear envelope. 
 
 Similarly to yeast, VAPB could be blocking transcription of ERSE element 
dependent genes by ATF6α and NF-Y. In yeast Opi1 is on the ER membrane and it’s 
binding to the Scs2 MSP domain can regulate INO1 transcription. In yeast UPR 
(inositol starvation) the transcription factor Hac1 controls binding of Opi1 to INO1 
promoter elements (Kagiwada and Zen, 2003). Binding of ATF6α to promoter 
elements could be regulated in a similar way. In order to verify this, chromatin 
immunoprecipitation experiments (Kuo and Allis, 1999) would need to be 
performed; check whether VAPB overexpression or reduction of expression with 
siRNA can affect binding of ATF6α to promoter elements. 
 ER to Golgi transport is inhibited when VAPA and VAPB
P56S
 are 
overexpressed (Prosser et al., 2008), but VAPB has no effect. VAPA and VAPB form 
heterodimers and thus VAPB overexpression could block ATF6α trafficking to the 




 could be a stronger 
inhibitor of ATF6α because it might have a higher affinity for VAPA than wild-type 
VAPB. 
 Proteolysis of ATF6α in the Golgi apparatus is performed by S1P and S2P 
proteases. VAPB is not enriched in the Golgi cisternae, but nevertheless is present. 
VAPB-ATF6α association could potentially inhibit proteolysis of ATF6α thus 
reducing the amounts of the active N-terminal portion of ATF6α that translocates to 
the nucleus. Fluorescent live microscopy following ATF6α translocation while VAPB 
is overexpressed or reduced with siRNA could reveal if VAPB can interfere with this 
part of the ATF6α cycle. Finally, the nuclear envelope is an ER subdomain 
surrounding the nucleus; VAPB and ATF6α are present in the nuclear envelope and 
their interaction there could regulate ATF6α activation. 
 
VAPB and the UPR 
 We show in this study that VAPB overexpression or reduction by siRNA 




 A synthetic ATF6 promoter in p5xGL3ATF6 that has been shown to be 
responsive not only to endogenous ATF6α but also XBP1(Wang et al., 2000). 
 The human XBP1 endogenous promoter in pGL3-XBP1-(-330)-luc . 
 The human BiP endogenous promoter in pGL3-GRP78-(-132)-luc. 
 Luciferase assays are powerful tools for investigating various effects on 
promoter elements; the ATF6α promoter is sensitive to ATF6α levels but also to 
XBP1 levels as ATF6α and XBP1 dimerize and both bind to these promoter elements 
(also see chapter 3.1, background); we show that VAPB can interact with ATF6α and 
therefore the inhibition observed is most likely due to this interaction. We also 
proceed to show that VAPB overexpression inhibits XBP1 reporter activation from 
the endogenous XBP1 promoter; conversely the BiP reporter is induced by VAPB 
overexpression. In accordance with this, siRNA mediated reduction of endogenous 
VAPB expression reverses the overexpression effect observed for XBP1 and BiP 
reporters. For XBP1 and BiP reporters the effect is observed for the endogenous 
promoter of the relative human genes which suggests a transcriptional regulation of 
those promoters from VAPB and VAPB
P56S
 levels. ATF6α and XBP1 heterodimerize 
(Yamamoto et al., 2007) and for both reporters the effect of VAPB overexpression is 
inhibitory, which might suggest an active participation of VAPB in regulating the 
dynamics of this dimer and thus UPR regulation. Activation of the BiP chaperone 
constitutes the main part of the UPR response to unfolded protein accumulation in 
the ER lumen; VAPB induces BiP activation, while VAPB
P56S
 does not. In ALS8, 
failing to activate the BiP response could impede folding of unfolded proteins and 
lead to cell death. Interestingly the VAPB
P56S
 effect observed for XBP1 and BiP 
transcriptional activation is dependent on the presence of the endogenous protein. On 
the other hand, overexpression of VAPB and VAPB
P56S
 but not GFP or tubulin 
reduces cell viability after ER stress. This shows that when the balance of VAP 
proteins is perturbed, cells are more susceptible to apoptotic death once their UPR 
has been activated. 
 In conclusion, VAP proteins are here shown to be involved in regulation of 
the transcriptional activation of the UPR by a) acting on several UPR-ERSE 
associated promoter elements and b) by directly interacting with the UPR transducer 
ATF6α. The P56S ALS8 associated mutant displays a similar effect (which might be 
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more potent for the same amount of protein) which is however dependent on the 
presence of the endogenous protein. Nevertheless VAP protein levels seem to 
regulate the UPR and affect cell viability once the UPR is activated. Apart from the 
activation phase of the UPR, VAPs could be acting on the recovery phase of the cell. 
 
The MSP domain 
 The MSP domain is the most conserved domain of VAP proteins and its Ig-
like fold has been implicated in various protein-protein interactions (Tarr and Scott, 
2005). Middleton, 2005 showed that MSP overexpression is toxic to cells and 
primary neurons and also that MSP of VAPA interacts with ATF6α.We have shown 
that VAP MSP is released after VAP protein cleavage and that VAPB cleavage is 
neuron tissue specific (Gkogkas et al., 2008) and Tsuda et al., 2008 showed that 
drosophila VAP is cleaved and secreted. 
 In this study we show that VAPB MSP is a key regulator of the UPR and 
affects cell viability. When overexpressed MSP inhibits transcriptional activation of 
the ATF6α and XBP1 reporters and is the most potent inhibitor amongst VAPB 
domains; the BiP reporter is induced and MSP is again the most potent activator 
amongst VAPB domains. The MSP in all three aforementioned instances retains its 
overexpression effect when the endogenous VAPB is blocked with siRNA. MSP
P56S
 
inhibits ATF6 and XBP1 reporters but has no effect on BiP activation. Moreover the 
MSP
P56S
 overexpression effect is dependent on the presence of endogenous VAPB. 
Furthermore, overexpression of MSP and MSP
P56S
 EGFP fusion proteins forms large 
cytoplasmic aggregates and is toxic to cells (Middleton, 2005); in addition, MSP and 
MSP
P56S
 overexpression in cells that have been induced with the N-glycosylation 
inhibitor tunicamycin (UPR is induced) reduces cell viability via apoptosis. 
 We additionally show that neuron specific VAPB cleavage can occur in a 
dissociated cortical neuron culture, in spinal cord tissue but not in glial primary 
cultures, HEK293, NSC34 or C6 glioma cells. Although proteolysis can be seen in 
embryonic brain tissue, it is not observed at day 1 in vitro of the dissociated cultured 












 are cleaved while VAPB
P56S
 is not; also the D130E 
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mutant is proteolysed more. Remarkably, mouse VAPB
A130E
 but not VAPB
A130D
 
inhibits ATF6α, XBP1 reporters and induces the BiP reporter more than wild-type 
VAPB or VAPB
P56S
 in HEK293 cells; From all the aforementioned constructs in 
HEK293 cells only VAPB
A130E
 is proteolysed and it’s that construct that has a more 
potent effect on UPR activation (the three reporters used). 
 To sum up, endogenous VAPB and not VAPA are cleaved in a neuron specific 
manner and this proteolysis most likely releases the MSP domain. The MSP 
monomer overexpression is toxic to cells and reduces cell viability after ER stress; 
moreover the wild-type MSP is a potent inhibitor of ATF6 and XBP1 and a potent 
inducer of BiP; the P56S mutant functionality depends on the endogenous VAPB 
protein. Our data suggests that MSP
P56S
 is not cleaved, while the D130E increases 
the proteolysis of the protein. The fact that VAPB gets cleaved only in neurons could 
be highlighting an important physiological function of the protein. Non-cleavage of 
VAPB
P56S
 and enhanced cleavage of VAPB
D130E
 are two paradigms of aberrant 
proteolysis of VAPB in neurons associated with ALS8 mutations. Finally, the 
proposed secretion of the MSP domain (Tsuda et al., 2008) could be a mechanism via 
which neurons act on glial cells or other neurons. 
 
VAPB domains 
 We have shown using ATF6, XBP1 and BiP reporters that overexpression of 
VAPB truncations has different effects on transcriptional activation of these 
reporters. The C-terminal hydrophobic tail of VAPB localizes to the ER membrane 
and when overexpressed has no effect on any of the three reporters. The Coiled-Coil 
domain participates in promiscuous protein-protein interactions and inhibits the 
ATF6 reporter activation but has no effect on XBP1 and BiP reporters. Moreover 
when the endogenous VAPB expression is blocked with siRNA, the Coiled-Coil 
effect is abolished, suggesting a dependency from the endogenous VAPB Coiled-Coil 
or MSP domain or another unidentified factor. These data reveal that the cytoplasmic 
domains of VAPB can participate in UPR regulation. Additionally, overexpression of 
CC reduces viability of NSC34 cells after ER stress by inducing apoptosis, 
suggesting that CC levels are important for UPR regulation and can lead to cell death 
when their balance is perturbed. The MSP and CC domains might interact on the 
171 
 
same molecule or in VAPB dimers. VAPA and VAPB high sequence similarity and 
the fact that they heterodimirize could suggest a VAPA-VAPB modulation of the 
observed Coiled-Coil effect. Nevertheless, VAPB dimmers, multimers or VAPA-
VAPB heterodimers could affect regulation of the UPR by masking or titrating 
regulatory UPR VAP domains (MSP, CC). A mutagenesis study of the observed 
inhibition or induction of the luciferase reporters could highlight important residues. 
  
A model for ALS8 motor neuron degeneration 
 Neuron specificity of VAPB cleavage and subsequent release of the MSP 
domain becomes extremely important in a motor neuron context. We have shown 
that the MSP domain when overexpressed is toxic and renders cells more vulnerable 
after ER stress, while it has a profound effect on UPR transducers activation. Motor 
neurons have long processes that enervate muscles; many cellular factors are 
transported along the axon and reach the terminals of long processes (Van Den Bosch 
and Robberecht, 2008). 
 The fact that VAPB is cleaved only in neurons might reflect a need for local 
regulation in the long neuronal processes or crosstalk with other cells (glia) in the 
nervous system. We show that increased amounts of MSP are toxic and kill cells via 
apoptosis; it could be that intracellular amounts of free MSP domain need to be 
regulated and the cell cannot handle the excess protein. Apart from the observed 
toxicity, overexpression of MSP has a profound effect on the UPR response; we 
show that overexpression of MSP after ER stress reduces cell viability by inducing 
apoptotic death. Therefore, apart from the profound effect on transcriptional 
activation, increased intracellular MSP reduces cell viability and renders cells more 
vulnerable to induction of apoptosis following ER stress. Full length VAPB 
overexpression has a similar effect but not as profound (for transcriptional regulation 
and cell death). On the other hand, MSP
P56S
 transcriptional regulation for ATF6 and 
XBP1 reporters is dependent on endogenous VAPB, while the MSP
P56S
 has no effect 
on BiP reporter activity; moreover, expressed human VAPB
P56S
 does not get cleaved 
in neurons. These data suggest that the P56S mutation might block VAPB neuron 
specific cleavage. In drosophila Tsuda et al., 2008 showed that the P56S mutant also 






























Figure 7.2 A model for MSP function in neurons. 
 
Schematic representation of a motor neuron and the effect of VAPB neuron specific 
cleavage. 




















released in the cytoplasm. 
2: MSP gets secreted and can act on other cells either via the ephrin receptor (Tsuda 
et al., 2008) or another unidentified route. 
3: MSP is targeted to dendrites where it could associate with the UPR machinery on 
ER microdomains. 
4: MSP could be acting indirectly on UPR gene transcription in the nucleus or 
directly by being transported in the nucleoplasm where it could associate with 
nuclear ATF6α. Nevertheless, the MSP domain could be acting on various ERSE 
elements. 
5: MSP could act on ER microdomains in synapses along the motor neuron axon. 
6: MSP could act on muscle cells in the motor neuron Neuromuscular Junction. 
 
 
Our data suggest that human VAPB
P56S
 in a rat neuron dissociated culture does not 
get cleaved. Conversely, D130E and del160 VAPB mutants get cleaved and the 
D130E mutant displays enhanced cleavage (and potent inhibition of ATF6, XBP1 
and induction of BiP). 
 As depicted in Figure 7.2, enhanced cleavage or no cleavage could potentially 
interfere with the proposed MSP pathway in motor neurons. MSP could be in the 
cytoplasm after cleavage of membrane bound VAPB and subsequently could be 
secreted and act on other cells. MSP could be transported down the axon and act on 
distal ER microdomains by interacting with ATF6α or affect nuclear UPR response 
indirectly or by nuclear internalization. Also, MSP could be acting on muscle cells at 
the Neuromuscular junction (NMJ). In this context non-cleavage (P56S) or enhanced 
cleavage (D130E) could affect the various points of regulation by the MSP domain. 
 In P56S ALS8 patients described so far there two alleles of VAPB; wild-type 
VAPB and the P56S mutant. Interaction between the two alleles could be pivotal for 
development of motor neuron degeneration; non-cleavage of P56S could affect the 
balance of VAPB proteins by heterodimerization. Our data suggest that the MSP
P56S
 
can have a regulatory effect on UPR provided the endogenous protein is present. 
However non-cleavage of VAPB
P56S
 suggests that the MSP
P56S
 monomer might not 
exist as a monomer in neurons; if it does get cleaved as Tsuda et al., 2008 suggest for 
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the drosophila protein our data supports that the domain produced is non-functional 
regarding transcriptional activation of the UPR. 
 Tsuda et al., 2008 suggest that the MSP domain behaves like a hormone by 
acting on the ephrin receptors of neighbour cells. We propose that the MSP domain 
has a key intracellular UPR regulatory role which affects motor neuron viability in 
uninduced or ER stress induced cells; this physiological function can be perturbed by 
ALS8 associated mutations (P56S, D130E, del160). 
  
VAP and ALS 
 Motor neuron degeneration in late onset ALS (like ALS8) suggests that 
neurons die as a result of an accumulation of insults (protein misfolding, oxidative 
stress, mitochondrial dysfunction, inflammation) throughout life or as a result of an 
acute change in cell physiology underlined by a change in gene interactions that is 
correlated with aging or environmental cues; most likely a cellular factor gains some 
form of toxicity that accelerates disease progression or manifestation (Boillee et al., 
2006). Moreover, sporadic and familial cases display similar pathology. 
 Recently, the participation of non-neuronal cells in motor neuron 
degeneration is being extensively studied (Nagai et al., 2007). ALS is a multifactorial 
disease and ultimately cell death is a combination of multiple pathway participation 
in a non-cell autonomous manner.  
 Perturbation of transcriptional regulation within motorneurons can lead to cell 
death as it has been shown for many neurodegenerative diseases (Chu et al., 2007). 
We have shown that VAP proteins and their ALS associated mutants participate in 
UPR associated promoter elements regulation. It could be that VAP proteins 
contribute to ALS pathogenesis by misregulating transcription factor promoter 
elements. Studying VAP proteins and their involvement in late-onset ALS in neuronal 
and nonneuronal cells could highlight new therapeutic avenues. 
 
Conclusion 
 This study highlights a novel interaction for the ALS8 associated VAPB gene 
with the Unfolded Protein Response of the Endoplasmic Reticulum. ALS is a disease 
of motor neurons and therefore validation for this interaction and modulatory effect 
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of VAPB levels on UPR regulation in motor neurons is necessary. We have 
developed and applied three straightforward assays for monitoring the effect of 
VAPB levels on the UPR; a luciferase based transcriptional assay and a cell death 
assay and a fluorescent protein complementation assay. If VAPB proves to be a 
biomarker for ALS8 in motor neurons then these assays can be used for drug 
discovery. Until now VAPB has been associated with ALS8 via the large Brazilian 
pedigree (Nishimura et al., 2004); further epidemiological studies might highlight 
VAPB as an ALS8 candidate gene and therefore elucidating its participation in the 
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A mis-sense point mutation in the human VAPB gene is associated with a familial form of motor neuron
disease that has been classified as Amyotrophic Lateral Sclerosis type VIII. Affected individuals suffer
from a spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) or an atypical slowly progressing
form of ALS. Mammals have two homologous VAP genes, vapA and vapB. VAPA and VAPB share 76% similar
or identical amino acid residues; both are COOH-terminally anchored membrane proteins enriched on the
endoplasmic reticulum. Several functions have been ascribed to VAP proteins including membrane traffick-
ing, cytoskeleton association and membrane docking interactions for cytoplasmic factors. It is shown here
that VAPA and VAPB are expressed in tissues throughout the body but at different levels, and that they
are present in overlapping but distinct regions of the endoplasmic reticulum. The disease-associated
mutation in VAPB, VAPBP56S, lies within a highly conserved N-terminal region of the protein that shares
extensive structural homology with the major sperm protein (MSP) from nematodes. The MSP domain of
VAPA and VAPB is found to interact with the ER-localized transcription factor ATF6. Over expression of
VAPB or VAPBP56S attenuates the activity of ATF6-regulated transcription and the mutant protein
VAPBP56S appears to be a more potent inhibitor of ATF6 activity. These data indicate that VAP proteins inter-
act directly with components of ER homeostatic and stress signalling systems and may therefore be parts of
a previously unidentified regulatory pathway. The mis-function of such regulatory systems may contribute to
the pathological mechanisms of degenerative motor neuron disease.
INTRODUCTION
A dominantly inherited familial form of motor neuron disease
characterized in a large Brazilian family was recently shown
to be associated with a mis-sense mutation in the human
vapB gene (1). Affected individuals suffer from three different
pathological conditions; a late on-set slowly progressing spinal
muscular atrophy (SMA), a slowly progressing late on-set
atypical amyotrophic lateral sclerosis ALS8 or a typical
severe rapidly progressing ALS (2,3). Although familial forms
of disease may represent less than 5% of the total incidences
of ALS (4,5), they exhibit the same phenotypic heterogeneity
as the more common sporadic disease (6–8). Information on
the mechanistic basis of familial motor neuron diseases may,
therefore, be relevant to all forms of motor neuron disease.
The first VAP protein was identified in Aplysia californica
from its interaction in a yeast two-hybrid screen with
VAMP/Synaptobrevin, hence the nomenclature VAMP/
Synaptobrevin Associated Protein (9). VAP proteins are
highly conserved, with homologous proteins found in all
eukaryotes (10–15). There are two mammalian genes VapA
and VapB (16). The proteins contain three prominent structural
features; the N-terminal domain of approximately 120 amino
acids is highly homologous to the nematode major sperm
protein (MSP) (17), the central domain is amphipathic and
predicted to form a coiled–coil structure, and the C-terminal
20 amino acids are hydrophobic and act as an intracellular
membrane anchor (13,15,16).
The MSP domain binds to the ‘two phenylalanines in an
acid tract’, or ‘FFAT’ motif found in several cytoplasmic
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lipid-binding proteins (18–20). The structural basis of this
interaction was recently determined for the MSP domain of
VAPA (21). Thus, VAP proteins may act as docking sites
for cytoplasmic factors to interact with the ER. VAP proteins
may also act to maintain the structure of intracellular mem-
branes such as the ER, by interacting with the cytoskeleton
and mediating membrane trafficking (13,15,22).
The disease-associated mutation in ALS8 is a C to T substi-
tution within exon 2 of the vapB gene replacing a proline
residue with a serine in a highly conserved region of the
protein. The mutant protein, VAPBP56S, forms aggregates
when expressed in cultured cell lines or primary hippocampal
neurons (1). The relationship of these aggregates to the patho-
logical mechanism of the disease is not known. It has been
suggested that the presence of aggregates containing
VAPBP56S may result in disruption of the proteasome, acti-
vation of ER stress responses, fragmentation of the Golgi
apparatus and induction of apoptosis (23). Teuling et al. (24)
have also demonstrated that expression of VAPBP56S recruits
the wild-type protein into aggregates and causes disruption
of ER structure.
In this report, we show that both VAPA and VAPB are ubi-
quitously expressed but at differing levels in different tissues
and that they accumulate on overlapping but distinct regions
of the ER. Both VAPA and VAPB are shown to be capable
of interacting with the ER stress regulated transcription
factor ATF6, and over expression of VAPB or VAPBP56S
attenuates the activity of an ATF6/XBP1 regulated promoter.
This suggests that VAPB can have an inhibitory effect on
ATF6 dependent transcription and that the disease-associated
mutant, VAPBP56S, has an enhanced inhibitory activity
towards ATF6-dependent transcription compared to the wild-
type protein. An interaction between VAP proteins and
ATF6 may represent a previously uncharacterized mechanism
of ER homeostatic and stress response regulation.
It is concluded that the mis-regulation of ER stress response
and homeostatic regulatory systems may contribute to the
pathological mechanism of degenerative motor neuron
disease associated with the VAPBP56S mutation.
RESULTS
VAPA and VAPB are expressed ubiquitously but at
differing levels in different tissues
Immunoblot analysis of selected tissues from an adult male rat
demonstrated that both VAPA and VAPB proteins are present
in all tissues examined, but at different relative levels
(Fig. 1A). This is in agreement with the wide expression
profile of mRNA published previously (13,16,25). A second
protein of slightly larger molecular weight is detected in the
testis by VAPA anti-sera. An additional, less abundant,
protein of approximately 14 kDa is detected by both anti-
serum. The VAPB-related signal is a doublet, the expression
of which is tightly restricted to the forebrain and cerebellum
extracts, and not detected in the other tissues tested
(Fig. 1A). The 14 kDa VAPA-related polypeptide is more
widely expressed and detectable in pancreas, liver, forebrain,
lung and thymus, kidney and testis; low levels are seen in
the cerebellum and no signal is detected in heart or skeletal
muscle. A peptide of similar size has been predicted from a
splice variant of VAPB, termed VAPC. However, the
peptide used to generate the VAPB anti-serum is not present
in VAPC (16), and the VAPA anti-sera do not cross react sig-
nificantly with vapB-derived species (Supplementary Material,
Figure S1). It is concluded that these smaller molecular weight
immunoreactive species are most likely generated by proteol-
ysis of the VAP proteins.
It has been shown previously that both VAPA and VAPB
are enriched on the ER membrane (13,15,21). A distinct sub-
cellular distribution for the two proteins is seen by
co-immunostaining of HEK293 cells (Fig. 1B). Both proteins
are localized in a reticular pattern, but they exhibit only a
modest level of co-localization. This distinct sub-cellular dis-
tribution of VAPA and VAPB is most striking in skeletal
muscle (Fig. 1C). Fluorescent immunocytochemistry indicates
a complementary distribution of VAPA and VAPB in the sar-
coplasmic reticulum. VAPA is enriched on the A- and
H-bands and the Z-line, while VAPB is restricted to the
I-band and T-system regions (Fig. 1C). The I-band is enriched
for IP3 receptors and RyR localize mainly at the T-system
(26); VAPA and VAPB may therefore be associated with dis-
tinct intracellular calcium stores.
Interactions of the VAP MSP domain
The ALS8-associated mutation in the VAPB protein lies
within a highly conserved region of the MSP domain. In a pre-
vious series of experiments, we had observed that, when
expressed as an EGFP fusion protein, the MSP domains of
both VAPA and VAPB formed intensely fluorescent, large
intracellular aggregates and were toxic to HEK293 and
PC12 cell lines, and to primary cultures of rodent hippocampal
neurons (Skehel, unpublished). To investigate possible mech-
anisms of the MSP domain toxicity, a yeast two-hybrid screen
was done to identify potential MSP interacting proteins. A
sequence corresponding to amino acids 1–107 of mouse
VAPA was used to screen a rat brain cDNA library. In
addition to a number of FFAT- and MSP domain-containing
proteins, a partial clone of the ER stress regulated transcription
factor ATF6 was identified (27).
To characterize this interaction further, expression con-
structs for full-length VAPA, VAPB and ATF6 were analysed
by a fluorescent peptide complementation assay (28) (Fig. 2).
In this assay, a fluorescent protein is generated from two sep-
arate parts of a split GFP, termed Venus1 and Venus2, only by
the association of two test polypeptides expressed as fusion
proteins. A functional fluorescent protein is generated when
the two test proteins directly interact. Although the initial
yeast two-hybrid interaction was between a truncated form
of ATF6 and the MSP domain of VAPA, an interaction
between full-length forms of VAPA and VAPB with ATF6
was readily detectable (Fig. 2). Similarly, the ALS8-associated
mutant VAPBP56S was shown to be capable of interacting with
ATF6 (Fig. 2). No interaction was detected between VAPA,
VAPB or ATF6 when co-expressed with heterologous
leucine zipper-Venus fusions. The reconstitution of a fluor-
escent protein clearly indicates that VAPA and VAPB are
capable of interacting with ATF6. Similar results were also
obtained with the converse Venus combinations, where
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ATF6 was expressed as a fusion with Venus 1, and the VAP
proteins were fused to Venus 2 (data not shown) (28).
Fluorescence analysis of HEK293 cells expressing EGFP-
VAPB and FLAG-tagged ATF6 shows extensive regions of
co-localization on the ER, but also some complementary
distribution (Fig. 3). The aggregates of EGFP-VAPBP56S
show some but not extensive co-localization with ATF6,
although we cannot discount that low antigen accessibility
may contribute to reduced ATF6 detection in VAPBP56S
aggregates. Expression of VAPBP56S does not appear to
cause gross disruption of ATF6 distribution in the ER (Fig. 3).
ATF6 is inhibited by VAPB and VAPBP56S
ATF6 is one of a family of transmembrane transcription
factors (29). It functions in a regulated transcription pathway
Figure 1. (A) Detection of VAPA and VAPB in different tissues. Anti-peptide anti-serum was raised to residues 174–189 of mouse VAPB. In the tissues indi-
cated, the predominant immunoreactivity is at approximately 27 kDa, in agreement with the molecular weight predicted from the cDNA. Both VAPA and VAPB
are expressed widely but at different levels. A faster migrating VAPB-related doublet signal of approximately 14 kDa is clearly detected in forebrain and
cerebellum protein extracts (arrows). The immunoblot is deliberately over exposed to demonstrate the restricted nature of this expression pattern. A faster
migrating immunoreactive species of approximately 14 kDa is also seen with VAPA anti-sera, however, in contrast to that seen for VAPB; this species is detect-
able in pancreas, liver, forebrain, lung and thymus, kidney and testis; low levels are seen in the cerebellum and no signal is detected in Heart or skeletal muscle.
(B) VAPA and VAPB are expressed in distinct reticular patterns. Indirect immunoflouroescence analysis of VAPA and VAPB in HEK293 cells reveals a reticular
pattern of expression, but detects very little co-localization of the two proteins. VAPA is shown in red and VAPB in green. (C) VAPA and VAPB are enriched in
a complementary distribution in skeletal muscle. Confocal micrographs of an immunocytochemically labelled transversus abdominis muscle from a 2 month old
mouse (VAPA in red, VAPB in green). The staining patterns of VAPB were consistent with it being located around putative I—band and T-system regions. In
contrast, VAPA was absent from these regions, and appeared to be more strongly expressed in the regions associated with A- and H-bands and Z-lines. A pseudo-
coloured electron micrograph is shown to indicate the position of VAPA and VAPB staining in relation to the structure of a muscle sarcomere.
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involved in ER homeostasis and response to stress known as
the unfolded protein response (UPR) (30–32). Upon accumu-
lation of unfolded proteins in the lumen of the ER, ATF6
translocates from the ER to the Golgi and is proteolyzed in
turn by S1P and S2P. This results in the release of the DNA
binding and transcription transactivation domain of ATF6
from the ER membrane allowing it to enter the nucleus and
activate transcription (27,33).
ATF6 appears to interact with several promoter elements
(31,34,35). A synthetic promoter has been generated that acts
as an ATF6/XBP1 dependent transcription reporter (31). To
determine if the interaction with VAPB affects the ability of
ATF6 to activate transcription, luciferase-based transient trans-
cription assays were done using this ATF6/XBP1-dependent
reporter of transcription (31). In HEK293 cells, basal levels
of transcription from this promoter are reduced by over-
expression of myc-tagged forms of VAPB or VAPBP56S
(Fig. 4A). ATF6/XBP1-mediated transcription activated by
the glycosylation inhibitor, tunicamycin, was also significantly
reduced by over expression of VAPB or VAP-BP56S (Fig. 4A)
(36,37). Increasing levels of ATF6 by co-expression of a
FLAG-tagged recombinant form of human ATF6 (38) increased
basal and tunicamycin-induced expression from the ATF6/
XBP1 reporter. In both cases, the elevated levels of ATF6/
XBP1 dependent transcription were also reduced by over
expression of either VAPB or VAPBP56S (Fig. 4B). This
effect requires the cytoplasmic domains of VAPB and does
not appear to be a non-specific consequence of increasing
levels of protein in the ER membrane since over expression
of a DsRed fluorescent fusion protein of the C-terminal
Figure 2. Peptide complementation assay for the interaction of VAPA and VAPB with ATF6. The coding sequences of mouse VAPA, VAPB and VAPBP56S
were expressed in HEK293 cells as fusion proteins with a truncated non-fluorescent form of YFP, Venus 1 (28). These proteins were co-expressed with the
complementary ATF6-Venus 2 fusion protein. Fluorescence indicates reconstitution of a functional YFP and therefore a direct interaction of VAPA and
VAPB with ATF6. Wild-type VAPB and mutant VAPBP56S are capable of interacting with ATF6. Controls in which a homodimerizing leucine zipper
peptide was expressed as either a Venus 1 or Venus 2 fusion proteins show no fluorescence when expressed with the complementary VAP or ATF6 fusion pro-
teins. Bright field or fluorescence images were acquired from live cells through cell culture plastic.
Figure 3. Co-localization of VAPB and ATF6. HEK293 cells were transfected
with FLAG-ATF6, EGFP-VAPB and EGFP-VAPBP56S. In colour plates,
FLAG-ATF6 is shown in red and EGFP-VAPB or EGFP-VAPBP56S is in
green. There is extensive, but not total co-localization of VAPB and ATF6
in a reticular distribution. ATF6 co-localizes with the aggregates formed by
VAPBP56S, but not in a punctate pattern. Note that VAPBP56S does not
cause a gross change in the distribution of ATF6.
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hydrophobic domain of VAPB does not reduce the basal or
tunicamycin-induced expression from the ATF6/XBP1 reporter
(Fig. 4A and Supplementary Material, Figure S3). Over
expression of VAP proteins does not reduce expression levels
of luciferase directed from a CMV promoter; therefore, the
repressive affect on the ATF6/XBP1 reporter is unlikely to be
the result of a general repression of transcription (Supplemen-
tary Material, Figure S4).
A similar inhibitory affect was also seen in the motor
neuron derived cell line NSC34 (Fig. 4C and D). In NSC34
cells, basal levels of expression from the ATF6/XBP1 reporter
are less than in HEK293, perhaps indicating lower levels of
endogenous ATF6.
Consistent with the inhibitory affect seen by over
expression of VAPB, siRNA-mediated reduction of endogen-
ous VAPB results in an increase of basal and induced levels
of ATF6/XBP1-dependent transcription (Fig. 5).
When equal amounts of expression plasmid DNA for VAPB
and VAPBP56S were used for cell-transfections, the overall
level of attenuation was similar between the wild type and
mutant forms of VAPB (Fig. 4). Immunoblot analysis of
total protein from transfected cells, however, indicated that
the mutant protein, VAPBP56S-myc, accumulated to signifi-
cantly lower levels, reaching only 20% of the level of wild-
type protein (Fig. 6). This suggests that VAPBP56S-myc may
exert a stronger inhibition on ATF6 than the wild-type
VAPB-myc, since a similar level of inhibition is achieved
from a lower amount of protein. The difference in protein
levels is less pronounced when VAPB and VAPBP56S are
expressed as EGFP fusion proteins (Fig. 6), which indicates
that the presence of the GFP moiety may have a stabilizing
affect on VAP-BP56S. Consistent with this, the inhibition
of ATF6/XBP1-dependent transcription is more pronounced
for VAPBP56S-GFP than VAPB-GFP (Fig. 6). Thus,
VAPBP56S appears to have a significantly greater inhibitory
affect on ATF6 mediated transcription than wild-type
VAPB. These results suggest that mis-regulation of ER
stress responses may be important for the pathological effect
of VAPBP56S that leads to motor neuron degeneration.
DISCUSSION
The identification of a mutated gene responsible for a familial
form of motor neuron disease greatly facilitates molecular and
cellular studies of potential disease mechanisms. Understand-
ing the cellular function of VAPB may indicate what molecu-
lar and cellular events are associated with the disease process
of ALS8. It is likely that this information will be of relevance
to both the inherited condition and the more common sporadic
forms of disease.
Previous studies have demonstrated a role for VAP proteins
on the ER. The N-terminal MSP domain contains an FFAT-
motif binding site (21). This interaction has been shown to
localize a number of cytoplasmic lipid-binding proteins to
the ER and ER-derived membranes (18–20,39). FFAT-
dependent interactions between VAPA and Nir2 and 3 have
also been shown to affect the gross structure of the ER (22).
Both VAPA and VAPB appear to be expressed at different
relative levels in specific tissues [(16,25) and this study].
Figure 4. VAPB and VAPBP56S inhibit transcription from an ATF6 regulated transcription reporter. (A) HEK293 were transfected with a reporter plasmid con-
taining the luciferase cDNA regulated by five ATF6/XBP1 binding sites, pGL3(5X)ATF6. Cell cultures were co-transfected with expression plasmids encoding
VAPB or VAPBP56S as myc-tagged fusion proteins (VAPB-myc and VAPBP56S-myc) or a monomeric red fluorescent fusion protein containing the C-terminal 41
amino acids of VAPB (VAPB-Cterm). Where indicated cultures were treated for 12 h with 2 mg/ml Tunicamycin to induce ER stress. VAPB and VAPBP56S
reduce constitutive levels of ATF6/XBP1 activity, while VAPB-Cterm had no effect. (B) Over expression of ATF6 as a ATF6-FLAG fusion protein increased
basal and tunicamycin-induced activity of the ATF6/XBP1 reporter gene, but in both cases, levels of activity were reduced by co-expression of VAPB-myc or
VAPBP56S-myc. (C and D) The same experiments using the motor neuron-like cell line NSC34 gave similar results.
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Both proteins are enriched on the ER and co-localize to a large
extent (24). There are, however, many regions where the two
proteins do not co-localize, suggesting they are present in dis-
tinct functional regions of the ER. This is most clearly seen in
skeletal muscle where VAPA is enriched within the A and H
bands and Z-line, whereas VAPB is seen predominantly in the
I-bands and T-region. The localization of VAPA is similar to
that of the IP3 receptor (26), whereas VAPB more closely
resembles the distribution of Ryanodine receptors (40). Any
disruption of VAPB function caused by the P56S mutation
associated with ALS8 might, therefore, affect intracellular
Ca2þ storage and Ca2þ signalling capacities. Intracellular
Ca2þ levels have been implicated in many degenerative con-
ditions (reviewed in 41), and inhibition of Ryanodine receptor
activity has been recently suggested as a possible pathological
mechanism for motor neuron disease (42).
The proline residue at codon 56 within the MSP domain
does not appear to contribute directly to FFAT-binding but
co-immunoprecipitation of FFAT-containing proteins is
reduced for VAPBP56S (24). Perturbation of FFAT-dependent
association with the ER could disrupt the sorting of lipids
within and between cellular membranes (19,20). A
phosphoinositide-binding activity has been identified in the
MSP domain of the yeast protein SCS2 that is a homologue
of VAPA and VAPB (43).
Disruption of the MSP domain in VAPBP56S could affect a
similar activity in the mammalian proteins. Changes in mem-
brane composition have been suggested as a cause of neurode-
generation (44), and hyperlipidaemia is one of the clinical
effects reported for VAPBP56S families (3). Disruption of ER
and Golgi structure and/or function has been suggested pre-
viously as a possible pathological mechanism for degenerative
diseases of neurons (45–47). More recently, ER stress in par-
ticular has been associated with sporadic and experimental
models of motor neuron disease (48–50), and neurodegenera-
tion in general (reviewed in 46,47,51). A recent report has also
suggested that VAPB levels may induce the ER UPR by
affecting the activity of IRE1 (23). In this report, we show
that VAPA and VAPB can interact directly with the
ER-localized transcription factor ATF6. Moreover, increasing
the expression of VAPB attenuates the activity of ATF6,
whereas reducing VAPB levels enhance ATF6-dependent
transcription. Over expression of the mutant protein
VAPBP56S appears to attenuate the activity of ATF6 more pro-
foundly than does wild-type VAPB. The pertinacious aggre-
gates formed by VAPBP56S do not appear to sequester ATF6
to a significant extent. The enhanced inhibitory affect of
VAPBP56S levels on ATF6 activity may not, therefore, be
due simply to a reduction in available ATF6. There are a
number of stages in the activation of ATF6 that VAPB
could influence. In response to accumulation of unfolded
protein in the ER lumen ATF6 translocates from the ER to
the Golgi. There it is sequentially processed by S1P and S2P
proteases to release an amino terminal portion of the protein
containing DNA binding and trans-activation domains (33).
The lumental COOH-terminal domain of ATF6 is required
to detect the accumulation of unfolded proteins in the lumen
of the ER. As VAPB has very little luminal structure, it is unli-
kely to directly inhibit the ability of ATF6 to detect ER stress.
Over expression of VAPB can disrupt membrane trafficking
and so may indirectly inhibit the activation of ATF6 by redu-
cing the translocation of ATF6 to the Golgi (15). Alterna-
tively, VAP proteins might directly inhibit the translocation
of ATF6 to the Golgi. It is also possible that VAP acts after
translocation of ATF6 to the Golgi by a mechanism similar
to that of Nucleobindin1 which represses S1P activation of
ATF6 (52).
VAPB may act at the level of transcription. The yeast VAP
homologue SCS2, originally identified as a suppressor of ino-
sitol auxotrophy, has been shown to localize activated genes to
the nuclear membrane via an interaction with a FFAT domain-
containing protein, Opi1 (10,53). The localization to the
nuclear membrane was essential for gene expression (53). If
an analogous situation existed in mammals, over expression
of VAPB could directly affect the activity of ATF6 at promo-
ters adjacent to the nuclear membrane.
Figure 5. VAPB siRNA reduces the levels of endogenous VAPB and increases basal ATF6/XBP1-dependent transcription. (A) Immunoblot analysis of HEK293
cells nucleofected with VAPB siRNA or GFP siRNA and non-transfected cells shows a 25% reduction in levels of endogenous VAPB when treated with VAPB
siRNA and no reduction in GFP siRNA treated cells. A 60 kDa non-specific band from longer exposures of the immunoblot serves as a loading control. Band
intensities were measured using ImageJ (NIH). (B) siRNA to VAPB increases basal and tunicamycin-induced, transcription from an ATF6/XBP1-regulated tran-
scription promoter.
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A regulatory role for VAP proteins on the surface
of the ER
The UPR and ERAD systems respond to the environment of
the lumen of the ER. Perhaps the interaction between the
VAP proteins and ATF6 represents an additional element of
ER regulation that responds to levels of proteins associating
with the surface of the ER, or to proteins that do not have sig-
nificant amounts of luminal structure.
VAP proteins interact with a broad range of other coiled–
coil containing proteins such as VAMP/Synaptobrevin and
syntaxin (12). If interactions of the coiled/coil domain also
affected the MSP domain-dependent inhibition of ATF6,
they could enable the levels of membrane proteins on the
surface of the ER to activate ATF6.
VAP proteins and Hepatitis C virus replication
The Hepatitis C virus has exploited potential structural and
regulatory functions of the VAP proteins. Hepatitis C repli-
cates in association with the ER. Two of the viral proteins
required for this association, NS5A and NS5B, can bind to
both VAPA and B, interacting with the coiled–coil and
MSP domains, respectively (54,55). Disrupting these inter-
actions or down-regulating VAPA and VAPB protein levels
inhibits virus replication (55,56). Hepatitis C protein
expression can also induce ER stress, activating both ATF6
and XBP1. This does not lead to a full UPR (57,58), and it
has been suggested that mis-regulation of the ER stress
response may in someway favour viral replication (58).
Perhaps a similar mechanism may contribute to the pathogen-
esis of VAPBP56S. The mutant protein could lead to a mis-
regulation of ER stress regulatory pathways via aberrant
ATF6 activity. Such mis-regulation could also have a role in
the pathological affects of Hepatitis C infection.
ATF6 activity and neurodegeneration
The increased level of ATF6 inhibition by VAPP56S suggests
that a possible pathological mechanism for ALS8 is
mis-function of homeostatic regulatory systems of the ER.
Kanekura et al. (23) recently demonstrated that increased
VAPB levels could induce the UPR as indicated by activation
of XBP1, and that the affect of VAPBP56S was to diminish this
activation. Our study suggests that VAP proteins can also
affect the activity of ATF6, and that the mutation VAPBP56S
may, have a greater effect than the wild-type protein VAPB.
From gene transcription analysis on the UPR in C. elegans,
it has been shown that ATF6 mainly contributes to tonic
levels of gene expression (59). In mammals, ATF6 appears
to have a more extensive role in the ER stress response,
where it is required for the induced expression of principal
ER chaperones, and also acts as a heterodimer with XBP1 to
induce components of the ER associated degradation
pathway (ERAD) (30).
The direct interaction between VAP proteins and ATF6
represents a previously uncharacterized mechanism for the
Figure 6. VAPBP56S accumulates to lower levels than VAPB. Immunoblot analysis of HEK293 cells expressing myc or GFP-tagged forms of VAPB and
VAPBP56S. Duplicate samples are shown, and relative levels expressed as a histogram of signal intensities. As both myc and GFP fusion proteins,
VAPBP56S accumulates to lower levels than VAPB. VAPBP56S-myc is 15% the level of VAPB-myc, and VAPBP56S-GFP is 50% the level of
VAPB-GFP. (A) The GFP moiety appears to have a stabilizing affect on the levels of mutant protein, allowing it to accumulate to higher levels than the myc-
tagged form. (B) Consistent with this the inhibition of ATF6-dependent reporter gene expression is reduced to a greater relative level by VAPBP56S-GFP than
VAPBP56S-myc. Band intensities were determined using ImageJ (NIH) Intensities for both myc and GFP, VAPB and VAPBP56S were normalized to the p38
loading control.
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regulation of transcriptional responses made to changes in ER
metabolism. Overall, VAP proteins may have structural and
regulatory functions based on interactions of the MSP
domain. The pathological mechanism in ALS8, therefore,
may be the result of an inability to deal appropriately with
different forms of ER stress.
MATERIALS AND METHODS
Antisera. VAPB-specific anti-serum was raised in sheep to a
multi antigenic peptide (MAP) form of a peptide correspond-
ing to amino acids 174–189 of mouse VAPB (Alta Bio-
science). This sequence is identical in rats and mice. The
serum was affinity purified using the immunizing peptide.
The VAPA anti-serum has been described previously (13).
Anti-myc was monoclonal 9E10 and anti-FLAG was M2
(Sigma).
Muscle staining
Muscle tissue was fixed in 0.1 M PBS containing 4% parafor-
maldehyde for 1–2 h.
Muscles were blocked in 4% BSA and 0.5% Triton-X (both
Sigma) in PBS for 30 min before incubation in primary anti-
bodies overnight at 48C. The primary antibodies used were
sheep anti-VAPB (1:200) and rabbit anti-VAPA (1:300).
After washing for 30 min in blocking solution, muscles were
incubated for 4–5 h in PBS containing secondary antibodies.
The secondary antibodies used were Donkey anti-Sheep Cy2
(1:100, Jackson Laboratories) and Donkey anti-Rabbit Cy3
(1:100, Jackson Laboratories). After a 2 h wash in PBS,
muscles were mounted on glass slides in mowoil mounting
medium [2.4 g mowoil (Poly vinyl Alcohol, Calbiochem),
6 g glycerol, 2.5% 1,4-diazobicyclo-octane (DABCO,
antifade, Sigma), 12 ml 200 mM Tris (pH 8.5)). These exper-
iments are not shown.
Preparations were analysed using a laser confocal scanning
microscope (Biorad Radiance 2000). The strobing function
was always enabled to prevent signal bleeding through from
one channel to another. Confocal z-series were merged using
Lasersharp (Biorad) software. All images were analysed and
prepared for presentation in Adobe Photoshop.
Cell staining
HEK293 cells grown on poly-D-lysine coated cover slips were
fixed in 3% paraformaldehyde, 0.03% glutaraldehyde (w/v) in
PBS, at room temperature for 20 min. Fixative was quenched
and cells permeablized with a solution of 50 mM NH4Cl, 0.2%
(w/v) Saponin (Sigma), for 15 min at room temperature. Cells
were washed, and antibodies diluted in a solution containing
0.2% (w/v) fish skin gelatin (Sigma G-7765), 0.02%
saponin, in PBS. Inverted cover slips were mounted in
Mowoil, and examined on a Zeiss Imager.Z1 microscope
fitted with a LSM 510 Meta confocal excitation/acquisition
system.
Peptide complementation
Full-length coding sequences for mouse VAPA, VAPB,
VAPAP56S, VAPBP56S and human ATF6a (NM_007348)
were amplified in a PCR that introduced flanking BspEI and
XbaI, or NotI and ClaI restriction sites, and sub-cloned into
pcDNA3.1(zeo)-Venus[1] or pcDNA3.1(zeo)-Venus[2],
respectively (28). HEK293 were transfected using Lipofecta-
mine 2000 (Invitrogen). For each transfection 200 ng of total
DNA was used. Images of living cells were acquired 24 h
after transfection on an Olympus IX70 fluorescence micro-
scope using Openlab software (Improvision). Representative
images are shown.
Transcription assay
HEK293 or NSC-34 cells were grown in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% foetal bovine serum.
Cells were transfected using Lipofectamine2000 (Invitrogen).
Each transfection mixture contained 300 ng of p5xATF6-GL3
(31) and 100 ng of the internal control renilla luciferase repor-
ter, pTK-RT. VAPB and VAPBP56S were expressed as EGFP-
fusion proteins derived from pEGFP-C1 (Clontech), or as myc
epitope tagged fusion proteins where the EGFP coding
sequence was replaced with a myc epitope coding sequence.
The total amount of DNA per transfection was 500 ng.
ATF6 was over expressed as a FLAG-tagged fusion protein
from pCMV-ATF6-3xFLAG7.1 (60). One hundred nanogram
of each VAPB and ATF6 expression plasmid was used, with
the total amount of DNA in each transfection made up to
600 ng with the vector pEGFP-C3 (Clontech). Twenty-four
hours after transfection ER stress was induced for 12 h with
2 mg/ml tunicamycin (Calbiochem). Cells were then lysed
and assayed for firefly and renilla luciferase activity using
the Dual GloTM Luciferase Assay System (Promega). Firefly
and renilla luminescence were measured using a FLUOstar
OPTIMA micro-plate reader (BMG LABTECH). Firefly luci-
ferase luminescence values are normalized to renilla firefly
luminescence values and are averages of four experiments
with SE.
siRNA transfection
106 HEK293 cells were nucleofected with 200 pMoles of
VAPB siRNA (Quiagen) or a control GFP-siRNA (Dharma-
con) using the Amaxa Biosystems nucleofector. Twenty-four
hours after nuclofection, cells were transfected with
p5xATF6-GL3 and pTK-RT as described above. After a
further 24 h, cells were treated with 2 mg/ml Tunicamycin
(Calbiochem) for 12 h and then assayed for luciferase activity
as above.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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